Behavioural and Neurochemical Effects of Acute (±) 3,4 methylenedioxymethamphetamine (MDMA) in the Dopamine D1 Receptor Mutant Rat by Squire, Hanna
 Behavioural and Neurochemical 
Effects of Acute (±) 3,4 
methylenedioxymethamphetamine 
(MDMA) in the Dopamine D1 
Receptor Mutant Rat 
 
by 
Hanna Squire 
 
 
 
 
A thesis 
submitted to the Victoria University of Wellington 
in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
Victoria University of Wellington 
2016 
2 
 
  
3 
 
Acknowledgements 
 
I would like to extend my sincerest thanks to everyone who helped me to complete this 
PhD. I am very fortunate to have had the opportunity to study in the behavioural 
neuroscience laboratory at Victoria where we have such an incredible team. The 
researchers, technicians, office staff and students alike create a stimulating yet supportive 
work environment, and I felt aided at every stage of my PhD.  
 
Special thanks must go to Professor David Harper for being the best and most 
approachable supervisor I could have hoped for. Thank you for always providing such 
helpful feedback and for all the thought-provoking discussions regarding behavioural 
neuroscience. You are an inspiring example of someone who manages to be hard-working 
and ambitious yet also super relaxed and loved by all. 
 
Huge thanks also go to: Mum (for your constant love and support often in the form of 
food packages); Dad (ditto, plus we can now watch Arsenal matches again); Simon (the 
best brother/friend/psychology buddy I could ask for); Bart Ellenbroek (an incredibly 
supportive and involved secondary supervisor); Amy (for editing my thesis and ruling at 
life); and Will (your support over the years is immeasurable and I’m a better person for 
having met you), as well as to all of my fantastic friends and lab mates who I hope remain 
in my life for years to come, including (but not limited to): Jonathan (Johnny-Beau), 
Hannah, Lucy, Graci, Claire, Tel, Tina, Joel, Matt, Sam, Sarah, Alana, Dane, Tash, 
Fraser, Sophie, Joyce, Jiun, Wendy (for the weekly avocados), Jeremy, Peter, Ross, 
Jason, Quenten, Bridget, Quelly, Chelsea, Mevagh, Rob, Tadhg, Ash and Blobfish.  
  
4 
 
  
5 
 
Table of Contents 
 
Acknowledgements……………………………………………………………. 3 
List of Abbreviations………………………………………………………….. 7 
Abstract……………………………………………………………………….. 9 
Chapter 1: General Introduction…………………………………………….. 11 
     A Background to MDMA Use and Abuse………………………………….. 17 
         A brief history of MDMA/”the truth of MDMA” (Wolfson, 1986)……... 17 
         MDMA use in New Zealand…………………………………………….. 19 
         Studying MDMA’s actions: Problems with using human participants….. 20 
         The pharmacology and physiological effects of MDMA………………… 21 
         Evidence for MDMA dependence………………………………………... 24 
         MDMA-induced cognitive changes……………………………………… 26 
             Cognitive changes associated with chronic or binge MDMA exposure.. 26 
             Cognitive changes associated with acute MDMA exposure: Proactive 
interference (perseveration) and DA D1-like receptors………………. 28 
     Using the DAD1-/- Rat Model to Investigate the Acute Effects of MDMA 
on Memory Performance……………………………………………………. 31 
         A brief history of transgenic mice models and the introduction of rat 
genetic models……………………………………………………………. 31 
         Dopamine, D1-like receptors and the DAD1-/- rat…………………………... 32 
         Dopamine & D1-like receptors in motivation and reward: Attribution of 
incentive salience…………………………………………………………... 37 
         Dopamine & D1-like receptors in movement………………………………. 42 
         Dopamine & D1-like receptors in memory………………………………. 44 
     The Current Study…………………………………………………………… 47 
         Phase 1……………………………………………………………………. 47 
         Phase 2……………………………………………………………………. 48 
         Phase 3……………………………………………………………………. 48 
Chapter 2: General Method………………………………………………….. 49 
Chapter 3: A Behavioural Characterisation of DAD1-/- Rats……………… 55 
     Method……………………………………………………………………… 59 
     Results………………………………………………………………………. 72 
6 
 
     Discussion…………………………………………………………………… 85 
Chapter 4: C-fos Expression and Locomotor Activity in DAD1-/- Rats 
Following Acute MDMA Administration……………………………………. 89 
     Method………………………………………………………………………. 91 
     Results………………………………………………………………………. 96 
     Discussion…………………………………………………………………… 109 
Chapter 5: Acute MDMA-induced Memory Deficits and the Role of the 
DA D1 receptor………………………………………………………………... 111 
     Method………………………………………………………………………. 114 
     Results……………………………………………………………………….. 118 
     Discussion…………………………………………………………………… 129 
Chapter 6: General Discussion……………………………………………….. 135 
References……………………………………………………………………… 145 
 
 
 
 
 
 
 
  
7 
 
List of Abbreviations 
 
2C-B   2,5-dimethoxy-4-bromophenethylamine 
2C-I   2C-I 2,5-dimethoxy-4-iodophenethylamine 
5-HT   5-Hydroxytryptamine; serotonin 
6-OHDA  6-hydroxydopamine 
AMPH   Amphetamine 
ANOVA  Analysis of variance 
ATS   Amphetamine-type stimulants 
cDNA   Complementary DNA 
CNS   Central nervous system 
CPA   Conditioned place aversion 
CPP   Conditioned place preference 
CS   Conditioned stimulus 
DA   Dopamine 
DAD1-/-  Homozygous dopamine D1 mutant 
DAD1+/-  Heterozygous dopamine D1 mutant 
DAD1+/+  Homozygous dopamine D1 wild-type 
DAT   Dopamine re-uptake transporter 
DL   Dorsolateral (part of the striatum) 
DM   Dorsomedial (part of the striatum) 
DMTS   Delayed matching to sample 
DNMTP  Delayed nonmatching to position 
ENU   N-ethyl-N-nitrosourea 
EP   Epinephrine 
IHC   Immunohistochemistry 
i.p.   Intraperitoneal injection 
HPS   Hippocampus 
KO   Knock-out 
L-DOPA  Levodopa 
LID   Levodopa-induced dyskinesia 
LSD   Lysergic acid diethylamide 
8 
 
LTD   Long-term depression 
LTP   Long-term potentiation 
M   Mean 
MDA   3,4-methylenedioxyamphetamine 
MDEA  3,4-methylenedioxy-N-ethyl-amphetamine 
MDMA  (±) 3, 4-Methylenedioxymethamphetamine; ecstasy 
METH   Methamphetamine 
mPFC   Medial prefrontal cortex 
Nacc   Nucleus accumbens 
NE   Norepinephrine 
NET   Norepinephrine re-uptake transporter 
NZ   New Zealand 
PCPA   p-chlorophenylalanine 
PD   Parkinson’s disease 
PTSD   Post-traumatic stress disorder 
PFC   Prefrontal cortex 
RPM   Revolutions per minute 
SD   Standard deviation 
SEM   Standard error of the mean 
SERT   Serotonin re-uptake transporter 
SNPc   Substantia nigra pars compacta 
SSRI   Selective serotonin re-uptake inhibitor 
UCS   Unconditioned stimulus 
UNODC  The United Nations Office on Drugs and Crime 
VTA   Ventral tegmental area 
w/v   Weight/volume percent 
 
 
  
9 
 
Abstract 
Rationale: (±) 3,4-methylenedioxymethamphetamine (MDMA; ‘ecstasy’) is a 
recreationally abused psychostimulant that leads to detrimental effects on memory 
performance. MDMA’s acute effects on memory are often attributed to a working 
memory impairment resulting from compromised serotonin systems. However, recent 
evidence from non-human animal experimental studies suggests that acute MDMA may 
impair memory performance through an MDMA-induced increase in dopamine (DA) 
release, leading to overstimulation of DA D1 receptors. The overstimulation of D1 
receptors during acute MDMA exposure is thought to indirectly impair memory by 
increasing a subject’s susceptibility to proactive interference, leading to a perseverative 
pattern of responding during memory tasks.  
Objective: This project investigates the hypothesis that acute MDMA impairs memory 
performance via overstimulation of D1 receptors. The acute actions of MDMA will be 
assessed using DA D1 mutant (DAD1-/-) rats which possess a selective down-regulation 
in functional DA D1 receptors. On the basis that acute MDMA impairs memory function 
via overstimulation of D1 receptors it is predicted that, compared to control rats, DAD1-/- 
rats will be protected from the acute memory deficits caused by MDMA. Due to the 
novelty of the DAD1-/- rat model, prior to the assessment of the acute effects of MDMA 
on memory performance in these rats, behavioural and neurochemical characterisations 
will be conducted.  
Methods: Firstly, a behavioural characterisation was conducted to explore the tendencies 
of DAD1-/- rats, compared to controls, in a drug free state. Behaviours relevant for 
motivation and reward, movement, and memory were the focus of the behavioural 
investigation due to evidence suggesting a role for D1-like receptors in these functions.  
Secondly, a neurochemical assessment of DAD1-/- and controls rats in response to 
MDMA (3 mg/kg) was assayed using c-fos expression, a marker for neuronal activity, in 
several brain regions with known DA innervation. Thirdly, to assess the acute effects of 
MDMA on memory performance, DAD1-/- and control rats were trained on a spatial 
working memory T-maze task, delayed non-matching to position (DNMTP), over 25 
sessions. Once trained, rats were administered either MDMA (1.5, 2.25 and 3 mg/kg) or 
saline fifteen minutes prior to testing on DNMTP, with all subjects experiencing all drug 
doses three time each. In addition, to further investigate the hypothesis that 
overstimulation of D1 receptors impairs memory performance, the effects of a D1 
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receptor agonist, SKF 81297 (0.5, 1, 1.5, 3, 4.5 mg/kg) on DNMTP performance were 
also assessed.  
Results: The behavioural characterisation revealed that DAD1-/- rats are capable of 
performing many behaviours relevant for reward processing, movement and memory 
function. However, DAD1-/- rats were impaired with regard to some reward-related 
behaviours, such as the acquitision of lever pressing for sugar pellets. The assessment of 
c-fos expression demonstrated that DAD1-/- rats express less c-fos in the medial prefrontal 
cortex, striatum and nucleus accumbens compared to control rats following MDMA 
administration. Lastly, the effects of acute MDMA administration on memory 
performance were tested. During the third block of MDMA administration, control rats 
demonstrated decreased accuracy on the DMNTP task at both the 2.25 and 3 mg/kg 
doses. The decrease in accuracy during MDMA exposure in control rats was driven by an 
increase in perseverative errors. On the contrary, DAD1-/- rats were not impaired on the 
DNMTP task following acute MDMA at any of the doses tested. Administration of SKF 
81297 did not lead to any systematic changes in performance, but at the 3 mg/kg dose 
DAD1-/- rats displayed increased accuracy compared to control rats.  
Conclusions: DAD1-/- rats were protected from an MDMA-induced decrease in accuracy 
on the DNMTP task compared to control rats. This finding challenges the assumption that 
MDMA’s acute effects on memory performance are wholly due to serononergic 
mechanisms. Specifically, the current study provides evidence for the hypothesis that 
acute MDMA exposure impairs memory performance in rats via overstimulation of D1 
receptors, caused by an increase in proactive interference.  
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Chapter 1: General Introduction 
The pharmacological and behavioural actions of the psychostimulant (±) 3,4 
methylenedioxymethamphetamine (MDMA; ‘ecstasy’) are unique when compared to 
other drugs of abuse, including related amphetamine (AMPH) derivatives. Whereas 
compounds with high abuse liability such as AMHP, cocaine or heroin stimulate 
substantial release of mesocorticolimbic dopamine (DA) and to a lesser extent brain 
serotonin (5-HT; 5-Hydroxytryptamine), recreational doses of MDMA preferentially 
stimulate the release of 5-HT (Baumann, Clark, & Rothman, 2008; Johnson, Hoffman, & 
Nichols, 1986; Steele, McCann, & Ricaurte, 1994; Schmidt, 1987). This characteristic has 
led to a great deal of research into MDMA’s effects with a focus on the contributions 
made by 5-HT (Colado, O’Shea, & Green, 2004). For example, acute MDMA exposure 
can lead to a pattern of symptoms known as 5-HT syndrome (Piper, Fraiman, & Meyer, 
2005; Spanos & Yamamoto, 1989; Tao, Shokry, & Callanan, 2015), and high or repeated 
doses of MDMA can lead to long-term depletions in 5-HT and 5-HT axons in rats, which 
many argue reflects 5-HT neurotoxicity (Battaglia et al .,1987; Benningfield & Cowan, 
2013; McCann, Szabo, Dannals, & Ricaurte, 1998; Molliver et al., 1990; Parrott, 2002; 
Schmidt & Kehne, 1990; Souza, Battaglia, & Insel, 1990; although see Baumann, Wang, 
& Rothman, 2007 for a review to the contrary). Furthermore, compared to addictive drugs 
that primarily exert their effects on DA systems, it has been hypothesised that MDMA’s 
increased potency for brain 5-HT stimulation underlies the lower acquisition rates of 
MDMA self-administration observed using animal models (Bradbury et al., 2013; Wang 
& Woolverton, 2007).  
Although it is well documented that MDMA exposure can lead to long-term 
depletions of markers of 5-HT neurotransmission, the risks stemming from consumption 
of MDMA are not necessarily known by MDMA users (Carlson, Falck, McCaughan, & 
Siegal, 2004; Strote, Lee, & Wechsler, 2002; Uosukainen, Tacke, & Winstock, 2015). 
Despite the possible neurotoxic effects of MDMA, hospital admissions and deaths 
associated with MDMA use are relatively rare (European Monitoring Centre for Drugs 
and Drug Addiction, 2015; Landry, 2002; although rates do appear to be increasing: 
Global Drug Survey, 2015), leading to the concern that MDMA may be perceived as a 
relatively safe drug (Kahn, Ferraro, & Benveniste, 2012; Parrott, 2014; Rivas-Vazques & 
Delgado, 2002). This is worrying in the face of widespread reports that MDMA exposure 
leads to adverse effects on cognitive performance which likely severely impact the lives 
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of MDMA users, for example on tests of memory and attention (e.g. Jacobsen, Mencl, 
Pugh, Skudlarski, & Krystal, 2004; Kalechstein, Garza, Mahoney, Fantegrossi, & 
Newton, 2007; Kuypers & Ramaekers, 2005; 2007; McCann, Mertl, Eligulashvili, & 
Ricaurte, 1999; Murphy, Wareing, Fisk, & Montgomery, 2009; Quednow et al., 2006; 
Rendell, Gray, Henry, & Tolan, 2007; Wareing, Murphy, & Fisk, 2004; Zakzanis & 
Young, 2001). Due to MDMA’s pronounced effects on 5-HT mechanisms and likely 5-
HT neurotoxicity, many researchers broadly attribute the cognitive deficits associated 
with MDMA administration to 5-HT dysfunction (Galizio, McKinney, Cerutti, & Pitts, 
2009; Kalechstein et al., 2007).  
With a focus here on MDMA’s ability to impair learning and memory, while 5-
HT is possibly involved there are several caveats to the position that alterations in 5-HT 
neurotransmission can account for all of MDMA’s effects on memory performance. 
Firstly, chronically administered regimens of MDMA that reliably and extensively 
compromise long-term 5-HT function in animal models do not necessarily lead to lasting 
memory deficits (e.g. Byrne, Baker, & Poling, 2000; Frederick et al., 1998; Moyano, 
Frechilla, & Rio, 2004; Robinson, Castaneda, & Whishaw, 1993; Taffe et al., 2001). 
Secondly, in a study by Moyano et al. (2004) systemic application of the 5-HT synthesis 
inhibitor p-chlorophenylalanine (PCPA), which depleted hippocampal 5-HT transmission 
by > 90%, did not lead to memory retention deficits on the passive avoidance task. 
MDMA administration still resulted in memory deficits subsequent to the treatment of 
PCPA, suggesting that 5-HT mechanisms were not a necessary cause for these MDMA-
induced impairments (Moyano et al., 2004). Thirdly, regimes of MDMA that are non-
toxic to 5-HT neurons have still been demonstrated to impair learning (Arias-Cavieres et 
al, 2010). Fourthly, memory impairments following acute MDMA exposure tend to 
emerge at a dose (~3 mg/kg via intraperitoneal (i.p.) injection) (Galizio, Byrd, Robinson, 
Hawkey, Rayburn-Reeves, & April, 2014; Galizio et al., 2009; Harper, 2013; Harper, 
Hunt, & Schenk, 2006; Harper, Wisnewski, Hunt, & Schenk, 2005; Kay, Harper, & Hunt, 
2010) at which there is a relatively greater increase in extracellular DA than 5-HT 
(Baumann et al., 2007). This dose effect is further demonstrated using the 3-lever drug 
discrimination paradigm in rats, where the subjective effects of MDMA after a dose of 3 
mg/kg appear similar to the potent DA agonist, AMPH, yet at lower doses MDMA and 
AMPH are successfully discriminated (Harper, Langen, & Schenk, 2014). Often, doses of 
MDMA lower than 3 mg/kg preserve memory function (Harper et al., 2005; Kay et al., 
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2010) despite still stimulating substantial 5-HT release (Baumann et al., 2008), with 
higher doses altering more general aspects of behaviour that interfere with performance 
on many behavioural memory tasks (e.g. Galizio et al., 2014; Kay et al., 2010). Lastly, 
recent studies have directly implicated DAergic substrates in MDMA’s effects on 
memory processes (Harper, 2013; Harper, Kay, & Hunt, 2011; Rozas et al., 2012). For 
example, in our laboratory it was demonstrated that acute MDMA (3 mg/kg) impaired 
performance on an operant delayed matching-to-sample (DMTS) working memory task, 
with this MDMA-induced deficit being ameliorated via concurrent administration of the 
DA D1-like receptor antagonist, SCH 23390 (Harper, 2013). Harper (2013) concluded 
that MDMA’s acute effects on memory performance may involve its agonist actions at 
DA D1 receptors. As discussed in more detail later in this chapter, the finding that D1 
receptors may be involved in MDMA’s effects on memory is not all that surprising given 
that this receptor is considered an important neural substrate for learning and memory 
(Castner, Williams, & Goldman-Rakic, 2000; Hotte et al., 2006; McNab et al., 2009; Nai 
et al., 2010).  
The caveats presented above suggest that some of MDMA’s effects on memory 
may be mediated by non-5-HTergic mechanisms. Possible sources of ambiguity in the 
interpretation of MDMA’s effects on memory are that the effects are typically attributed 
to 5-HT mechanisms even when markers of 5-HT integrity were not determined or 
deliberately manipulated (e.g. following MDMA administration, compromised 5-HT 
transmission is assumed and then associated with the observed cognitive impairments); 
and regardless of whether the drug regime was ‘acute’ (while under the influence of the 
drug), ‘sub-chronic’ (unclearly defined but approximately 1-4 days following drug 
treatment), ‘binge’ (high dose exposure) or ‘chronic’ (long-term effects). Due to previous 
findings in our laboratory centring on the acute actions of MDMA on memory 
performance (Harper, 2013; Harper et al., 2005; 2006), this PhD project further explores 
the hypothesis that acute MDMA acts to impair memory via its agonist actions at DA D1 
receptors from a behavioural neuroscience perspective.  
Although it is inaccurate to claim that all of MDMA’s effects on 5-HT are 
understood, by comparison MDMA’s effects on DA mechanisms have received 
considerably less attention. In vitro assay and in vivo microdialysis demonstrate that acute 
MDMA administration leads to pronounced increases in extracellular DA in the 
prefrontal cortex (PFC), striatum, nucleus accumbens (Nacc) and hippocampus (HPS) 
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(Baumann et al., 2008; Crespi, Mennini, & Gobbi, 1997; Gough, Ali, Slikker, & Holson, 
1991; Johnson et al., 1986; Shankaran & Gudelsky, 1998) and it has been suggested that 
the repeated use of MDMA may lead to a sensitised DA response that contributes to the 
transition from use to abuse (Schenk, 2011). The idea that DA may play a role in 
MDMA-induced memory deficits (Harper, 2013; Rozas et al., 2012) is in line with 
research suggesting that potent DA exerting drugs, such as methamphetamine (METH) 
and cocaine, also appear to impair memory via DA mechanisms (Macaskill, Harrow, & 
Harper, 2015; Shoblock, Maisonneuve, & Glick, 2003; Tomasi et al., 2007), and 
corroborates the large body of literature demonstrating that intact DA mechanisms, 
involving activation of D1-like receptors in mesocorticolimbic pathways, are required for 
normal memory function (Goldman-Rakic & Williams, 1995; Nai et al., 2010; Valentim 
Jr, Gontijo, Peres, Rodriques, & Nakamura-Palacios, 2009; Vijayraghavan, Wang, 
Birnbaum, Williams, & Arnsten, 2007).  
There is substantial evidence indicating that acute MDMA exposure can impair 
performance on learning and memory tests (Braida, Pozzi, Cavallini, & Sala, 2002; Bryne 
et al., 2000; Galizio et al., 2009; 2014; Harper, 2013; Harper et al., 2005; 2006; Hawkey 
et al., 2014; Kay et al., 2010; Kay, Harper, & Hunt, 2011; Kuypers & Ramaekers, 2005; 
2007; Marston, Reid, Lawrence, Olverman, & Butcher, 1999; Moyano et al., 2004; 
Moyano, Rio, & Frechilla, 2005). A central question of this project and a subject 
currently under consideration in the literature is whether these MDMA-induced 
performance deficits reflect a direct disruption of working memory processes or rather an 
indirect interference of working memory performance via alternative mechanisms 
(Galizio et al., 2014; Harper, 2013; Harper et al., 2005; Hawkey et al., 2014; Kay et al., 
2011). Initially, the finding that MDMA administration can cause impairments on tests 
used to assess working memory function led to the idea that MDMA directly impairs 
working memory processes (e.g. Braida et al., 2002; LeSage, Clark, & Poling, 1993; 
Marston et al., 1999). More recently, researchers probing the basis of MDMA’s effect on 
memory performance have implicated non-working memory processes as the source of 
the acute deficits.  
On many behavioural tests of memory designed for rodents, accurate responding 
is thought to involve two dissociable cognitive components: working memory and 
reference/procedural memory. Working memory can be thought of as task accuracy in 
situations where the appropriate response changes frequently (i.e. multiple times 
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throughout a session), which requires remembering episodic events occurring on a trial-
by-trial basis. In line with Baddeley’s (1986) conceptualisations, working memory 
involves the generation of internal representations of information, which are held and 
manipulated ‘online’ by executive systems, in order to guide action. By contrast, 
reference memory function is reflected by accurate responding when the appropriate 
response remains constant indefinitely across sessions. In this case, a pattern of behaviour 
is learned which does not need to be adapted trial-by-trial. The fact that many behavioural 
tests of memory confound assessment of reference versus working memory likely 
underlies the attribution of MDMA’s acute effects on performance to deficits in working 
memory. Using procedures that allow for the separation of working and reference 
memory components, recent studies have indicated that acute MDMA impairs reference 
memory processes (Braida et al., 2002; Galizio et al., 2014; Harper et al., 2011; Kay et 
al., 2010). The finding that acute MDMA impairs reference memory to a comparatively 
much greater extent than working memory is also consistent with several previous studies 
using non-acute regimes of MDMA administration (Able, Gudelsky, Vorhees, & 
Williams, 2006; Skelton et al., 2008; Sprague, Preston, Leifheit, & Woodside, 2003; 
Vorhees, Reed, Skelton, & Williams, 2004) as well as one study that did not explicitly 
tease apart working memory versus reference memory errors (Braida et al., 2002).  
However, the emerging theme that acute MDMA impairs reference rather than 
working memory does not provide a complete picture of MDMA’s acute effects on 
memory performance. Identifying the type of memory errors caused by acute MDMA is 
certainly useful, yet we also require a description of how the subjects’ pattern of 
responding is disrupted during MDMA exposure. To address this, a possible mechanism 
by which MDMA impairs memory in rodents has been presented on the basis of data 
collected in our laboratory (Harper and colleagues, 2005; 2006; 2011; 2013). Using the 
DMTS task, acute MDMA appears to decrease accuracy by increasing proactive 
interference. Specifically, when exposed to MDMA rats displayed response perseveration 
whereby they tended to repeat their response given on the directly previous trial, rather 
than performing the currently required response (Harper and colleagues, 2005; 2006; 
2011; 2013). The finding that MDMA increases perseveration has been reported 
elsewhere (Galizio et al., 2009; Montgomery, Fisk, & Newcombe, 2005; Verrico et al., 
2008), yet this phenomenon has not been fully characterised. Related to the previously 
mentioned possible role of DA D1 receptors in MDMA’s effect on memory performance, 
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Harper (2013) found that D1-like receptor antagonism attenuated MDMA’s effect on 
accuracy by directly decreasing perseverative responding. Therefore, this project will 
explore the idea that MDMA impairs performance on memory tests by increasing 
perseverative responding caused by MDMA’s agonist actions at DA D1 receptors. 
The current investigation expands on the finding that DA D1-like receptors are 
involved in MDMA’s impact on memory processes by examining D1 receptors in 
isolation from other binding sites, which are targeted by non-selective DA D1 receptor 
ligands. To isolate D1 receptors, a novel animal model with down-regulated DA D1 
receptor function – the DA D1 mutant (DAD1-/-) rat – will be used. As there are no 
published behavioural studies using the DAD1-/- rats to date, the first data chapter 
(chapter 3) presents a behavioural assessment of the DAD1-/- rats in a drug-free state, 
with regard to behaviours that are thought to engage D1 receptor processes. This 
behavioural profile is necessary in order to account for any baseline performance 
differences that may be present between the DAD1-/- rats and controls (DAD1+/- or 
DAD1+/+ rats). The next data chapter (chapter 4) investigates the DAD1-/- rats’ 
neurochemical response to acute MDMA using immunohistochemical analysis of c-fos 
expression in several brain regions with known DAergic innervation. This explores 
whether the DAD1-/- rats display an altered neurochemical response to MDMA, and 
allows for correlation between c-fos expression and MDMA-induced locomotor activity. 
Subsequent to the behavioural and neurochemical profiling of DAD1-/- rats, the last data 
chapter (chapter 5) presents an exploration of MDMA’s acute effects on memory 
performance and the role of D1 receptors.  
The following sections of the current chapter commence with a background to the 
use and effects of MDMA, with particular attention paid to MDMA’s acute actions 
observed in rat subjects. The involvement of DA and D1-like receptors in MDMA’s 
cognitive and behavioural effects are then outlined. The latter half introduces the DAD1-/- 
rat model and discusses the use of genetic animal models in behavioural neuroscience. 
Relevant behavioural and neurological functions involving DA and D1-like receptors are 
then summarised, which serve to guide the experimental direction of this project. Lastly, 
the three ensuing data chapters are outlined and the central questions of this thesis are 
stated. 
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A Background to MDMA Use and Abuse 
MDMA is a recreationally administered ring-substituted AMPH with both 
stimulant- and hallucinogenic- eliciting properties (Gold, Koob, & Meyer, 1988; Kalant, 
2001). MDMA is the active compound in street-sold ecstasy and, despite being a 
controlled substance in much of the world since the 1980s, is widely used in the club and 
rave scenes (Schwartz & Miller, 1997). High use of MDMA among the party scene likely 
reflects its unique profile of subjective effects which are viewed as complimentary to this 
setting. In general, a standard dose of MDMA (~ 75-120 mg) is reported to produce 
AMPH-like stimulation, perceptual alterations, and alertness, coupled with feelings of 
emotional closeness to others, euphoria and reduced anxiety (Baylen & Rosenberg, 2006; 
Peroutka, Newman, & Harris, 1988; Solowij, Hall, & Lee, 1992). Negative effects are 
also reported, including depersonalisation, anxiety, tachycardia and bruxism (Peroutka et 
al., 1988; Vollenweider, Gamma, Liecht, & Huber, 1998). This experience typically 
peaks 30-90 minutes after administration, before wearing off after 3-4 hours, sometimes 
followed by an extended comedown period of anhedonia (Cami et al, 2000; Cohen, 
1995).  
The interchangeable terms ‘entactogen’ and ‘empathogen’, denoting a class of 
psychoactive drugs, were coined in reference to the distinct spectrum of psychological 
effects produced by MDMA and related compounds such as 3,4-
methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-N-ethyl-amphetamine 
(MDEA), mephedrone, 2,5-dimethoxy-4-bromophenethylamine (2C-B) and 2C-I 2,5-
dimethoxy-4-iodophenethylamine (2C-I). Stemming from MDMA’s acute ability to 
engender emotional openness in this regard, there is a subset of psychotherapists and 
clinicians who have explored the use of low doses of MDMA as an in-session therapeutic 
tool for the treatment of post-traumatic stress disorder (PTSD) and related disorders 
(Bouso, Doblin, Farre, Alcazar, & Gomez-Jarabo, 2008; Hysek et al., 2013; Sessa, 2007). 
Evidence that MDMA may inflict 5-HT neurotoxicity, and that MDMA use is associated 
with cognitive impairments and other negative effects, warrants caution going forward 
with further pre-clinical research necessary to elucidate the short- and long-term effects of 
MDMA prior to human trials.  
A brief history of MDMA/”the truth of MDMA” (Wolfson, 1986). MDMA has 
been among the most popular psychotropic drugs since the mid-1980s (Freudenmann, 
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Öxler, & Bernschneider‐Reif, 2006), yet it was synthesised considerably earlier than this. 
In the medical literature, it is often reported that MDMA was originally patented in 
Germany in 1912 by a pharmaceutical company, Merck, as an appetite suppressor or 
anorectic drug (Climko, Roehrich, Sweeny, & Al-Razi, 1986; Kalant, 2001). Contrary to 
this assertion, however, and after examination of primary documents from Merck’s 
archives, Freudenmann et al. (2006) concluded that although MDMA was synthesised by 
Merck in 1912, it was developed as a precursor in a novel chemical pathway for a blood 
clotting agent. During their investigation into the origin of MDMA, Freudenmann et al. 
(2006) also uncovered the first two documented instances, in 1927 and 1959, of basic 
pharmacological testing of this compound, which at the time was called 
‘Methylsafrylamin’. The first instance of a regular scientific publication on MDMA was 
not until 1960 (Biniecki & Krajewski, 1960), yet merely a decade later MDMA tablets 
were first seized and identified from the streets of Chicago (Gaston & Rasmussen, 1972).  
The first known animal experiments using MDMA were conducted over 1953-54 
but were not published until 1973 due to being a classified project supported by the US 
army (Hardman et al., 1973). These experiments used MDMA as one of seven chemical 
analogues of lysergic acid diethylamide (LSD) in order to test the toxicity and 
behavioural correlates of LSD in five species of lab animals: the mouse, rat, guinea pig, 
dog and monkey. Based on these data, it was later concluded that MDMA was less toxic 
than MDA but more toxic than LSD (Shulgin, 1986).  
It took another five years after the publication of the initial toxicology study, 
reported by Hardman et al. (1973), before the first non-clinical reports of the effects of 
MDMA were described in humans (Shulgin & Nichols, 1978). However for at least two 
years prior, MDMA’s entactogenic properties were being employed by clinical 
psychologists who freely administered this psychostimulant to patients during therapy 
sessions to aid in the establishment of rapport between patient and therapist and to elicit 
an openness of emotional expression (Greer, 1985; Shulgin, 1990; Wolfson, 1986). 
Wolfson (1986) eloquently conveyed the opinion of MDMA-proponent therapists in his 
account of “The Truth of MDMA” (pp. 331): 
“The fundamental truth is that MDMA provides in its totality an unprecedented 
access to an experience that human beings value and may wish to have the opportunity to 
repeat at a future date. The second part of this truth is the almost uniform observation 
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that those who have had the MDMA experience wish to share it with others and believe it 
has the ability to alter lives, even societies, positively. Nor has anyone been able to say 
otherwise after hundreds of thousands of experiences with MDMA. This is the completion 
of the fundamental truth: there are almost no critics of the experience itself.” 
Wolfson’s assertion that people wish to repeat the MDMA experience appears to 
inadvertently prophesise our current conceptualisations of MDMA dependence (described 
below). Considering MDMA’s acute subjective effects, it is not surprising that during the 
late 1970s in the USA MDMA use acquired fervent support among rave goers, despite 
public controversy and outcry from those opposed to this new psychostimulant (Shulgin, 
1990). Early reports of MDMA use were limited to case studies and prevalence data, with 
popular opinion spreading that MDMA was not addictive and that it was infrequently 
used for recreational purposes (Peroutka, 1990; Solowij et al, 1992). The term ‘ecstasy’ 
was coined in California in 1984, only one year before the American Drug Enforcement 
Agency, listed MDMA as a Schedule I controlled substance, officially coming into effect 
on 1 July 1985 (The New York Times, 1985) despite little evidence of reported MDMA 
harm at that stage. Soon after, many other countries followed America’s lead and also 
prohibited MDMA, including New Zealand in 1987 (www.drugfoundation.org.nz).  
The recreational use of MDMA and ecstasy began escalating worldwide from the 
late 1990s (Schifano, Corkery, Deluca, Oyefeso, & Ghodse, 2006). The United Nations 
Office on Drugs and Crime (UNODC) estimated that, globally, around 19 million 
(between 10 and 28 million people or 0.2 - 0.6 per cent of the population) aged 15-64 
used ecstasy at least once in 2012 (UNOCD, 2015). Although worldwide ecstasy use 
appears to be in gradual decline, prevalence rates for Europe, North America and Oceania 
(including New Zealand at 2.9 per cent) remain above the global average (UNOCD, 
2015).  
MDMA use in New Zealand. MDMA is the second most frequently used illegal 
substance in New Zealand, after cannabis. The detrimental repercussions stemming from 
use of ecstasy have been identified as a significant area of concern for New Zealand (NZ) 
(Wilkins et al., 2004). The prevalence of MDMA use and manufacture in NZ has rapidly 
increased over recent years (Ministry of Health, 2010; Wilkins, 2002; Wilkins, Bhatta, 
Pledger, & Casswell, 2003; Wilkins & Sweetsur, 2008), with a corresponding surge in the 
amount of MDMA seized by customs and a rise in the number of clandestine drug 
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laboratories that manufacture MDMA (and other AMPH-type substances; ATS) being 
detected by the NZ police (Wilkens, 2002). The most recent data available on ecstasy use 
in New Zealand was sampled during the 2007/08 period (Ministry of Health, 2010) which 
estimates that, across 16 – 64 year olds, 2 – 3.1 per cent of people used ecstasy at least 
once in the previous year. By comparison, the global prevalence of people aged 15 - 64 
years, also surveyed in 2007, was estimated as 0.2 per cent of people aged between 15 – 
64 year old (UNODC, 2008). This clearly illustrates the high rate of ecstasy use in New 
Zealand compared to the global scene.  
The rise in consumption of MDMA throughout NZ has been linked to parallel 
increases in a myriad of social and health consequences, including hospital admissions for 
drug-induced psychosis, violent crimes and thefts (Wilkins, 2002), cases of mental 
illness, injury while under the influence of MDMA, incidences of domestic violence, 
relationship breakdown, and child neglect (Wilkins & Sweetsur, 2008). Despite our 
awareness of these detrimental outcomes stemming from the manufacture, sale and use of 
MDMA, efforts to regulate MDMA have been met with limited success. An improved 
understanding of the effects of MDMA would allow for informed and evidence-based 
decision making about, and attitudes towards, the use of MDMA. 
Studying MDMA’s actions: Problems with using human participants. 
Studying human users to examine the effects of MDMA is problematic. Firstly, ecstasy 
users are often consumers of a variety of other drugs, such as cannabis, alcohol, opiates 
and other ATS (Schifano, Di Furia, Forza, Minicuci, & Bricolo, 1998). This makes it 
difficult to separate the effects that derive from MDMA use from those of other drugs. 
Secondly, whilst the main stimulant ingredient of street-sold ecstasy tablets is purported 
to be MDMA, the purity of ecstasy can change dramatically (UNODC, 2015; Parrott, 
2004; Schifano et al., 2006) meaning that the perception of an ecstasy users’ MDMA 
consumption may not reflect their actual MDMA consumption. Thirdly, the use of human 
subjects in MDMA trials may be confounded by the characteristics of the people that 
volunteer their participation in such research, with regard to their past drug histories, 
personality attributes and attitudes. Fourth, it is not feasible to detect subtle neurological 
pathologies caused by MDMA, or to map the drug’s mechanism of action, in living 
subjects. Fifth, necessary ethical considerations regarding the administration of MDMA 
to human subjects can constrain the ability of researchers to carry out controlled studies 
using large subject numbers or high doses of MDMA, leading to self-report measures of 
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drug use being a main source of data in this area (Schifano et al., 1998). Lastly, studies 
that report measures of brain activity in human drug users (in which no drugs are 
administered) necessarily rely on correlational analysis to determine whether drug use is 
associated with a particular pattern of activity which in turn is associated with 
assessments of cognitive ability. This means that the possibility that there are pre-existing 
differences between drug-using versus non drug-using participants which influenced drug 
taking behaviour cannot be ruled out.  
In light of the above limitations, it can be difficult to interpret findings from 
human studies that investigate the impacts of drugs on brain function. As such, the use of 
animal models to investigate the neurological actions of drugs of abuse has been 
invaluable. Due to shared ancestry between mammalian genomes and the subsequent 
structural and functional similarities at the levels of anatomy, cell biology and 
physiology, the appropriate use of animal testing to study human pathology is highly 
relevant. This approach also affords stringent control over the test subjects’ genetic and 
environmental backgrounds, which minimises confounds and reduces statistical variance. 
Within the context of MDMA research the use of rats is favoured over the use of mice 
subjects due to mice demonstrating a response to MDMA characterised by long-term DA 
depletions rather than 5-HT depletions, which is typical of rats, humans and non-human 
primates (for a review see Colado et al., 2004). The following section deals with evidence 
pertaining to the pharmacology and physiological effects of MDMA that has, unless 
specified, been determined using rats.  
The pharmacology and physiological effects of MDMA. MDMA is a 
synthesised ‘designer drug’, with early clandestine laboratories seeking to create a blend 
of stimulant ‘AMPH-like’ and hallucinogenic ‘mescaline-like’ effects (Climko et al., 
1986). MDMA is a derivative of METH – its parent compound is AMPH – however its 
chemical structure differs from these related stimulants in one vital respect (see figure 1). 
MDMA is “ring substituted” meaning that it has a methylenedioxy (-O-CH2-O) group 
attached to positions 3 and 4 of the aromatic ring of the AMPH molecule (Kalant, 2001). 
MDMA is a substrate for monoamine transporters (Baumann et al., 2007), and broadly 
speaking its biological effects appear similar to 5-HT, DA and epinephrine (EP) 
stimulation (Kalant, 2001).  
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Figure 1. Comparison of amphetamine (AMPH), methamphetamine (METH), 3,4-
methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) 
molecules. Sourced from Baumann et al., 2007. 
 
Although MDMA has in common with its AMPH analogs (and other drugs of 
abuse) the ability to stimulate action of brain DA, MDMA has a unique pharmacological 
profile compared to other drugs. In vivo rat brain slice and in vitro microdialysis 
experiments demonstrate MDMA’s enhanced potency for 5-HT stimulation, and 
decreased potency for DA release (Baumann et al., 2005; 2007; Gudelsky & Nash, 1996). 
Dialysate samples from rat Nacc collected 20 minutes after i.p. injection of 1 mg/kg 
MDMA showed a tenfold rise in 5-HT, but only a twofold rise in DA (Baumann et al., 
2007). The mechanism by which MDMA stimulates the release of monoamines is largely 
through binding to transporter proteins (5-HT: SERT; DA: DAT; NE: NET) and 
stimulating reverse-transport, non-exocytotic release of 5-HT, DA and NE (Berger, Gu, & 
Azmitia, 1992; Crespi et al., 1997; Green, Mechan, Elliot, O’Shea, & Colado, 2003). 
Furthermore, MDMA prevents vesicular uptake of cytosolic 5-HT (Battaglia, Brooks, 
Kulsakdinun, & Souza, 1988; Rudnick & Wall, 1992).  
The acute physiological effects of MDMA administration vary, depending on dose 
and route of administration and the users’ immediate environment. Typically, human 
users ingest MDMA orally (ecstasy or ‘E’ tablets) or by snorting the powder. A standard 
dose administered is 1-2 ecstasy tablets or approximately 80-100 mg of MDMA (although 
the dose can vary considerably), equating to around 1-3 mg/kg (Green et al., 2003; 
Schifano, 2004). Given that the acute neurochemical, endocrine and behavioural effects 
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of MDMA are similar across rats and humans when using comparable doses (e.g. 1-3 
mg/kg) (Baumann et al., 2007), the physiological effects of MDMA as measured in rats 
will be described below.  
Preferential stimulation of 5-HT is thought to be at the root of MDMA’s primary 
acute physiological effects (Colado & Green, 1994; Green, O’Shea, & Colado, 2004) with 
the two most widely reported being hyperthermia (Dafters, 1995; Gordan, Watkinson, 
O’Callaghan, & Miller, 1991; Nash, Meltzer, & Gudelsky, 1988) and symptoms of ‘5-HT 
syndrome’ (Parrott, 2002; Slikker et al., 1989; Spanos & Yamamoto, 1989). Although 
limited research has looked at the hyperthermic response to MDMA, it can be reversed 
through pre-treatment with 5-HT antagonist ketanserin (Nash et al., 1988). 5-HT 
syndrome, however, has been the subject of intense investigation and its mechanisms are 
still unclear. It is characterised by hyperlocomotion, reciprocal forepaw treading, head 
weaving, piloerection, flattened body posture, hind limb abduction, proptosis, ataxia, 
unawareness, and when particularly severe, leading finally to convulsions and death 
(Green & Heal, 1985). Other physiological effects include elevated heart rate and mean 
arterial pressure (O’Cain, Hletko, Ogden, & Varner, 2000). 
Administration of MDMA can lead to chronic selective dysfunction in markers of 
5-HT transmission after only a single high dose, and certainly after repeated doses 
(Battaglia et al.,1987; Benningfield & Cowan, 2013; McCann et al., 1998; Molliver et al., 
1990; Parrott, 2002; Schmidt & Kehne, 1990; Souza et al., 1990). There is on-going 
debate over whether the observed 5-HT dysfunction reflects 5-HT neurotoxicity or 
another mechanism that disrupts 5-HT transmission more transiently (see Baumann et al., 
2007). Common findings used to support the hypothesis that MDMA is neurotoxic to 5-
HT neurons are that MDMA administration reduces 5-HT nerve terminal integrity 
(Sprague et al., 2003), causes persistent inactivation of tryptophan hydroxylase activity 
(the rate limiting step in 5-HT synthesis), depletes brain tissue 5-HT and reduces SERT 
binding and functions (Battaglia et al., 1987; Schmidt et al., 1987). Using 
immunohistochemistry O’Hearn et al. (1988) found cortical and subcortical areas 
displayed 5-HT neuron axon and terminal loss after MDMA treatment, and axon and 
terminals that remained demonstrated structural damage. Despite these markers of 
compromised 5-HT nerve terminal integrity, Baumann et al. (2007) argue that there are 
several caveats to the hypothesis that MDMA causes 5-HT neurotoxicity. Briefly, 
MDMA-induced reductions in 5-HT function and SERT binding have been found to 
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recover (Scanzello, Hatzidimitriou, Martello, Katz, & Ricaurte, 1993). Also, other drugs 
that are not considered to be neurotoxins, such as selective 5-HT re-uptake inhibitors 
(SSRIs), demonstrate similar effects such as sustained depletions of brain tissue 5-HT and 
decreased SERT binding. SSRIs have even been found to cause structural damage to 5-
HT terminals, resembling MDMA damage (Kalia, 2000). While collectively these data do 
suggest that 5-HT terminals are not destroyed subsequent to MDMA exposure, the debate 
remains open.  
Evidence for MDMA dependence. The focus of this thesis is on the acute effects 
of MDMA and as such it is only partially relevant to provide an analysis of MDMA 
dependence. However, possibly the most important reason we study drugs of abuse, at all 
levels of analysis, is because some people transition from casual drug use to compulsive 
drug taking, leading to a myriad of health risks and psychological and social harms 
(Everitt & Robbins, 2005). Evidence for dependency, then, further necessitates an 
understanding of MDMA’s acute effects.  
Although MDMA was originally conceived of as a non-addictive substance 
(Peroutka, 1990), there is now evidence that some human users meet criteria for MDMA 
dependency, albeit to a lesser extent than for other drugs of abuse that elicit greater DA 
stimulation (Degenhardt, Bruno, & Topp, 2010; Jansen, 1999; von Sydow, Lieb, Pfister, 
Höfler, & Wittchen, 2002). An important paradigm used to model addiction in animal 
subjects is the self-administration paradigm (described in more detail by Schenk, Gittings, 
Johnstone, & Daniela, 2003). When used with rats, a typical procedure involves placing 
the subject in an operant chamber where they are presented with two levers: an active 
lever that, upon depression, leads to infusion of drug directly into the subject’s jugular 
vein, and an inactive lever, the pressing of which leads to an infusion of saline. Animals 
will self-administer drugs that are abused by humans (Pickens & Harris, 1968; Schenk & 
Partridge, 1997; Schenk et al., 2003) and invariably these drugs stimulate substantial 
release of mesolimbic DA, particularly in the Nacc (Chiara & Imperato, 1988). Under 
normal conditions, 80 – 100 % of rats will acquire self-administration of classic drugs of 
abuse such as cocaine and AMPH (e.g. Carroll & Lac, 1997), whereas only 50 – 60 % of 
rats will reliably self-administer MDMA (Bradbury et al., 2014; Schenk, Colussi-Mas, 
Do, & Bird, 2012; Schenk et al., 2007).  
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One hypothesis for why MDMA self-administration is lower than for other drugs 
of abuse predicts that the massive release of 5-HT following MDMA administration 
inhibits or flattens the reinforcing effects of MDMA (Bradbury et al., 2013; Oakly et al., 
2014; Schenk, 2011). Neurotoxic lesions to 5-HT systems have been found to greatly 
enhance the reinforcing properties of MDMA (Bradbury et al., 2013), and using in vivo 
microdialysis it was demonstrated that subjects which self-administer MDMA have a 
correspondingly smaller 5-HT response to MDMA than subjects which failed to meet the 
criteria for MDMA self-administration (Bradbury et al., 2013). With repeated exposure to 
MDMA, subjects can develop tolerance (when a substance has a progressively diminished 
effect) to the 5-HTergic properties of MDMA (Do & Schenk, 2013), with behavioural 
markers of acute 5-HT syndrome following MDMA in rats appearing less pronounced 
over time (Marston et al., 1999). Simultaneously, subjects develop sensitisation (when a 
substance has a progressively increased effect) to the DAergic component of MDMA 
(Bradbury, Gittings, & Schenk, 2012). Repeated exposure to acute MDMA administration 
in rats leads to incremental increases in locomotor activity across sessions, with this 
increase in activity being associated with DA stimulation (Bradbury et al., 2012; Schenk 
& Bradbury, 2015). A sensitised response to the DA-stimulating effects produced by 
drugs of abuse is thought to increase wanting for the drug, rather than liking, resulting in 
escalated drug taking (see below for discussion of the incentive salience hypothesis which 
provides a description of DA’s role in reward – Berridge & Robinson, 1998). Thus, the 
neuroadaptions underlying both tolerance and sensitisation to MDMA appear to interact 
to increase the likelihood that a subject will develop MDMA self-administration, or 
dependence, over time.  
Consistent with animal studies, investigations of patterns of MDMA use in human 
subjects have found that with repeated exposure, more experienced users gradually 
increase their MDMA dose often by several times over. Initially, users typically 
administer 1-2 tablets, whereas more experienced users may administer 2-3 and some 
people have admitted to using 10-25 tablets in a single session (Parrott, 2005). 
Worryingly, compared to cocaine or heroin users, MDMA-dependent individuals were 
found to report less desire to decrease their drug consumption, less desire to receive help 
for their drug taking, and fewer risks associated with their drug taking (Uosukainen et al., 
2015). Given that MDMA is considered an addictive substance, and in combination with 
the detrimental effects of MDMA use, especially, as discussed below, on cognitive 
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functions, comprehensive analysis of the behavioural and neurochemical effects of 
MDMA is warranted.  
MDMA-induced cognitive changes.  
Cognitive changes associated with chronic or binge MDMA exposure. Even 
after long periods of abstinence, human users of MDMA often exhibit persistent cognitive 
changes, most notably on tasks of memory such as deficits in verbal recall (Bolla, 
McCann, & Ricaurte, 1998; McCardle, Luebbers, Carter, & Croft, 2004; Morgan, 
Impallomeni, Pirona, & Rogers, 2006; Parrot & Lasky, 1998; Parrott, Lees, Garnham, 
Jones, & Wesnes, 1998; Quednow et al., 2006), increased impulsivity (Clark, Robbins, 
Ersche & Sahakian, 2006; Morgan, McFie, Fleetwood, & Robinson, 2002; Morgan et al., 
2006; Quednow et al., 2007) and impaired executive functions including decision making 
and attention (Morgan et al., 2006; Quednow et al., 2007). As previously noted, the most 
consistent neurochemical outcome stemming from repeated or high doses of MDMA 
exposure in rat subjects is a reduction in markers of 5-HT neurotransmission. It has been 
commonplace for researchers to draw on these neurochemical studies using rats and 
attribute MDMA’s disruptive effects on cognition in human subjects to compromised 5-
HT function. For example, Quednow et al. (2007) investigated impulsivity and decision-
making in a group of heavy ecstasy users. This study employed remarkably strict 
inclusion criteria, recruiting individuals that used MDMA 50 or more times over the past 
year, had less history with other psychotropic drugs other than MDMA, had no family 
history of a severe mental illness, no current mental illness and no history with legitimate 
psychotropic medication as well as produce a clean drug test by way of urine sample. 
Using the go/no go task to measure impulsivity, and an adaptation of the Iowa gambling 
task to measure decision making, they found that heavy ecstasy users were significantly 
impaired on both tasks compared to drug naïve participants. Quednow et al. (2007) 
interpreted these findings in line with neurochemical studies using animal subjects that 
present evidence of 5-HTergic dysfunction following chronic MDMA exposure and 
argued that the deficits observed were consistent with a 5-HT deficit. However, without 
the ability to directly measure 5-HT integrity when employing human participants, it is 
difficult to be confident when considering the source of the various cognitive deficits 
associated with MDMA use. Furthermore, neurochemical studies suggesting that MDMA 
is neurotoxic to 5-HT neurons in rats use extremely high doses of MDMA which are 
generally well higher than those taken by human MDMA users (e.g. Battaglia et 
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al.,1987). Behavioural studies in rats using doses of MDMA that are comparable to those 
taken by human users are therefore important for investigating the neurological changes 
responsible for the chronic cognitive deficits observed following MDMA exposure.  
Although some of the evidence is mixed, cognitive changes stemming from prior 
administration of MDMA in rats is fairly consistent with the human literature. Previous 
MDMA exposure in rats has been associated with decreased sustained attention (Dalley et 
al., 2007; Piper et al., 2005), impaired effort-based decision making (Schulz, Becker, 
Nagel, Ameln-Mayerhofer, & Koch, 2013) and impaired memory performance, which is 
characterised by an increase in reference as opposed to working memory errors (Able et 
al., 2005; Harper et al., 2013; Kay et al., 2011; Piper & Meyer, 2004; Skelton et al., 2008; 
Sprague et al., 2003; Vorhees et al, 2004). Again, although researchers typically attribute 
these cognitive impairments to 5-HT dysfunction, there is evidence that MDMA’s effects 
on memory performance involve non-5-HT mechanisms. For example, rats repeatedly 
administered MDMA for four consecutive days demonstrated a pronounced 5-HTergic 
deficit seven days after the drug treatment, yet these 5-HT depleted animals do not 
display a memory deficit on passive avoidance learning when tested at this time (Artaiz, 
Del Rio, & Lasheras, 1996; Barrionuevo, Aguirre, Del Rio, & Lasheras, 2000; Moyano et 
al., 2005), although impairments were observed on the days on which rats were treated 
with MDMA. What is more, other experimental manipulations causing compromised 5-
HT integrity, such as treatment with the 5-HT synthesis inhibitor PCPA, have been found 
to have no disruptive effects on memory performance using passive avoidance learning 
(Misane, Johansson, & Ove Ogren 1998; Moyano et al., 2004).  
While prior MDMA exposure may not always cause lasting memory deficits, such 
as with passive avoidance learning, indicating that memory function may not be impaired 
by MDMA-induced disruptions of 5-HT, other studies have found lasting memory 
impairments following repeated administration of MDMA which may relate to 
compromised 5-HT function (e.g. Able et al., 2005; Harper et al., 2013; Piper et al., 2004; 
Skelton et al., 2008; Vorhees et al, 2004). Furthermore this could indicate that the passive 
avoidance learning task is not sensitive enough to detect long-term cognitive changes 
caused by MDMA. Thus it is valuable to further investigate the relationships between 
chronic MDMA exposure, 5-HT function and memory performance using a wider range 
of behavioural paradigms. However, there may be other factors contributing to MDMA’s 
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disruptive effects on memory given that neurotoxic regimens of MDMA and 5-HT 
disruptive compounds do not necessarily produce learning and memory deficits in rats.  
One marked discrepancy between investigations of human users of MDMA and 
rats treated with MDMA relates to measures of long-term changes in impulsivity. Despite 
long-term increases in impulsivity being a major finding in studies of human MDMA 
users, rats treated with MDMA do not exhibit long-term changes in impulse control (Bird 
& Schenk, 2013; Dalley et al., 2007; Saadat, Elliott, Green, & Moran, 2006), even after 
MDMA administration led to long-term decreases in markers of 5-HT transmission 
(Saadat et al., 2006). However, what animal studies can contribute to the debate regarding 
chronic MDMA exposure and impulsivity is that individuals with high basal levels of 
impulsivity (i.e. trait impulsivity rather than manipulating impulsivity by way of lesions 
or pharmacological application) may be more vulnerable to developing addiction-like 
behaviours (Bird & Schenk, 2013). Indeed, that impulsivity is a predisposing factor to 
addiction-like behaviours has been demonstrated using a wide range of drugs of abuse 
(Jupp, Caprioli, & Dalley, 2013; Molander et al., 2011).  
The inconsistent conclusions deriving from human versus rat subjects in terms of 
MDMA’s long-term effects on impulsivity illustrates the limitations to studying long-
term drug effects in human users. The inability to control for poly-drug use and pre-
existing individual traits when employing human subjects means that the direction of 
causal relationships, i.e. whether a drug causes a particular effect or conversely whether a 
trait increases the likelihood of drug taking, may be misinterpreted. With this in mind, the 
acute effects of MDMA on cognition, discussed below, were gleaned from studies using 
non-human animal subjects.  
Cognitive changes associated with acute MDMA exposure: Proactive 
interference (perseveration) and DA D1-like receptors. The most frequent cognitive 
deficit reported subsequent to acute MDMA exposure in rats is impaired memory 
performance. Memory performance deficits following acute MDMA administration have 
been observed using a variety of procedures including DMTS (Harper, 2013; Harper et 
al., 2005; 2006), the radial arm maze (Braida et al., 2002; Harper et al., 2011; Kay et al., 
2010) passive avoidance learning (Moyano et al., 2004; 2005), the double Y-Maze 
(Young, McGregor, & Mallet, 2005), repeated acquisition procedures (Galizio et al., 
2009; 2014) and the olfactory Span Task (Hawkey et al., 2014). As previously noted, the 
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memory deficits seen on these tasks tend to emerge, or are at the greatest magnitude, 
when MDMA is administered systemically at a dose of ~3 mg/kg (Galizio et al., 2009; 
2014; Harper, 2013; Harper et al, 2005; 2006; Hawkey et al., 2014; Kay et al., 2010), 
with lower doses often leaving performance intact (Frederick, Gillam, Allen, & Paule, 
1995) and higher doses often causing a more general behavioural impairment, meaning 
subjects can no longer perform the task (Galizio et al., 2014; Kay et al., 2010). Of 
particular relevance is that when MDMA is administered at a dose of 3 mg/kg, as opposed 
to at a lower dose, there is a relatively greater increase in MDMA-induced synaptic DA 
relative to 5-HT measured using microdialysis (Baumann et al., 2007). Correspondingly, 
the discriminative stimulus properties of MDMA appear to be more DAergically 
mediated when administered at 3 mg/kg (Harper et al., 2014).  
Consistent with the effects of chronic administration of MDMA, acute MDMA 
has been found to increase reference memory-type errors (Braida et al., 2002; Galizio et 
al., 2014; Kay et al., 2010). The idea that MDMA impairs reference rather than working 
memory is relatively recent, possibly because many behavioural tests of memory 
confound working and reference memory processes. By using carefully designed 
behavioural studies, researchers can tease apart working and reference memory 
components in order to study MDMA’s effects on memory performance. Harper et al. 
(2005) used an operant DMTS task in which rats were reinforced when they responded on 
the lever that they were presented with at the beginning of the trial. Harper et al. (2005) 
found that MDMA’s detrimental effects on accuracy were delay-independent meaning 
that when there was no delay between sample presentation and choice selection, rats still 
demonstrated a deficit in performance during acute MDMA exposure. Presumably under 
conditions of no delay working memory processes are not required for accurate 
responding. Given that the nature of the memory impairments caused by MDMA could 
not always be attributed to working memory deficits, alternative avenues have been 
explored.  
Using a version of the radial arm maze that allows for separation of reference 
versus working memory errors, Kay et al. (2010) found that acute MDMA significantly 
increased reference memory errors to a greater extent than working memory errors. Akin 
to reference memory errors on the radial arm maze, Galizio et al. (2014) found that acute 
MDMA disrupted responding on the stable-response component during a repeated 
acquisition procedure. By employing alternating multiple schedules, rats were tested on 
30 
 
‘place acquisition learning’ (where the correct response changes across sessions) as well 
as ‘performance’ (where the correct response remains constant across sessions). Galizio et 
al (2014) found that doses of MDMA which impaired accuracy of place acquisition 
learning also impaired performance of the previously well-learned response, with the 
authors interpreting this finding as reflecting a reference memory deficit. That MDMA 
produces an increase in reference memory errors implies that MDMA interferes with the 
general rules or strategies required for accurate responding on memory tasks (Kay et al., 
2010) while leaving episodic memory for events and stimuli encountered during a session 
or trial (i.e. working memory) relatively intact.  
A possible mechanism underlying the reference memory impairment observed 
during MDMA exposure has been proposed by Harper and colleagues (2005; 2006; 2013) 
on the basis of findings using an operant-based DMTS task with rats. At the start of each 
DMTS trial, one lever was inserted into the chamber (either on the left or right side of the 
chamber) and rats were trained to press on this lever. After an intervening second lever 
press on the back chamber lever, rats were presented with both the left and the right front 
levers (choice phase) and were required to respond on the lever that they were presented 
with during the sample phase. Acute MDMA administration produced a pattern of errors 
indicative of perseverative responding, or proactive interference, in that rats made 
response errors characterised by the repetition of a choice made on the immediately 
preceding trial, as opposed to the current trial’s required response (Harper, 2013; Harper 
et al., 2005; 2006). When the delay between the sample and choice phases was increased, 
acute MDMA-induced proactive interference was alleviated, suggesting that the rats 
could still respond accurately under MDMA exposure, again demonstrating intact 
working memory processes. Furthermore, Harper (2013) found that the MDMA-induced 
perseverative pattern of responding was ameliorated via concurrent administration of the 
DA D1-like receptor antagonist SCH 23390. This finding is interesting because it 
provides the starting point for a novel exploration of a mechanism by which MDMA may 
impair behavioural responses at the acute level. That D1-like receptors may be molecular 
targets through which MDMA induces response perseveration also coincides with 
previous literature suggesting that D1-like receptors may mediate perseverative 
responding (Diekamp, Kalt, Ruhm, Koch, & Güntürkün, 2000; Ralph, Paulus, Fumagalli, 
Caron, & Geyer, 2001; Zahrt, Taylor, Mathew & Arnsten, 1997).  
31 
 
In contrast to the finding that chronic MDMA administration does not lead to 
long-term increases in impulsivity in rats, acute and sub-chronic MDMA exposure does 
tend to increase behavioural impulsivity in rats (Bird & Schenk, 2013; Dalley et al., 2007; 
van Wel et al., 2012). Impulse control critically depends on intact monoaminergic 
corticostriatal projections, and in particular on DA systems in the frontal cortex (for a 
review see Jupp et al., 2013), suggesting that MDMA’s acute effects on DA transmission 
may contribute to the increase in impulsive behaviour observed during drug treatment. 
Related to the previous discussion of MDMA-induced perseveration, impulsive 
responding and perseverative responding may involve overlapping neural mechanisms in 
that they are both intimately related to frontally-mediated executive functions, including 
attention and decision-making processes (Chadasama et al., 2003; Robbins, Weinberger, 
Taylor, & Morris, 1996).  
The current project aims to expand on the finding that DA D1 receptors may be a 
target through which MDMA induces response perseveration. However, there are 
limitations to using pharmacological agents that block or potentiate action at the DA D1 
receptor site (discussed below). Recently, a novel genetic animal model was generated 
that provides an exciting new avenue regarding isolation of DA D1 receptor function. The 
following sections of this thesis will 1. provide background to genetic animal models used 
frequently in behavioural neuroscience; 2. present the novel animal model used here – the 
DAD1-/- rat; 3. discuss relevant functions of D1-like receptors and finally, 4. describe the 
present investigation.   
Using the DAD1-/- Rat Model to Investigate the Acute Effects of MDMA on Memory 
Performance 
A brief history of transgenic mice models and the introduction of rat genetic 
models. During the 1980s behavioural neuroscientists and geneticists witnessed the 
development and proliferation of targeted gene mutation technologies in mice. There are 
now a number of procedural variations used to create transgenic mice, one main 
procedure being the insertion of mutated complementary DNA (cDNA) into embryonic 
stem cells (Crawley, 2007). Genetic engineering in mice has enabled researchers to create 
behavioural models of human psychiatric, neurodegenerative and neurodevelopmental 
diseases and to further our understanding of how genes shape behaviour (Crawley, 2007). 
Despite these methodological advances using mice, the ability to target genes in rats has 
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been hindered, in part, due to their lack of suitable embryonic stem cells. Rats are an 
extremely valuable model organism and have been used extensively in behavioural and 
biological research. Rats are larger than mice and have more accessible brains, and many 
organ specific disease models have been tailored to the rat. Many behavioural paradigms 
are specially designed and standardised for use with rats and considering the wealth of 
data generated using such paradigms, genetically modified rat models would be an 
important tool for behavioural neuroscientists and geneticists alike. What is more, rats 
and mice have been found to differ in their pharmacological responses to some drugs, 
such as MDMA, with rats’ responses often corresponding to those of human and non-
human primate subjects. For example, a well-documented finding is that in rats, humans 
and non-human primates, exposure to high doses of MDMA compromises 5-HT, but not 
DA, systems (Battaglia et al .,1987; Benningfield & Cowan, 2013; McCann et al., 1998; 
Molliver et al., 1990; Parrott, 2002; Schmidt & Kehne, 1990; Souza et al., 1990), yet the 
converse is true for mice (Colado et al., 2001; Logan, Laverty, Sanderson, & Yee, 1988). 
Considering these differences, it would be a major advantage to have both rat and mice 
gene mutant and knockout (KO) models available in order for researchers to select the 
most appropriate model to suit their investigation.  
Using selective inbreeding programmes, many phenotypic rat models have been 
developed that exhibit biomedical traits relevant for human pathological conditions 
(Jacob & Kwitek, 2002). It would greatly aid our understanding and treatment of such 
conditions if we were able to identify the underlying gene mutations. In the early to mid-
2000s, the genome of the laboratory rat Rattus norvegicus was sequenced by the Rat 
Genome Sequencing Consortium, highlighting a recent effort to establish the rat as a 
genetic model. At a similar time, the first strains of KO rat models using N-ethyl- N-
nitrosourea (ENU)-driven target selected mutagenesis were created (Smits et al., 2006; 
Smits, Mudde, Plasterk, & Cuppen, 2004; Zan et al., 2003). The current research serves to 
report a battery of behavioural experiments conducted using one of these novel rat 
models: the DA D1 receptor mutant (DAD1-/-) rat (Smits et al., 2006). The phenotypic 
characterisation of this novel rat genotype is of great importance, as it is likely to become 
a useful tool with which to investigate the behavioural functions of DA D1 receptors.  
Dopamine, D1-like receptors and the DAD1-/- rat. DA is the predominant 
catecholamine neurotransmitter in the mammalian brain where it is involved in the regulation 
of memory, impulsivity and decision making, reinforcement and motivation, endocrine 
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regulation, and locomotion. There are four major DA pathways in the central nervous system 
(CNS; figure 2). DA cell bodies located in the ventral tegmental area (VTA) project to limbic 
regions, including the Nacc and septal nuclei, and to the frontal cortex, comprising the 
mesolimbic and mesocortical pathways, respectively. Primarily, mesocorticolimbic systems 
mediate DA’s role in reward and the attribution of incentive salience to reward-related stimuli 
(Berridge, 2007; Pierce & Kumaresan, 2006), as well as learning and memory processes 
(Cools & D’Esposito, 2007). Projections originating from DA cell bodies located in the 
substantia nigra pars compacta (SNPc) innervate the dorsal striatum and form the nigrostriatal 
pathway. The nigrostriatal pathway is involved in motor control and has been extensively 
studied due to its role in movement disorders such as Parkinson’s disease (Deumens, 
Blokland, & Prickaerts, 2002). A fourth, less infamous, DA tract is the tuberoinfundibular 
pathway which projects DA from the hypothalamus to the pituitary gland (Carson et al., 
1977), playing a role in hormone regulation and maternal behaviour.  
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Figure 2. Schematic of the four main DA projection pathways as viewed from the mid-
sagittal section in a human brain. Image was adapted from National Institutes of Health 
(2014). 
 
DA is regulated by five isolated G-protein coupled receptors, which have been 
subdivided into two receptor sub-families based on these receptors’ biochemical and 
pharmacological properties (reviewed in Missale, Nash, Robinson, Jaber, & Caron, 1998; 
Jaber, Robinson, Missale, & Caron, 1996; Vallone , Picetti, & Borrelli, 2000). The D1-like 
receptor sub-family comprises the D1 and D5 receptors; whereas the D2-like receptor sub-
family includes the D2, D3 and D4 receptors.  
D1- and D2-like receptors often appear to regulate DA through antagonistic, or 
opponent, processes. Firstly, D1- and D2-like receptor activation has contrasting effects on 
second messenger systems. While D1-like receptors activate adenylate cyclase and are 
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therefore positive regulators of intracellular cyclic AMP (cAMP), ultimately facilitating 
neurotransmitter release (Cameron & Williams, 1993), D2-like receptors inhibit adenylate 
cyclase and the production of cAMP, thereby decreasing cellular firing (Missale et al., 1998). 
Secondly, DA neurons display two modes of transmitter release, characterised by either tonic 
(sustained or background) cellular firing, versus phasic (transient or bursting) cellular firing 
(Goto, Otani & Grace, 2007; Grace, 1991; 1995). Tonic DA levels are found to be 
consistently present in low concentrations in the synaptic cleft, whereas phasic spike-
dependent DA release results in high concentrations of extracellular DA which is rapidly 
inactivated via re-uptake (Cohen, Braver, & Brown, 2002; Goto et al., 2007). There is 
evidence to suggest that these dissociable patterns of cell firing differentially involve D1-and 
D2-like receptors. Pharmacological manipulation of D1-like receptors results in changes in 
tonic DA release, whereas phasic bursts of DA release may more readily activate D2-like 
receptors (Cohen et al, 2002). While the precise contributions to behaviour made by tonic 
versus phasic firing remain elusive, it has been proposed that phasic firing may occur in 
response to behaviourally relevant external stimuli, with tonic DA predominantly playing a 
regulatory role, and being active under basal conditions (Cohen et al., 2002; Grace, 1995).  
A final example of the antagonistic relationship between D1- and D2-like receptors 
relates to the two separate striatal populations of GABA-containing medium-sized spiny 
projection neurons (MSNs). Striatonigral MSNs comprise what is known as the ‘direct 
pathway’ which contains neurons that selectively express D1-like receptors and substance P. 
By contrast, striatopallidal MSNs form the ‘indirect pathway’ and express D2-like receptors 
and enkephalin (Smith, Beyan, Shink, & Bolam, 1998; Yung, Smith, Levey, & Bolam, 1996). 
These pathways have been found to play opposing roles in various functions that are 
orchestrated by basal ganglia structures, including motor control (Groenewegen, 2003), 
reward and aversive learning (Hikida, Kimura, Wada, Funabiki, & Nakanishi, 2010; Kravitz, 
Tye, & Kreitzer, 2012) and drug-related behaviours (Lobo & Nestler, 2011). As one example, 
behavioural sensitisation produced by repeated administration of AMPH was attenuated 
following transient inhibition of D1-like expressing MSNs, yet facilitated following inhibition 
of D2-like expressing MSNs (Ferguson et al., 2011).  
Given the close functional ties between D1- and D2-like receptors, as well as the 
complex nature of DA signalling more generally, determining the behavioural functions of 
individual DA receptors can be difficult. Recognising this caveat, our current understanding 
of the roles played by DA and D1-like receptors in behavioural processes is presented below. 
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D1 receptors are the most highly expressed of the DA receptors (Dearry et al., 1990; 
Weiner et al., 1991) and have widespread distribution throughout the CNS, in particular 
within DA’s projection pathways. D1 receptor mRNA has been detected in many subcortical 
brain structures, including the caudate-putamen, Nacc and olfactory tubercle, and to a lesser 
extent in the limbic system, cerebral cortex, amygdala, thalamus and hypothalamus (Fremeau 
et al., 1991). These findings were further substantiated using D1 subtype-specific antibodies, 
with the exception of the thalamus and hypothalamus (Levey et al 1993).  It is not surprising, 
then, that D1 receptors have been implicated in a broad range of cognitive and behavioural 
processes such as working memory (Rieckmann, Karlsson, Fischer, & Backman, 2011, 
Muller, Cramon, & Pollmann, 1998), motivation (Spina et al., 2010) and movement (Plaznik, 
Stefanski, & Kostowski, 1989).  
The most widely used method to investigate the behavioural functions of brain 
receptors in rats is the assessment of behaviour following administration of pharmacological 
agents, or ligands, that potentiate (i.e. an agonist) or block (i.e. an antagonist) the function of a 
given receptor. A limitation of this approach when applied to D1 receptors is that D1 receptor 
ligands will bind to both D1 and D5 receptors, as well as other non-DA receptors (e.g. 
Ramos, Goni-Allo, & Aguirre, 2005), and currently there are no pharmacological agents that 
can selectively bind to D1 receptors. The lack of pharmacological specificity of D1-like 
receptor ligands constrains our ability to determine the separate roles of the D1 and D5 
receptors despite the fact that these receptors appear to perform distinct functions in the brain 
(e.g. Centonze et al., 2003).  
The DAD1-/- rat provides researchers with an unprecedented method by which to 
examine the behavioural functions of D1 receptors in rats. Using [3H]SCH23390 
autoradiography, Homberg et al. (in press) observed down-regulated D1 receptor function in 
the DAD1-/- rats, with [3H]SCH23390 binding to DAD1-/- brain slices decreased by 50% in 
the PFC, subcortical regions, substantia nigra (SN) and by 20% in the olfactory tubercle. D5 
receptors in this rat are intact meaning that DAD1-/- rats can be used to examine the 
behavioural roles that D1 receptors normally performs devoid of D5 receptor involvement. 
Down-regulated D1 receptor function in DAD1-/- rats is further supported by the finding that 
cocaine-induced locomotor activity was strongly reduced in these animals (unpublished data, 
reported in Muller, Olivier, & Homberg, 2010). Not only does the DAD1-/- rats model 
circumvent the issue posed by a lack of pharmacological agents specific for D1 vs. D5 
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receptors, but by being a mutant model leading to reduced D1 function rather than a complete 
KO, this tool might also be of more relevance to humans. 
Although the DAD1-/- rat is a novel model of down-regulated D1 function and there 
are no published articles using this strain as of yet, there are some preliminary findings on the 
nature of the DAD1-/- rats reported from our laboratory and a collaborating laboratory. 
Physically, DAD1-/- rats weigh 15-25% less than littermate wild type (DAD1+/+) and 
heterozygous DA D1 (DAD1+/-) rats but no other gross physically abnormalities are apparent. 
Behaviourally, compared to wild types the DAD1-/- rats performed normally on the elevated 
plus maze, implying no differences between groups in levels of anxiety. Performances in the 
Morris water maze did differ, however, with DAD1-/- demonstrating slower swimming speeds 
and a possible memory deficit. However, overall there is a paucity of behavioural data using 
the DAD1-/- rats. Therefore, the current project will conduct a behavioural battery to 
investigate the behavioural tendencies of this strain and to assess their usefulness as a 
behavioural animal model. We selected tasks based on evidence, described below, suggesting 
that D1-like receptors play a regulatory role in motivation and reward, movement, and 
memory processes.  
Dopamine & D1-like receptors in motivation and reward: Attribution of 
incentive salience. Despite mesolimbic DA projections often being branded the ‘reward 
pathway’ of the brain, this label has been heavily criticised as it fails to recognise the 
specific nuances of DA’s role in reward processing (Salamone & Correa, 2012). Many 
stimuli perceived as pleasurable or rewarding activate mesolimbic DA (Di Chiara & 
Imperato, 1988; Phillips, Robbins, & Everitt, 1994; Tanda & Di Chiara, 1998) yet the 
precise role played by DA in reward has been highly contested for several decades. In a 
review by Berridge (2007) it was argued that there are three main explanatory categories 
of the causal role played by DA in reward, namely which argue that mesolimbic DA 
either mediates 1. the hedonic impact of reward (‘liking’); 2. learned predictions of future 
rewards and prediction-error signals (‘learning’) or; 3. motivation to pursue rewards 
through the attribution of incentive salience to reward-related stimuli (‘wanting’).  
The anhedonia hypothesis (Wise, 1982; 1985), which held that mesolimbic DA 
stimulation produced subjective feelings of pleasure, was formed on the basis of several 
observations. Firstly, in 1954, Olds and Milner presented the earliest demonstration of 
brain stimulation reward. Olds and Milner (1954) showed that electrical stimulation of the 
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septal area, a limbic region that receives DA projections from the VTA, produced 
rewarding effects, or positive reinforcement, which gave rise to acquisition and extinction 
curves for operant lever pressing in much the same way as a primary reward. This 
landmark finding appeared to suggest that there were ‘reward centres’ in the brain and 
provided a basis for studying the neurological mechanisms of reward. Secondly, Wise 
(1982) reported that acute administration of neuroleptic drugs, which decrease 
mesolimbic DA transmission, in rats led to anhedonia-like behaviours, and disrupted 
positively reinforced responding. The evidence in favour of DA as a substrate for reward 
led to the notion that DA signals correspond to the hedonic properties of rewards (Wise, 
1982; 1985). In the 1980s the hedonia hypothesis of DA function was very influential in 
neuroscience and indeed remnants of the idea that DA acts as a ‘liking’ signal (or reward 
neurotransmitter) is still present in popular culture and even some scientific literature 
today.  
One major caveat of the hedonia hypothesis is that it cannot account for the 
observation that the onset of a DA signal in response to the presentation of a rewarding 
stimulus changes with repeated exposure to that reward. When a rewarding stimulus is 
encountered for the first time, limbic neurons are activated with close temporal proximity 
to the presentation of the rewarding stimulus (thought to signal ‘liking’) (Wise, 1982; 
1985). Upon successive presentations of the same rewarding stimulus, the corresponding 
DA signal can come to occur in anticipation of the reward, in response to the presentation 
of predictive conditioned stimuli (CS) (de la Fuente-Fernandez et al., 2002; Schultz, 
1998; 2004; Schultz, Dayan, & Montague, 1997). Given that the reward is still ‘liked’ 
despite the presentation or consumption of the reward not corresponding to DA signalling 
implies that the hedonic component of reward is mediated by neural mechanisms other 
than mesolimbic DA. 
The observation that mesolimbic DA neurons respond to stimuli that are 
predictive of reward formed the basis of prediction error hypotheses of DA function 
(Schultz, 1998; 2004; Schultz et al., 2007). Largely based on electrophysiological, 
neurotransmitter release and imaging data, prediction error hypotheses suggest that DA 
codes for reward learning. In other words, learning accounts of DA’s function in reward 
hold that DA modulates synaptic plasticity that supports the neural representations of S-S 
(stimulus-stimulus) or S-R (stimulus-response) associations (Everitt, Dickinson, & 
Robbins, 2001; Schultz, 1997; 2004; Schultz et al., 1997). Such theories imply that 
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normal learning could not occur in the absence of DA. However, using a genetic mouse 
model lacking the enzyme tyrosine hydroxylase (meaning that these mice cannot 
synthesise DA), Hnasko, Sotak, and Palmiter (2005) and Robinson, Sandstrom, 
Denenberg, and Palmiter (2005) demonstrate that S-S and S-R links can be formed in the 
absence of intact DA systems in T-maze and conditioned place preference (CPP) tasks. 
Furthermore, pharmacologically-induced mesolimbic lesions in rats did not inhibit the 
production of conditioned taste aversion (Berridge & Robinson, 1998), further suggesting 
that DA is not necessary for new reward learning. Additionally, there is evidence 
indicating that manipulations affecting mesolimbic DA transmission lead to behaviour 
changes consistent with the idea that DA mediates ‘wanting’ for rewards, rather than 
learning about rewards. For example, hyper-DAergic mice display a greater willingness 
to work for rewards on a progressive ratio schedule, yet did not appear to like the food 
rewards more and did not display enhanced learning, compared to normal mice 
(Cagniard, Balsam, Brunner, & Zhuang, 2005; Yin, Zhuang, & Balleine, 2006).  
The incentive salience hypothesis of DA’s role in reward can account for the fact 
that many manipulations of brain DA seem to alter ‘wanting’ for rewards, whilst leaving 
‘liking’ and ‘learning’ intact. Incentive salience posits that DA mediates the attribution of 
motivational value to rewards and reward-related stimuli, or ‘wanting’ for rewards 
(Berridge 2007; Berridge & Robinson, 1998).Within the incentive salience framework, 
mesolimbic DA is a neural signal which assigns conditioned motivation to conditioned 
stimuli (CS), or stimuli that are associated with rewards. In the first instance, ‘wanting’ is 
attributed to a neutral CS due to an associated unconditioned stimulus (UCS; i.e. the 
reward) producing a ‘liked’, hedonic response (via non-DA mechanisms). Once a CS has 
acquired motivational value, it can act to powerfully modulate cue-triggered responding 
(e.g. priming; Berridge, 2004), as well as acting to enhance a subject’s motivation to 
acquire the associated reward (Di Ciano, Underwood, Hagan, & Everitt, 2003). A 
consequence of the attribution of incentive salience to a CS is that this CS can also 
become ‘wanted’ by the subject, sometimes resulting in approach or consummatory 
behaviour directed toward the CS (e.g. Uslaner, Acerbo, Jones, & Robinson, 2006).  
As well as accounting nicely for behaviours relating to the receipt of ‘natural’ 
primary rewards, the incentive salience hypothesis has been extended to apply to drug 
rewards in a theory called the incentive sensitisation hypothesis (Robinson & Berridge, 
2008; Robinson et al., 1993). Incentive sensitisation explains the finding that mesolimbic 
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DA systems develop neural sensitisation in response to repeated drug exposure, 
corresponding to parallel increases in ‘wanting’ or craving (behavioural sensitisation) for 
the drug and drug-associated stimuli (Anderson & Pierce, 2005; Lett, 1989; Vezina, 
2004). 
While certain aspects of mesolimbic DA functioning are still contested, the 
incentive salience account certainly presents a good case for DA acting to mediate the 
attribution of motivational value to relevant reward stimuli. What then is the current 
picture of the contributions made by D1-like receptors in the context of reward? When 
applied systemically, D1-like receptor antagonists decrease operant responding for 
rewards including food, deep brain stimulation, self-administered drugs and conditioned 
rewards, as well as the expression of CPP (Acquas, Carboni, Leone, & Di Chiara, 1989, 
Anderson, Bari, & Pierce, 2003; Beninger et al., 1987; Beninger & Miller, 1998; 
Nakajima, 1986). Intracerebroventricular D1-like receptor blockade has also been found to 
prevent CPP which was previously elicited using both ethanol and acetaldehyde in rats (Spina 
et al., 2010). Similarly in D1 receptor deficient mice, El-Ghundi, O’Dowd, Erclik, & George 
(2003) found an attenuation of responding for sucrose in an operant conditioning task. These 
findings broadly suggest that D1-like receptor activation is necessary for the performance 
of reward-directed behaviours. It is interesting that the converse effect on behaviour is not 
found using D1-like receptor agonists. In general, systemic administration of D1-like 
receptor agonists disrupts operant responding for rewards (Beninger & Rolfe, 1995; 
Hoffman & Beninger, 1989a; Katz & Witkin, 1992; Ranaldi, Pantalony, & Beninger, 
1995), often does not produce CPP and can even produce conditioned place aversion 
(CPA) (Hoffman & Beninger, 1989b; White, Packard, & Hiroi, 1991). However, there 
have been exceptions regarding findings using CPP, with Abrahams, Rutherford, Mallet, 
and Beninger (1998) testing an array of D1-like receptor agonists at various doses, and 
finding that SKF 82958 at a dose of 0.05 mg/kg produced CPP. Furthermore, it has been 
argued that CPA by systemic D1-like agonists may be caused by the non-specific effects 
of these agents (White et al., 1991). 
On the face of it, the finding that systemic administration of D1-like receptor 
antagonists and agonists can attenuate the performance of reward-related behaviour 
appears contradictory. However, Beninger and Miller (1998) present a compelling 
account for why activation of D1-like receptors using systemic D1-like agonists might 
impair responding on some reward paradigms. Briefly, Beninger and Miller (1998) argue 
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that under drug-free conditions the receipt of a reward or the presentation of CS that 
predict reward generate an intense and short-lived peak of mesolimbic DA release in the 
synapse which subsequently interacts with D1-like receptors – this is termed a ‘DA 
signal’. When a direct acting D1-like receptor agonist is administered, it continuously 
binds to D1-like receptors rather than mimicking the time-course of a genuine DA signal 
produced by, or associated with, reward stimuli. In this way, Beninger and Miller (1998) 
suggest that medium to high doses of D1-like receptor agonists obscure the DA signal 
associated with natural reward stimuli. They argue that some reward paradigms are 
therefore more likely to be disrupted by D1-like agonists, such as in operant 
reinforcement where the presentation of a given stimulus comes to control behaviour and 
the timing of the DA signal is crucial. On the contrary a paradigm such as CPP, which 
does not rely on the timing of the DA signal to elicit a reward response, would be less 
disrupted by D1-like agonists. This explanation can account nicely for findings from 
studies using systemic application of D1-like receptor agonists, which find that D1-like 
agonists disrupt operant responding for reward (Beninger & Rolfe, 1995; Hoffman & 
Beninger, 1989a; Katz & Witkin, 1992; Ranaldi et al., 1995), yet that a D1-like agonist 
has been reported to produce CPP (Abrahams et al., 1998).  
 As well as reward, D1-like receptors are also involved in movement and memory 
processes (discussed below). Because D1-like receptor ligands are not solely selective for 
D1 receptors, potential global effects of systemic administration of D1-like receptor 
agents cannot always be ruled out. By using local administration of D1-like receptor 
agonists or antagonists, the role of D1-like receptors in reward have been more finely 
dissected (Andrzejewski, Spencer, & Kelley, 2006; Baldo, Sadeghian, Basso, & Kelley, 
2002; Ikemoto, Glazier, Murphy, & McBride, 1997; Koch, Schmid, & Schnitzler, 2000; 
Nowend, Arizzi, Carlson, & Salamone 2001; White et al., 1991). In particular, activation of 
D1-like receptors in the Nacc, and more so in the shell than in the core, appears to be 
important for reward processing. The Nacc is in a prime anatomical position to act as an 
interface between motivation and action (Robbins & Everitt, 1996), given that it receives 
DAergic innervation from the VTA and projects via the ventral pallidum to premotor and 
cortical motor areas (Mogenson, Brudzynski, Wu, Yang, & Yim, 1993). Intra-accumbal 
administration of the D1-like receptor antagonist SCH 23390 disrupts conditioned operant 
responding for palatable rewards (i.e. sugar pellets), but also coincides with a compensatory 
increase in consumption of freely available, but less preferable, chow (Koch et al., 2000; 
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Nowend et al., 2001), indicating that D1-like receptors in the Nacc are not required for 
consummatory behaviour.  Nowend et al. (2001) also found that after intra-accumbal infusion 
of SCH 23390 rats still displayed a preference for palatable food in a free choice test 
suggesting that the hedonic evaluation of the reward is intact. Furthermore, although systemic 
application of SKF 38393 produced CPA, intra-accumbal infusion of this drug produced CPP 
(White et al., 1991). Taken together, these studies suggest that mesolimbic D1-like receptors 
are required for behaviours relevant for the receipt of natural rewards. 
Extending these findings to addiction research, low doses of the D1-like receptor 
agonist SKF 81297 were self-administered by rhesus monkeys (Weed, Vanover, & 
Woolverton, 1993). However, Ikimoto et al. (1997) found that SKF 38393 (a less selective 
D1-like receptor agonist compared to SKF 81297) was not self-administered by rats and only 
when SKF 38393 was mixed with equimolar proportions of quinpirole, a D2-like agonist, 
would the rats acquire self-administration. Although D1-like receptors are often thought to 
play a more critical role in reward than D2-like receptors (reviewed in Beninger & Miller, 
1998) some studies demonstrate synergistic effects of D1- and D2-like receptors in the Nacc, 
for example in terms of primed reinstatement of drug-seeking using self-administration 
(Schmidt, Anderson, & Pierce, 2006). However, SCH 23390 administered into the Nacc shell 
attenuated cocaine-primed drug seeking in rats without the co-administration of a D2-like 
receptor antagonist (Anderson et al., 2003). These findings indicate that D1-like receptors are 
involved in drug-associated reward behaviours. 
Taken together, mesolimbic D1-like receptors appear critical for reward processing in 
a manner consistent with the incentive salience hypothesis (Berridge 2007; Berridge & 
Robinson, 1998). To determine whether the down-regulation of functional D1 receptors  in 
DAD1-/- rats leads to an impairment in reward processing, specifically in terms of reward 
‘wanting’, DAD1-/- rats will be compared with controls in terms of sucrose preference, 
latency to consume freely available sugar pellets, and lever pressing for sugar pellet 
reinforcement in an operant chamber.  
Dopamine & D1-like receptors in movement. Research investigating the motor 
deficits caused by Parkinson’s disease (PD) has firmly established a role for DA and D1-
like receptors in movement processes. PD is characterised by the neurodegeneration of 
DA neurons, mainly in the SNPc, leading to drastically reduced DA neurotransmission in 
basal ganglia motor circuits leading to severe disturbances of voluntary motor control 
43 
 
(Anglade et al., 1997; Jankovic, 2008). As well as highlighting an important role for DA 
in the execution of movement, PD research has also shown that D1 signalling is an 
essential component of motor output.  
Firstly, rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the 
nigrostriatal pathway are widely used as a model for PD-like symptoms (Deumens et al., 
2002; Lundblad et al., 2002; Truong, Allbutt, Kassiou, & Henderson, 2006). Using 6-
OHDA lesioned rats, Gulwadi et al. (2001) found that the selective D1-like receptor 
agonist, dinapsoline, effectively reversed impaired motor control. Although human PD 
patients do not respond as positively to D1-like receptor treatment, possibly due to a lack 
of ligand specificity as well as the development of rapid tolerance to some D1-like 
compounds (Asin & Wirtshafter, 1993), some clinical trials using selective D1-like 
agonists to treat PD patients have been met with success (e.g. Rascol et al., 1999).  
Secondly, levodopa (L-DOPA), a precursor for DA which can cross the blood-
brain barrier, is a common drug treatment for PD. While initial L-DOPA administration is 
effective at alleviating PD symptoms, chronic use can result in the development of L-
DOPA-induced dyskinesia (LID), which is a debilitating side-effect of L-DOPA 
treatment. LID is characterised by involuntary motor fluctuations where movement is 
flowing and dance-like, with patients appearing to be writhing or twisting. The expression 
of LID is linked to over-active D1 receptor signalling in the direct striatonigral pathway 
(Aubert et al., 2005; Darmopil, Martin, de Diego, Ares, & Moratalla, 2009), 
demonstrating that both under- and over-activation of D1-like receptors can lead to 
movement disturbances.  
Evidence from PD research strongly suggests that nigrostriatal D1-like receptor 
activation is required for controlled movement. Consistent with this evidence is that 
pharmacological manipulation of D1-like receptors via application of D1-like receptor 
agonists and antagonists produce dose-dependent increases (Ralph & Caine, 2005; 
Schindler & Carmona, 2002) or decreases (Hoffman & Beninger, 1985; Meyer, Cottrell, 
Van Hartesveldt, & Potter, 1993), respectively, in spontaneous locomotor activity in rats. 
That D1-like receptors are an important neural substrate for movement is relevant for the 
current investigation of the acute behavioural effects of MDMA for several reasons. Firstly, 
many (if not all) behavioural tasks, including those used for the current investigation of 
memory performance, involve a movement component. In the context of a maze- or operant-
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based memory task, if the DAD1-/- rats were to have altered baseline levels of motor output, 
for instance if they moved less than control rats, then this could decrease their accuracy on the 
memory task by increasing the delay between acquisition and retrieval of memories for task-
relevant stimuli. Secondly, acute MDMA administration reliably produces hyperlocomotion, 
with D1-like receptors playing a role in this effect (Ball, Budreau, & Rebec, 2003; Bubar, 
Pack, Frankel, & Cunningham, 2004). If MDMA-induced hyperlocomotion were to interfere 
with the subjects’ performance on the behavioural tasks, and if DAD1-/- rats have a reduced 
locomotor response to acute MDMA compared to control rats, task performance could be 
more greatly affected in the control rats than DAD1-/- rats through mechanisms other than 
memory function or proactive interference. Given these potentially confounding factors, 
chapter 4 will investigate the locomotor tendencies of DAD1-/- rats compared to controls in a 
drug-free state, and chapter 5 will examine whether the DAD1-/- rats display an altered 
locomotor response to acute MDMA compared to controls in the context of an 
immunohistochemical analysis of MDMA-induced c-fos expression.  
Dopamine & D1-like receptors in memory. Memory involves the set of 
processes by which organisms encode, store and retrieve information (Melton, 1963). 
Both the HPS and PFC have been extensively studied for their roles in memory and 
cognition, with mesocorticolimbic DA systems having important neuromodulatory 
functions in these areas (PFC: Goldman-Rakic, 1995; HPS: Lisman & Grace, 2005). D1-
like receptors are expressed in both the HPS (Fremeau et al., 1991) and PFC (Muly, 
Szigeti, & Goldman-Rakic, 1998) where they mediate diffuse inputs from DA midbrain 
neurons and contribute to memory function.  
Investigators of memory function seek to understand how experience comes to 
modify the brain in order to form a neural representation of this in-coming information. 
One form of neuroadaption relevant for the encoding of memories is synaptic plasticity. 
The strengthening or weakening of synaptic connections in the HPS by way of long-term 
potentiation (LTP) or long-term depression (LTD), respectively, is thought to underlie the 
encoding of long-term memories (Bliss & Collingridge, 1993; Lemon & Manahan-
Vaughan, 2006). There is clear evidence that DA affects the induction of LTP and LTD 
(Lisman & Grace, 2005; Thomas & Malenka, 2003; Sajikumar & Frey, 2004) and that 
activation of D1-like receptors is involved in these processes. For example, application of 
D1-like agonists can enhance LTP in the HPS (Li, Cullen, Anwyl, & Rowan, 2003), 
whereas the administration of D1-like antagonists block the expression of LTP (Frey, 
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Matthies, Reymann, & Matthies, 1991). Similarly, in vitro analysis of CA1 neurons in rat 
HPS slices demonstrates that activation of D1 receptors enhances LTD and D1-like 
antagonism blocks the induction of LTD (Chen et al., 1996). In sum, these studies suggest 
that D1-like receptors in the HPS are important for synaptic plasticity that may underlie 
the formation of long-term memories.  
In the PFC, which orchestrates working memory processes (Braver et al., 1997; 
Goldman-Rakic, 1995), the level or amount of DA transmission appears to be critical for 
optimal working memory function. Specifically, too much or too little DA stimulation in 
the PFC leads to impairments in working memory in humans (Cools & D’Esposito, 
2011), non-human primates (Vijayraghavan, Wang, Birnbaum, Williams, & Arnsten, 
2007; Williams & Goldman-Rakic, 1995) and rats (Seamans, Floresco, & Phillips, 1995; 
1998; Zahrt et al., 2007). That under- or over-stimulation of DA in the PFC impairs 
working memory forms the basis of the inverted-U theory of PFC DA transmission and it 
has since been demonstrated that, in particular, D1-like receptor stimulation mediates this 
effect. In a seminal study, Williams and Goldman-Rakic (1995) used local iontophoretic 
application of the D1-like receptor antagonist SCH 39166 in the dorsolateral PFC of 
monkeys to investigate the cellular basis of working memory. When SCH 39166 was 
applied at a dose just above threshold for effect, this resulted in the enhancement of 
neuronal memory fields by increasing firing selectively for the preferred direction of 
pyramidal cells during the delay period of the oculomotor delayed response task. Memory 
fields have been defined as the maximal firing of a neuron during a working memory task 
delay period, in response to the presentation of a stimulus in a given location of the 
subjects’ visual field. Using the same procedure, they then found that SCH 39166 actually 
abolished these memory fields when further iontophoretic application was applied. These 
findings led Williams and Goldman-Rakic (1995) to suggest that dopaminergic signalling 
within the dorsolateral PFC must fall between an optimum range in order to be beneficial 
to resulting memory performance.  
Since the discovery that D1-like receptors may mediate the relationship between 
DA transmission in the PFC and working memory performance in primates, this finding 
has also been supported using rats. Zahrt et al., (1997) trained rats on a delayed-
alternation task in a T-maze, where subjects were reinforced for alternating their arm 
visits with a delay period between each arm visit. The length of the delay period was 
adjusted for each subject to produce ~ 80 % accuracy (delays ranged from 5-30 seconds) 
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in order to be able to detect both improvements and impairments following drug. The rats 
were then administered microinfusions of saline, 0.05 or 0.5 μg/0.5 μl of the D1-like 
agonist SKF 81297 into the PFC prior to the start of testing sessions. Zahrt et al. (1997) 
found that after the highest dose of SKF 81297 performance was significantly impaired, 
yet after the lower dose of SKF 81297 performance was not significantly affected. The 
impairment of delay-related spatial working memory was subsequently reversed when the 
0.5 μg/0.5 μl dose of SKF 81297 was concurrently applied with the D1-like antagonist 
SCH 23390 (0.03 mg/kg i.p.), suggesting that the effects on memory were due to excess 
stimulation of D1-like receptors rather than non-specific effects. Importantly, when SCH 
23390 0.03 mk/kg was administered alone performance was unimpaired yet using a 
higher dose, 0.035 mg/kg, SCH 23390 significantly impaired accuracy (Zahrt et al., 
1997). Other studies using rats have further demonstrated that when SCH 23390 is 
administered directly into the PFC, spatial working memory performance is impaired 
(Seamans et al., 1995; 1998). Taken together, these findings suggest that over- and under- 
stimulation of D1 receptors in the PFC can impair working memory processes in primates 
and rats. In light of evidence suggesting that D1-like receptors are integral for memory 
processes, the memory performance of DAD1-/- rats while in a drug-free state will be 
compared to control rats in chapter 3.  
The inverted-U relationship between D1-like receptor activation in the PFC and 
working memory function has shed light on the potential role of DA and D1-like 
receptors in working memory. In order for accurate responding on working memory 
tasks, stimuli are required to be held ‘online’ during the delay period because there are no 
stimuli presently available to guide responding. During the brief delay periods on 
working memory tasks PFC DA neurons are highly active, and appear to contribute to the 
active retention of task-relevant information (Kubota & Niki, 1971; for a review see 
Goldman-Rakic, 1995). As well as possibly contributing to the generation of an internal 
representation of to-be-remembered stimuli, DA neurons in the PFC inhibit spontaneous 
or background activity within the PFC (Ferron, Thierry, Le Douarin, & Glowinski, 1984; 
Mantz, Milla, Glowinski, & Thierry, 1988). These findings suggest that PFC DA, 
mediated by D1-like receptors, may act to selectively enhance task-relevant or salient 
information relative to background activity or spontaneous inputs in the PFC (Seamans et 
al., 1998). Consistent with this idea, application of D1-like receptor antagonists decrease 
the effectiveness of delay-period activity relative to background noise activity, leading to 
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more random modes of behaviour (Seamans et al., 1998). On the contrary, over-
stimulation of D1-like receptors would be expected to strongly inhibit PFC inputs in a 
manner that might restrict behavioural output. Accordingly, in Zahrt et al.’s, (1997) study, 
outlined above, it was reported that D1-like agonist administration into the PFC impaired 
delayed alternation by increasing response perseveration. That D1-like receptor activation 
in the PFC induced response perseveration is notably consistent with the main hypothesis 
of the current study – that acute MDMA impairs memory by increasing response 
perseveration via over-activation of D1 receptors. In order to investigate this hypothesis, 
memory performance following acute MDMA administration will be examined in chapter 
5. 
The Current Study 
 The present investigation employs the novel DAD1-/- rat model of down-regulated 
DA D1 receptor function to investigate the roles played by DA D1 receptors in some of 
the behavioural and neurochemical effects of acute MDMA administration. In the three 
ensuing experimental chapters (summarised below) the central questions explored are: 
1. When in a drug free state do DAD1-/- rats display an altered behavioural 
phenotype compared to control rats? (Chapter 3) 
2. Does a genetic reduction of functional D1 receptors lead to an altered 
neurochemical response to systemically applied acute MDMA compared to 
control rats? (Chapter 4) 
3. Do DAD1-/- rats show expression of MDMA-induced hyperlocomotion? (Chapter 
4) 
4. Does acute MDMA administration impair memory performance via its agonist 
actions at the DA D1 receptor? (Chapter 5) 
5. Does acute MDMA administration impair memory performance by increasing 
susceptibility to proactive interference? If so, does this increase in susceptibility to 
proactive interference appear to be mediated by MDMA’s agonist actions at DA 
D1 receptors? (Chapter 5) 
Phase 1 – behavioural characterisation of the DAD1-/- rats. Currently, little is 
known about this novel strain of rat and there are no published studies investigating MDMA 
exposure using DAD1-/- rats. As such, phase 1 (chapter 3) of experimentation involves 
conducting a battery of behavioural tasks to gain insight into whether the DAD1-/- rats differ 
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from controls in a drug-free state with regard to: 1. motivation to consume freely available 
sugar pellets; 2. the ability to autoshape to press a lever for food reinforcement; 3. locomotor 
tendencies in an open field; 4. balance performance on a narrow, elevated beam 5. memory 
performance in a T-maze and 6. novel odour recognition in their home cage. This 
‘behavioural profiling’ of the DAD1-/- rats is important in identifying the nature of subsequent 
behavioural changes predicted in Phase 2. 
Phase 2 – neurochemical assessment. Phase 2 (chapter 4) investigates a 
neurochemical response to MDMA that might be altered in the DAD1-/- rats. 
Immunohistochemistry (IHC) will be undertaken to investigate the role of the D1 receptor in 
the expression pattern of the immediate-early gene c-fos during acute MDMA exposure. C-
fos expression is a widely used marker for neuronal activity and will be assayed in response 
to an acute dose of MDMA 3 mg/kg administered via i.p injection in several brain regions, 
namely the medial prefrontal cortices (mPFC; infralimbic cortex, cingulate cortex and 
prelimbic cortex), the striatum (dorsolateral and dorsomedial), Nacc (core and shell), 
VTA and SNPc.  
Phase 3 – MDMA, memory/response perseveration and the D1 receptor. In phase 
3 (chapter 5) we originally planned to employ the DMTS procedure in order to investigate 
the central question of this research: is the D1 receptor implicated in the memory 
performance errors that are observed during acute MDMA exposure? Specifically, it is 
proposed that if MDMA interferes with memory via its agonist actions at the D1 receptor site 
then DAD1-/- rats should display relatively less response perseveration than controls during 
acute MDMA exposure. The initial choice of the DMTS task stemmed from its prior use with 
'normal' rats in the original research conducted by Harper and colleagues (2005, 2006 and 
2013). However, data from the behavioural assessment (chapter 3) suggests the need to 
consider alternate behavioural tasks for assessing memory function in the DAD1-/- rats. 
Instead of the DMTS task conducted in an operant chamber, this chapter will present data 
from a T-maze based memory task: delayed non-matching-to-position (DNMTP).  
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Chapter 2: General Method 
Subjects 
Across the three data chapters presented, 78 male rats from the outbred Wistar 
strain were used. This comprises 41 DAD1-/- rats, four DAD1+/- rats and 33 DAD1+/+ rats. 
On the basis of unpublished observations (personal communication with B. Ellenbroek, 
2012) indicating that the heterozygous (DAD1+/-) animals are both physically and 
behaviourally analogous to that of wild type (DAD1+/+) rats, heterozygous and wild type 
rats were used as control groups. Breeding and housing space constraints limited the 
ability to compare all three groups in any given experiment. Rats were between 3 - 12 
months old at the start of each experiment with the experimental and control groups being 
matched for age. Experimental and control groups were always matched in terms of their 
experimental histories. See tables 1, 2 and 3 for breakdowns of the information pertaining 
to the subjects used for each experiment. 
Consistent with Muller et al. (2010), the DAD1-/- rats’ free feeding weights (M = 
341 grams) were 15-20% less than the DAD1+/- (M = 408 grams) and DAD1+/+ (M = 398 
grams) control rats.  Rats were bred and housed at Victoria University of Wellington’s 
animal facility. All experimental procedures were conducted in accordance with Victoria 
University of Wellington’s animal care principles and were approved by the Victoria 
University of Wellington’s Animal Ethics Committee.  
Housing conditions. The rats were housed in pairs or triples (matched for 
genotype). Rats had access to laboratory grade animal chow and water ad libitum except 
during the autoshaping, consumption of sugar pellets and reinforced T-maze experiments, 
which relied on motivation to consume food. During these experiments, rats were put on a 
restricted food regime designed to maintain their weights at 85% of their free feeding 
weights (adjusted for growth). Their wire-top home cages (21.5cm x 19cm x 44cm) were 
lined with saw dust and contained a white tube enrichment item. The housing room was 
on a reverse 12-hour light/dark cycle (lights off between 7am and 7pm) and was kept at a 
constant temperature of 22.C. All experimental procedures took place during the rats’ 
dark cycle, between 9am and 6pm.  
Generation of the DAD1 mutant strain. DAD1-/- and DAD1+/- rats were 
generated using N-ethyl-N-nitrosourea (ENU)-driven target-selected mutagenesis, as 
described in detail by Smits et al. (2006). Administration of ENU, and generation of the 
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initial litter of mutant rats, was conducted at Radboud University in Nijmegen, the 
Netherlands. In 2011, a sample of the mutant progeny was transported to Victoria 
University of Wellington, NZ, where further offspring were reared.  
To briefly outline the ENU process and the generation of the DAD1 gene 
mutation, male outbred Wistar rats, 11 weeks of age, were administered three 
intraperitonial injections of ENU, one per week, in the following dose order: 30, 35 and 
40 mg of ENU/kg bodyweight. Three weeks after the last injection, the injected males 
were paired with wild type (DAD1+/+) outbred Wistar females, producing F1 progeny. 
Next, and because this mutagenesis technique can produce distinct and co-existing 
genetic mutations in the F1 offspring, each F1 juvenile was analysed for the presence of a 
genetic mutation using a tail sample. Of these offspring, one rat was identified that 
possessed the dopamine D1 mutant gene (i.e. DAD1-/-). This subject was subsequently 
bred with a DAD1+/+ rat of the same outbred Wistar strain, creating heterozygous 
dopamine D1 mutant (DAD1+/-) F2 progeny.  Next, these DAD1+/- offspring were mated, 
procuring litters that included DAD1-/- rats (F3 progeny). 
 Note regarding graphical figures. For all graphs, error bars represent standard 
error of the mean.  
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Table 1 
Genotype, weight and age information pertaining to all rat subjects in cohort one. Rats in 
cohort one were subjects in the autoshaping, free access to sugar pellets and balance 
beam experiments. 
Subject numbers Genotype Free feeding weight 
in grams 
Age at start of 
experiment/s 
1 DAD1-/- 336 5-6 months 
2 DAD1-/- 250 5-6 months 
3 DAD1-/- 285 5-6 months 
4 DAD1-/- 328 5-6 months 
5 DAD1+/- 407 5-6 months 
6 DAD1+/- 422 5-6 months 
7 DAD1+/- 434 5-6 months 
8 DAD1+/- 368 5-6 months 
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Table 2 
Genotype, weight and age information pertaining to all rat subjects in cohort two. Rats in 
cohort two were subjects in the immunohistochemical assay of c-fos expression 
experiment. 
Subject numbers Genotype Free feeding weight 
in grams 
Age at start of 
experiment/s 
9 DAD1-/- 342 11-12 months 
10 DAD1-/- 322 11-12 months 
11 DAD1-/- 312 11-12 months 
12 DAD1-/- 297 11-12 months 
13 DAD1-/- 308 9-10 months 
14 DAD1-/- 332 9-10 months 
15 DAD1-/- 318 9-10 months 
16 DAD1-/- 296 9-10 months 
17 DAD1-/- 309 9-10 months 
18 DAD1-/- 343 9-10 months 
19 DAD1-/- 348 9-10 months 
20 DAD1-/- 317 9-10 months 
21 DAD1+/+ 384 7-8 months 
22 DAD1+/+ 402 7-8 months 
23 DAD1+/+ 398 7-8 months 
24 DAD1+/+ 411 7-8 months 
25 DAD1+/+ 420 11-12 months 
26 DAD1+/+ 417 11-12 months 
27 DAD1+/+ 443 11-12 months 
28 DAD1+/+ 475 11-12 months 
29 DAD1+/+ 378 11-12 months 
30 DAD1+/+ 434 11-12 months 
 
  
53 
 
Table 3 
Genotype, weight and age information pertaining to all rat subjects in cohort three. Rats 
in cohort three* were subjects in the sucrose preference test, delayed non-matching-to-
position, open-field and rotarod experiments. 
Subject numbers Genotype Free feeding weight 
in grams 
Age at start of 
experiment/s 
31(2) DAD1-/- 374 3-4 months 
32(1) DAD1-/- 333 3-4 months 
33(2) DAD1-/- 372 3-4 months 
34(2) DAD1-/- 344 3-4 months 
35(2) DAD1-/- 416 5-6 months 
36(3) DAD1-/- 334 4-5 months 
37(2) DAD1-/- 375 4-5 months 
38(2) DAD1-/- 408 4-5 months 
39(2) DAD1-/- 388 4-5 months 
40(3) DAD1-/- 373 4-5 months 
41(2) DAD1-/- 445 4-5 months 
42(2) DAD1-/- 361 4-5 months 
43(1) DAD1-/- 307 5-6 months 
44(1) DAD1-/- 375 5-6 months 
45(1) DAD1-/- 281 5-6 months 
46(1) DAD1-/- 392 5-6 months 
47(1) DAD1-/- 330 5-6 months 
48(2) DAD1-/- 346 5-6 months 
49(2) DAD1-/- 350 5-6 months 
50(3) DAD1-/- 345 5-6 months 
51(3) DAD1-/- 362 5-6 months 
52(1) DAD1-/- 374 5-6 months 
53(1) DAD1-/- 372 5-6 months 
54(1) DAD1-/- 291 5-6 months 
55(1) DAD1-/- 308 5-6 months 
56(1) DAD1+/+ 288 3-4 months 
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57(3) DAD1+/+ 338 3-4 months 
58(2) DAD1+/+ 396 3-4 months 
59(1) DAD1+/+ 461 3-4 months 
60(2) DAD1+/+ 404 4-5 months 
61(2) DAD1+/+ 487 4-5 months 
62(2) DAD1+/+ 330 4-5 months 
63(2) DAD1+/+ 307 4-5 months 
64(3) DAD1+/+ 364 4-5 months 
65(2) DAD1+/+ 413 4-5 months 
66(1) DAD1+/+ 482 4-5 months 
67(2) DAD1+/+ 373 4-5 months 
68(1) DAD1+/+ 480 5-6 months 
69(1) DAD1+/+ 460 5-6 months 
70(2) DAD1+/+ 510 5-6 months 
71(2) DAD1+/+ 422 5-6 months 
72(2) DAD1+/+ 409 5-6 months 
73(2) DAD1+/+ 444 5-6 months 
74(1) DAD1+/+ 325 5-6 months 
75(2) DAD1+/+ 354 5-6 months 
76(1) DAD1+/+ 301 5-6 months 
77(1) DAD1+/+ 300 5-6 months 
78(2) DAD1+/+ 319 5-6 months 
*All subjects in cohort three were used in the sucrose preference test. This cohort was 
then split into three groups: The 1st group (rats marked with (1)) comprises subjects used 
for the 1st rotarod test (minimal handling group), the 2nd group (rats marked with (2), n = 
24) comprises rats who completed the delayed non-matching-to-position, open-field and 
2nd rotarod (extensive handling group) experiments, and the 3rd group (rats marked with 
(3), n = 6) comprises subjects used in the delayed non-matching-to-position task who did 
not acquire the task. 
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Chapter 3: A Behavioural Characterisation of DAD1-/- Rats  
DA’s actions in the brain are mediated by five receptors (D1-D5), but a lack of 
selective ligands for these receptors has hindered our ability to determine their specific 
functions. As a result, DA receptors have been categorised into two families of receptors 
based on similar molecular structures and pharmacology - the D1-like (D1 and D5) and 
D2-like (D2, D3 and D4) families. D1-like receptor ligands stimulate both D1 and D5 
receptors (Tiberi et al., 1991) and for the most part the contributions to behaviour made 
by D5 receptors are overlooked (Khan et al., 2000; Rivera et al., 2002). The relatively few 
studies that have assessed D1 and D5 receptors separately suggest that they play different 
roles in DA neurotransmission. For instance, D1 and D5 receptors are distributed 
differently throughout the rat brain (Tiberi et al., 1991), and additionally, D5 receptors 
display a 5 to 10-fold higher affinity for DA than D1 receptors (Grandy et al., 1991; 
Sunahara et al., 1991) suggesting that D5 receptors may participate highly effectively in 
DA mediated functions (Khan et al., 2000). Using D1 receptor knockout mice, Centonze 
et al. (2003) found that D1 and D5 receptors exert distinct actions with regard to striatal 
synaptic plasticity and spontaneous motor activity. Centonze et al. (2003) suggest that D1 
receptors may be relatively more important than D5 receptors for the induction of striatal 
long-term potentiation (LTP), yet D5 receptors may play a larger role than D1 receptors 
in striatal long-term depression (LTD). What is more, SCH 23390 (a D1/D5 antagonist) 
decreased spontaneous motor activity in rats with ablated D1 receptors as well as control 
animals suggesting that D5 receptors may be critical neural substrates for movement 
(Centonze et al., 2003).  
Not only do D1-like receptor ligands bind to D1 and D5 receptors, but in general 
they will also bind to non-DAergic receptors as well. For example, approximately a 
quarter of cortical binding by SCH 23390 (considered a selective D1 antagonist) was 
displaced by prior 5-HT2A receptor antagonism as measured by PET in non-human 
primates (Ekelund et al., 2007). A further limitation of using pharmacological 
manipulations to examine the functions of D1 receptors is that medium-high doses of D1-
like receptor agonists can flood synapses with DA, thereby obscuring the natural DA 
signal required for the performance of DA mediated behaviours (Beninger & Miller, 
1998).  
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A novel aspect of the current project is the use of DAD1-/- rats to investigate the 
role of D1 receptors in some of MDMA’s acute effects. DAD1-/- rats have a selective 
genetic down-regulation (~ 50%) in functional D1 receptors, but intact D5 receptors. This 
model stands to be an incredibly useful tool with which to further our understanding of 
the behavioural and neurochemical functions of D1 receptors. Because of the novelty of 
this rat model, and due to the fact that D1 receptors are involved in a range of 
conceptually distinct functions, a necessary starting point is to conduct a behavioural 
characterisation of the DAD1-/- rat phenotype in a drug-free state. Rather than conducting 
an exhaustive characterisation, this behavioural profile will focus on behaviours that 
involve D1-like receptors, and that are relevant to our later investigation into the nature of 
D1 receptor function in the effects of acute MDMA on memory (i.e. the focus of the 
chapter 5). There are three broad areas of behaviour that have been selected for analysis, 
specifically consummatory and reward-related behaviours, movement and spontaneous 
locomotor activity, and memory performance.  
Firstly, based on extensive evidence suggesting a role for D1-like receptors in 
reward processes (Beninger & Miller, 1998), it is hypothesised that the DAD1-/- rats will 
display altered reward-related behaviours. To test this, food deprived DAD1-/- rats will be 
compared to controls (either DAD1+/- or DAD1+/+ rats) with regard to 1. whether they 
display a preference for sucrose solution over water when both are freely available in the 
home cage; 2. latency to consume ten freely available odourless sugar pellets used in 
operant tasks in our lab and; 3. autoshaping to press a lever for reinforcement (sugar 
pellets). Because DA and D1 receptors have been implicated in behaviours consistent 
with wanting rather than liking rewards (Berridge 2007; Berridge & Robinson, 1998), it is 
predicted that the DAD1-/- rats will perform similarly to control rats on the first two tasks 
(i.e. sucrose preference and consuming sugar pellets) which aim to detect hedonic liking 
of palatable rewards. However, with regard to autoshaping to press a lever for palatable 
rewards, it is predicted that the DAD1-/- rats may be impaired in acquiring this behaviour, 
manifesting as fewer lever presses than controls. In support of this prediction, El-Ghundi 
et al. (2003) reported that D1 receptor deficient mice demonstrated attenuated lever 
pressing for sucrose. In addition, D1-like receptor antagonism disrupts the acquisition and 
maintenance of operant responding for palatable food rewards (Baldwin, Sadeghian & 
Kelley, 2002; Beninger et al., 1987; Beninger & Miller, 1998; Koch et al., 2000; 
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Nakajima, 1986; Nowend et al., 2001). In sum, it is expected that DAD1-/- rats will 
demonstrate intact liking, but impaired wanting for rewards. 
Secondly, this chapter provides an assessment of movement in the DAD1-/- rats. A 
movement assessment is important because there is strong evidence that D1-like receptors 
are involved in movement (Aubert et al., 2005; Darmopil, Martin, de Diego, Ares, & 
Moratalla, 2009; Bergquist, Shahabi, & Nissbrandt, 2003; Drago et al., 1994; Hoffman & 
Beninger, 1985; Meyer et al., 1993; Ralph & Caine, 2005). Motor proficiency is required 
for the investigation of MDMA’s acute effects on memory performance presented in 
chapter 5. Therefore it is relevant to examine the motor capabilities of the DAD1-/- rats 
compared to controls in order to take into account any baseline movement differences that 
may exist between the groups. The movement assessment will compare DAD1-/- rats to 
controls with regard to: 1. locomotor tendencies and spontaneous activity in an open field; 
2. crossing a narrow, elevated balance beam and; 3. motor coordination on a rotarod. 
Firstly, due to D1-like receptor antagonists reducing spontaneous movement in rats (e.g. 
Hoffman & Beninger, 1985; Meyer et al., 1993), it is predicted that DAD1-/- rats will 
display reduced movement compared to controls on the two tasks in which voluntary 
movement is measured, namely in the open field and balance beam tasks. In addition, a 
benefit of measuring locomotor tendencies in an open field is the ability to assess for 
potential differences in anxiety-like behaviour by separately analysing activity that is 
performed in the periphery versus centre zones of the arena. Although in general rats 
display pronounced thigmotaxis (a tendency to prefer the periphery relative to the centre 
of an open field), anxiolytic agents have been found to preferentially increase activity in 
the central zone, relative to increases observed in the periphery (Treit & Fundytus, 1988). 
As an explorative assessment, it will be useful to compare the activity patterns of DAD1-/- 
rats and controls to assess whether DAD1-/- rats display altered levels of anxiety-like 
behaviour in a novel environment. Secondly, regarding the rotarod test in which rats are 
placed on a rotating rod to measure co-ordination, D1 knockout mice demonstrated 
impaired performance on the rotarod (Drago et al., 1994), and microinjection of SCH 
23390 into the SN of rats led to impaired rotarod performance (Bergquist et al., 2003) 
suggesting that D1-like receptors are required for skilled rotarod performance. Thus it is 
predicted that the DAD1-/- rats will demonstrate impaired performance on the rotarod test 
compared to control rats. 
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Lastly, D1-like receptors are critically involved in memory function. While the 
roles of D1-like receptors in memory are still being clarified, they appear to be involved 
in the formation of memories via mechanisms of synaptic plasticity such as LTP and 
LTD, as well as guiding behaviour during working memory tasks (Frey et al., 1991; Li et 
al., 2003; Williams and Goldman-Rakic, 1995; Zahrt et al., 1997). Given that D1-like 
receptors are important for memory, it is possible that a reduction in functional D1 
receptors will result in the DAD1-/- rats demonstrating impaired baseline memory 
function compared to control rats. Alternatively, and with the inverted-U theory of DA 
transmission in the PFC in mind (which posits that too much or too little PFC DA impairs 
memory function) (Williams and Goldman-Rakic, 1995; Zahrt et al., 1997), it is possible 
that the DAD1-/- rats possess sufficient D1 receptor function to support DA 
neurotransmission within the optimum levels required for memory function.  
Planned experiments for chapter 5 included conducting the delayed nonmatching 
to sample (DMTS) test of working memory in an operant chamber in order to investigate 
the acute effects of MDMA on memory performance in the DAD1-/- rats. Prior to testing 
the effects of MDMA on memory function in the DAD1-/- rats, it is necessary to assess 
the ability of DAD1-/- rats on tasks that are required for performance on the DMTS task. 
As previously mentioned, the ability for DAD1-/- rats to autoshape to press a lever will be 
investigated. Learning to lever press for sugar pellet reinforcers is required if memory 
performance following acute MDMA administration is to be assessed using the DMTS 
task. If the DAD1-/- rats do not autoshape to lever press we will need to consider 
alternative memory tasks to access memory function in the DAD1-/- rats. Therefore, 
DAD1-/- and controls rats will also be compared with regard to performance on a 
reinforced spatial memory task using the delayed nonmatching to position (DNMTP) 
paradigm in a T-maze. Although the DNMTP task is conducted in a T-maze and does not 
require an operant lever press in order for the subject to receive a reward, the trial 
structure of the DNMTP task is similar to that of the DMTS task. The DNMTP paradigm 
involves a sample phase, a delay period, and a choice phase, with the subject being 
required to remember which arm to enter during the choice phase in order to attain 
reinforcement. During the sample phase one of the T-maze arms is blocked off, and the 
opposite arm is baited with a food reinforcer for the subject to consume. Once the subject 
has consumed the reinforcer, there is a brief delay period after which the subject is 
returned to the maze for the choice phase. During choice, both arms are open but only the 
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opposite arm to the previously baited arm contains a food reinforcer. Thus to attain 
maximum reinforcement the rat is required to learn to always alternate their arm entry 
during the choice phase.  
In T-maze experiments similar to DNMTP rats display a tendency to 
spontaneously alternate their arm visits on successive trials (Dember & Fowler, 1958; 
Lalonde, 2002; Rodriguez, Gomez, Alonso & Afonso, 1992). The tendency to alternate is 
hypothesised to reflect an attempt to maximise exploration of the environment and it is 
thought to involve memory in that by alternating their arm choice the rat is remembering 
which arm it visited previously and visiting a different arm on this occasion (Dember & 
Fowler, 1958; Lalonde, 2002; Rodriguez et al., 1992). Thus, an assessment of memory 
performance using the DNMTP paradigm will be two-fold. Firstly, whether the DAD1-/- 
and DAD1+/+ rats demonstrate spontaneous alternation in training trial one will be 
examined (i.e. before the subject has learnt that during the choice phase the arm opposite 
to the sample arm will be baited). Based on previous studies, it is predicted that the 
control animals will tend to alternate their arm visits ~70% of the time (e.g. Rodriguez et 
al., 1992). Due to a correct response during the choice phase requiring subjects to 
alternate their arm visit relative to the sample arm, an alternation rate of ~70% translates 
to an accuracy score of ~70%. Secondly, whether the DAD1-/- rats improve their accuracy 
over the 25 training sessions in a manner similar to control rats will be examined.  
Method 
See the general method section (chapter 2) for information pertaining to 
generation of the DAD1-/- and DAD1+/- rat genotypes, housing conditions, and for a 
summary table of the subject groups employed for each experiment.  
Behavioural Paradigms  
 Sucrose preference test. 
 Subjects. Forty-eight adult male Wistar rats (25 DAD1-/- and 23 DAD1+/+ - cohort 
three) were subjects in this experiment. The subjects were housed individually during this 
experiment which took place over five consecutive days, 24 hours per day. Following the 
completion of this experiment subjects were re-housed into groups of three, matched by 
genotype. Laboratory grade animal chow was available ad libitum.  
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Apparatus. The experiment was conducted in the rat’s assigned cage, which was 
identical to their home cage, and they were housed in their usual housing room which had 
a reversed light-dark cycle (lights on at 7 am).  Due to space restrictions, the rats were 
split into five groups – four groups of 10 (five DAD1-/- rats and five DAD1+/+ rats per 
group) and one group of eight (five DAD1-/- rats and three DAD1+/+ rats) which were run 
through the experiment one group at a time (25 days total). The sucrose solution (10 % 
w/v) was made fresh each day by dissolving 100 grams of white cane sugar in 1 litre of 
water. Water and sucrose solutions were dispensed in white plastic drinking bottles which 
contained leak-stoppers in the drinking tube in order to ensure the consumption 
measurements were as accurate as possible.  
 Procedure. This experiment investigated whether DAD1-/- rats demonstrate a 
preference for sucrose solution over water when they are simultaneously available in the 
home cage. The first four days of the experiment involved the subjects having free access 
to sucrose solution and water, on separate days, which alternated over the four days 
(habituation period). For example, a subject may have had access to water on day one, 
sucrose on day two, water again on day three and sucrose on day four - half of the rats 
received this order, with the other half receiving the reverse order. The side of the cage 
(left or right) on which sucrose and water were presented was counterbalanced for each 
rat to avoid position preferences being formed. On day five (choice day), subjects had 
simultaneous access to both sucrose solution and water. The position of the bottle, left or 
right, was randomly assigned for each rat and counterbalanced across genotype. Drink 
bottles, containing either water or sucrose solution, were weighed before and after each 
day (24 hour intervals) in order to record consumption. 
 Performance measures. Although consumption during the first four days 
(habituation period) was examined to ensure subjects were drinking the water and sucrose 
solutions, data for analysis were collected on the choice day. Four measures were 
calculated for each subject:  
1. amount of sucrose solution consumed in grams;  
2. amount of water consumed in grams; 
3. total amount consumed (i.e. consumption of sucrose solution + water) and;  
4. percentage of sucrose solution consumed relative to total consumption. 
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 Planned data analysis. Group means were obtained for each of these four 
measures as a function of genotype. The amount of liquid consumed in grams (of each 
sucrose and water) was then analysed using a 2 (genotype) x 2 (solution) mixed measures 
analysis of variance (ANOVA) with genotype as a between-subjects variable and solution 
as a within-subjects variable. Next, the total amount of liquid consumed and the 
percentage of sucrose consumed relative to water were separately analysed using 
independent samples t-tests with genotype as a between-subjects variable. All statistical 
analyses were conducted using IBM SPSS Statistics version 19.0 for windows. The alpha 
level for statistical significance was set at p < 0.05. Greenhouse-Geisser corrections were 
used in the event of Mauchly’s test of sphericity being violated.  
Consumption of freely available sugar pellets.  
Subjects. Eight adult male Wistar rats (four DAD1-/- and four DAD1+/- – cohort 
one) were subjects in this experiment. The subjects were on a restricted food regime to 
maintain their weights at 85% of their free feeding weights. This involved feeding each 
cage of two rats once per day, seven days a week, approximately 24 grams of rat chow. 
Apparatus. A clean cage which was identical to the home cages was used as the 
testing arena in all trials. In between each trial, the cage was wiped clean with Virkon ‘S’ 
disinfectant (Southern Veterinary Supplies, Palmerston North, NZ to remove any 
olfactory cues, and fresh saw dust was laid down to line the cage. At one end of the cage, 
ten 45 mg Bio-serv® sugar pellets were placed in a round, white ramekin dish (diameter 
= 9cm). 
Procedure. This experiment assessed whether white odourless sugar pellets, used 
in lever-operated operant chambers in our lab, are consumed within a similar time-frame 
by both DAD1-/- and DAD1+/- rats when the pellets were freely available. Each session 
began by placing the rat in the test cage at the opposite end from the sugar pellets, and 
facing in the direction of the pellets. Once the rat was placed in the cage, the lid was 
immediately placed on top of the cage and a timer was started. The trial terminated once 
the rat had consumed all of the sugar pellets, or after 25 minutes had passed. If the sugar 
pellets were not consumed within 25 minutes, the data from this trial were not included in 
the final analysis. Once the trial had ended, the rat was removed from the testing cage and 
returned to their home cage. Each rat completed three trials, with approximately seven 
days separating each testing day.  
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Performance measure. The time taken in seconds to consume all ten sugar pellets 
was recorded for each of the three sessions, per rat.  
Planned data analysis. Group averages of the time taken to consume all ten 
pellets were calculated as a function of genotype and session. These data were analysed 
using a 2 (genotype) x 3 (session) mixed measures ANOVA, with genotype as a between-
subjects variable and session as a within-subjects variable. In the event that an interaction 
between genotype and session is detected, independent samples t-tests will be conducted 
post hoc for each session separately with genotype as a between-subjects variable and 
time taken to consume the pellets as the dependent measure. All statistical analyses 
presented in this chapter were conducted using IBM SPSS Statistics version 19.0 for 
windows. The alpha level for statistical significance was set at p < 0.05 across all 
analyses. Lastly, for repeated measures analyses, Greenhouse-Geisser corrections were 
used in the event of Mauchly’s test of sphericity being violated. 
 Autoshaping to lever press, FR-1 reinforcement.  
Subjects. Eight adult male Wistar rats (four DAD1-/- and four DAD1+/- – cohort 
one) were subjects in this experiment. During this experiment the rats were on a restricted 
food regime to maintain their weights at 85% of their free feeding weights. This involved 
feeding each cage of two rats once per day, seven days a week, approximately 24 grams 
of rat chow. Prior to the start of this experiment these rats were subjects in the 
consumption of sugar pellets experiment reported above.  
Apparatus. Rats were trained in Med Associates® standard rat operant chambers 
(ENV 008) measuring approximately 31 cm x 31 cm x 25 cm. The experiment was 
conducted in a room adjacent to the home cage room. Each rat was assigned to an 
experimental chamber in which it performed all training. There were two response levers 
situated on the front interface panel of each chamber, 5 cm above the floor, and 1 
response lever located in the middle of the opposite wall. A sugar pellet dispenser (which 
delivered 45 mg Bio-serv® sugar pellets) was located at floor level between the two 
levers on the front panel. Lever presses were recorded on a PC that was located in the 
adjacent room.  
Procedure. This experiment followed the standard autoshaping procedure used in 
our laboratory (Harper, 2013; Harper et al., 2005; 2006). The autoshaping procedure 
involved the following sequence of events: one of the three levers (randomly determined) 
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was inserted into the chamber and the corresponding light above it was illuminated. If 
after 12 seconds the rat had not responded on the lever, the lever was retracted, the light 
turned off and a sugar pellet was delivered. Thirty seconds later, one of the 3 levers was 
inserted and another trial began. If during the presence of the lever the rat made a single 
response then that lever was immediately retracted, the light turned off and a sugar pellet 
delivered. 
Rats were exposed to nine autoshaping sessions each and the sessions lasted until 
80 pellets were delivered or 30 minutes had elapsed, which ever occurred first. During 
training the room lights were switched off. 
Performance measure. For each rat, the number of lever presses performed 
during each of the nine sessions was recorded.  
Planned data analysis. Group averages of the number of lever presses per session 
were calculated as a function of genotype. The number of lever presses over each session 
were subsequently analysed using a 2 (genotype) x 9 (session) mixed measures ANOVA 
with genotype as a between-subjects variable and session as a within-subjects variable. In 
the event that an interaction between genotype and session is detected, independent 
samples t-tests will be conducted post hoc for each session separately with genotype as a 
between-subjects variable and the number of lever presses as the dependent measure.  
Open field.  
Subjects. Twenty-four adult male Wistar rats (11 DAD1-/- and 13 DAD1+/+ – 
group two from cohort three) were subjects in this experiment. These rats were previously 
subjects in a maze task used for the current thesis (DNMTP – acquisition presented in the 
current chapter, drug doses presented in chapter 5) during which they experienced several 
acute drug administrations including non-neurotoxic doses of MDMA, SKF 81297 (D1-
like receptor agonist) and saline. There was a two week washout period after the 
completion of the maze task and prior to starting the open field experiment to minimise 
carry-over effects from the drug treatments. Groups were matched with regard to their 
previous experiment and drug treatment histories. The maze experiment was conducted 
over a three and half month period, thus at the beginning of the open field experiment 
subjects were six - nine months old. 
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Apparatus. Horizontal movement and rearing were observed in eight Plexiglas 
open field chambers (Med Associates Inc, USA; model ENV-515) measuring 42 cm x 42 
cm x 30 cm. The chambers were set in sound attenuating boxes. Horizontal movement 
(distance travelled in cm) was recorded using four sets of 16 infra-red sensors spaced 
evenly on the walls of the chamber which created a photobeam lattice, squares of the 
dimension 25 mm x 25 mm, which was located 4 cm above the floor of the chamber. A 
second photobeam lattice was located 15 cm above the floor of the chamber which 
detected vertical movement (rearing counts). A PC located in the experimental room 
recorded distance travelled and rearing counts.  
Procedure. Each rat’s activity was recorded on three separate sessions over the 
space of nine days (one session every three days) and on each session their activity was 
recorded for 30 minutes. At the start of a session, subjects were transported into the 
experimental room and habituated to the room for 30 minutes. Rats were then carefully 
placed into an assigned activity box which triggered the start of activity recording. During 
recording the main room light was switched off and a red light was used for illumination. 
To mask any extraneous noises, a white noise generator was used during the sessions. 
After 30 minutes rats were immediately removed from the chambers and placed back in 
their home cages in their home cage room. The chambers were thoroughly cleaned with 
Virkon ‘S’ disinfectant after each session. 
Performance measures. In each of the three 30 minute sessions, activity was 
recorded in six 5 minute time intervals. Horizontal locomotor activity was measured as 
distance travelled in cm. Rearing counts were defined as the interruption of the upper 
photo beams, one count per interruption. Activity in the centre and periphery of the 
chamber was analysed separately, with the central zone defined as the inner 19 cm x 19 
cm area, with the rest of the chamber being the periphery.  
Planned data analysis. To generate time-course data, each subject’s distance 
travelled in cm and rearing counts in the centre or periphery were separately averaged 
across the three sessions for each of the six 5 minute time intervals. Subject averages for 
each of the six 5 minute time intervals were then used to calculate group time interval 
averages as a function of genotype and location (periphery and centre). The group time-
course data for both distance travelled in cm and rearing counts were analysed separately 
for each location using four 2 (genotype) x 6 (time) mixed measures ANOVAs with 
65 
 
genotype as a between-subjects variable and time as a within-subjects variable. In the 
event that an interaction between genotype and time is detected, independent samples t-
tests will be conducted post hoc for each time interval separately with genotype as a 
between-subjects variable and distance travelled or rearing counts in either the centre or 
periphery as the dependent measures.  
Balance beam.  
Subjects. Eight adult male Wistar rats (four DAD1-/- and four DAD1+/- – cohort 
one) were subjects in this experiment. Laboratory grade animal chow and water was 
available in their home cages ad libitum. Prior to the start of this experiment these rats 
were subjects in the consumption of sugar pellets and autoshaping experiments reported 
above.  
Apparatus. See figure 3 for a diagram of the beam apparatus. The beam was 80 
cm in length and raised 80 cm off the ground using plastic supports to suspend both ends. 
The beam was suspended as such that at one end, the starting end, there was a sheer drop 
and at the opposite end, the finishing end, there was a ledge, on top of which sat the 
subject’s home cage. At the starting end of the beam a line was marked across the beam at 
20 cm from the sheer edge (on the opposite end to the home cage). Foam padding 10 cm 
in thickness was on the ground beneath the beam in order to prevent injury in the event 
that an animal fell off the beam.  
 
 
Figure 3. Diagram of the balance beam apparatus.  
 
100cm 
80 cm 
80cm 
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Procedure. The balance beam task has been employed to study the movement 
deficits in Parkinson’s disease using rat and mice models. Performance on the balance 
beam requires balance and co-ordinated movement (Truong, Allbutt, Kassiou, & 
Henderson, 2006).  
A trial on the balance beam began when the experimenter carefully placed a 
subject on the beam, with all four of its feet behind the starting the line located at the 
sheer end of the beam and with the rat facing the home cage. Once the rat was secure on 
the beam, the experimenter released the rat and started a timer. To complete the trial the 
subject was required to walk the full length of the beam and enter their home cage within 
2 minutes. There were two balance beam sessions over the space of one week. Both 
sessions involved all rats experiencing three trials (i.e. there was a total of six trials per 
rat).   
Performance measures. Initially, there were two timing measures recorded during 
each trial:  
1. latency to step over the 20 cm line, determined once a weight bearing footstep was placed 
entirely over the 20 cm line, representing the latency to begin the task and;  
2. latency to reach the home cage (determined once all four feet were off the beam and in 
the home cage). 
However, so few trials were completed by DAD1-/- rats that in the place of latency 
measures, the dependent variable used was whether or not the trial was completed within 
the 2 minute time frame. 
Planned data analysis. Given that the dependent measure used generates a 
dichotomous categorical variable (was the trial completed, yes or no?) and given the 
small sample size, Fishers exact test was used to analyse the data which was grouped by 
genotype. Separate tests were calculated for each of the six trials with genotype as a 
between-subjects factor and whether or not the trial was completed as an outcome 
variable. 
 Rotarod. 
Subjects. This experiment was conducted twice with two different groups of rats. 
The apparatus and procedure used were identical across both replications, but the two 
groups differed in the amount of handling they experienced prior to the rotarod 
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experiment. The minimally handled group comprised 18 adult male Wistar rats (ten 
DAD1-/- and eight DAD1+/+ – group one from cohort three) which were handled for five 
consecutive days prior to the start of the experiment. The extensively handled group 
comprised 24 adult male Wistar rats (11 DAD1-/- and 13 DAD1+/+ – group two from 
cohort three) which were subjects in a previously conducted maze task (DNMTP - 
acquisition presented in the current chapter, drug doses presented in chapter 5) and 
experienced three and a half months of handling, four – five days per week prior to the 
start of the rotarod experiment. Handling was manipulated due to the control rats in the 
first group that was run (minimally handled group) not performing the task well.  
Apparatus. The rotarod apparatus was constructed in-house based on standard 
rotarod dimensions used frequently in the literature. The rotarod consisted of a white 
plastic cylindrical rod which had a 30 cm circumference and was 10 cm wide. During the 
experiment the subjects perched on the rod which mechanically rotated along its axis. To 
improve traction for the rats there was sand paper covering the exterior of the rod which 
was attached with adhesive. At each length of the rod there were white, round Plexiglas 
sheets attached which created walls on the rod measuring 22 cm from the axis of the rod. 
These walls ensured that the subject could not climb off of the rod during the experiment. 
The rod was suspended 21 cm above the floor from the highest point of the rod where the 
rats would sit. There was a small enclosed space underneath the rod in which the animals 
were contained in, in the event that they came off of the rod. The rotation speed of the rod 
could be increased or decreased manually using a dial which was located on the external 
motor used to power the rod.  
Procedure. On each day of the experiment the subjects were transported in their 
home cages to the experiment room. The home cages sat on a large table and rats were 
habituated to the room for 30 minutes. The subjects were first habituated to the rotarod 
when it was stationary over the course of three sessions which were separated by a day 
off between each session. Habituation involved placing a rat on the rod several times and 
releasing the rat to ensure that it was able to sit on the rod unassisted. Next the subject 
was gently held next to the stationary rod and rats could voluntarily step onto the rod. 
After three sessions of habituation, the rats that reliably stepped onto the rod and sat 
unassisted advanced to the testing phase.  
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The experiment phase began 48 hours after the third habituation session. The 
experiment phase involved 6 sessions – three training sessions and three testing sessions 
using three different rod rotation speeds (10, 20 and 30 revolutions per minute (RPM)). 
Specifically, on day one of the experimental phase there was a training session using the 
10 RPM speed. Forty-eight hours later there was a testing session using the 10 RPM 
speed. Forty-eight hours after the 10 RPM testing session, a second training session was 
conducted using the 20 RPM speed which was again followed up 48 hours later with a 
testing session using the 20 RPM speed. This structure was repeated for the 30 RPM 
speed. On the day of each session, rats were habituated to the experiment room for 30 
minutes with the rotarod motor running so that the subjects habituated to the sound of the 
motor. Each training session began by gently holding the rat adjacent to the rod while it 
was stationary and allowing them to step onto the rod. They were then gently removed 
from the rotarod, the rotarod was turned on and the rat was held close to the rod once 
again to allow the rat to step onto the rod while it was rotating. A timer was started as 
soon as the rat was walking on the rod unassisted to record the time the rat spent on the 
rod. The trial was terminated in the event that the rat fell from the rod or until 2 minutes 
elapsed, which ever occurred first. If the rat did not voluntarily step onto the rod after 
several attempts, the rat was placed back into its cage and the next rat began its trial. On 
each training session the rats had five trials each, with approximately 15 minutes in 
between each of these five trials. On each training session the subjects were required to 
spend at least 10 seconds or more on two or more trials out of 5 to advance to the next 
session. Testing sessions were identical to training sessions except that only one trial was 
conducted, rather than five.  
Performance measures. Data for analysis was collected on the three test days. 
The amount of time each rat spent on the rod at the three speeds tested was determined in 
seconds.  
Planned data analysis. Time spent on the rod in seconds was averaged by 
handling group (minimal versus extensive handling) and genotype. Time spent on the rod 
was to be separately compared in the two handling groups using two 2 (genotype) x 3 
(RPM) mixed measures ANOVAs with genotype as a between-subjects factor and RPM 
(10, 20 or 30 RPM) as a within-subjects factor. In the event that an interaction between 
genotype and session is detected, independent samples t-tests will be conducted post hoc 
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for each RPM separately with genotype as a between-subjects variable and time spent on 
the rad as the dependent measure.  
 Delayed non-matching to position. 
Subjects. Thirty adult male Wistar rats (15 DAD1-/- and 15 DAD1+/+ rats – groups 
two and three from cohort three) were used in this experiment. Water and wood shavings 
were available ad libitum in the home cages. The subjects’ weights were maintained at 
85% of their free feeding weights with food pellets delivered to their home cages seven 
days a week straight after experimentation had been completed on experimental days. 
These rats were drug naïve, and were subjects in the sucrose preference test which is also 
presented in this chapter.  
Apparatus. This paradigm was conducted using a wooden T-maze which had 
metal inners inserted into it to form the walls of the maze. This was done in order to 
create taller walls and shorter arm and stem lengths than provided by the wooden maze. 
The metal inserts were 30 cm high, the two arms were 30 cm long and the stem was 45 
cm long. The width of the maze throughout was 9 cm. The stem was painted grey and the 
arms were painted black. Two pieces of black plexi-glas that were the same height as the 
maze walls were used to block the maze arms. These “doors” were attached at the top of 
the maze, and acted as sliding doors that were controlled manually when they were 
needed to block off either of the arms. Where the doors crossed the arms to block entry 
were defined as the entry lines to the arms.  
White odourless sugar pellets (45 mg Bio-serv®) were used as reinforcement. The 
sugar pellets were delivered at the end of each T-maze arm, in round white plastic 
containers (3 cm across) which were secured to the floor of the maze using adhesive.  
Procedure. This experiment was conducted on weekdays between the hours of 9 
am and 6 pm. Rats were handled for 5 – 10 minutes each on five consecutive days prior to 
the start of this experiment. The day after the last handling day, rats began four days of 
habituation to the T-maze apparatus. Habituation sessions involved placing a rat in the 
stem of the maze and allowing them to explore the maze for 5 minutes. On days one and 
two of habituation there were five sugar pellets available to the rats in the maze – one in 
each of the containers at the end of the maze arms, one in the middle of each of the arms 
and one at the junction of the two arms and the stem. On days three and four of 
habituation there were four sugar pellets in the maze, two in each of the containers at the 
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end of the arms. On day four of habituation the subjects who reliably ate the sugar pellets 
from both the left and right maze arms advanced to the training stage of the experiment.  
Training sessions began the day following the last habituation day. There were 25 
training sessions conducted, with six trials per session. Each trial was separated by a 5 
minute inter- trial interval. Each trial involved a sample presentation phase, a delay and a 
choice phase. During sample presentation either the left or right arm was baited with one 
sugar pellet and entry to this arm was unimpeded. Entry to the opposite arm was blocked 
using the Plexiglas door thus only the sample arm was able to be accessed by the rat. The 
rat was placed at the end of the stem of the maze, facing the junction between the stem 
and the arms, and was given 2 minutes to consume the pellet. Once the rat entered the 
baited arm (deemed the sample arm) defined as when all four feet had crossed the entry 
line, the door was slid closed to confine the subject to this arm. On the contrary, if the 
subject did not enter the sample arm within the allotted 2 minutes, the rat was removed 
from the maze and the trial was terminated. Once the rat had consumed the pellet, it was 
removed from the arm and placed in a holding cage for 10 seconds which was situated on 
a table behind the stem end of the maze. During this brief delay both doors were slid open 
and both arms appeared to be re-baited. In reality, only the previously blocked arm was 
baited and the sample arm was unbaited. Thus in order to retrieve the reward the rat was 
required to visit the opposite arm to the sample arm. The choice phase began after the 
delay period. The rat was placed in the stem of the maze and given 2 minutes to explore. 
If the rat entered one of the arms, the door to that arm was slid closed and the rat was 
confined to that arm. In the event that the arm entered was the previously baited arm (i.e. 
the sample arm) which was now unbaited, the rat was confined to this arm for 2 minutes. 
If the rat alternated their arm entry and entered the baited arm, the rat was allowed to 
consume the pellet and then removed from the maze and placed back into their home 
cage. If the rat did not enter either of the arms during the 2 minutes given then the rat was 
removed from the maze and the trial was terminated. Lastly, the experimenter monitored 
the consumption of the sugar pellets and in the event that a rat entered an arm but did not 
consume an available sugar pellet within 1 minute, the trial was terminated.   
Whether the baited arm during the sample phase was on the left or right side was 
pseudo-randomly selected and counterbalanced across both groups of rats. Of the six 
trials conducted per session per rat, three of the sample arms were on the left, and three 
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were on the right. Between each trial the maze was wiped out thoroughly with Virkon ‘S’ 
disinfectant.  
Performance measures. Three performance measures were collected:  
1. whether the arm entered during the choice phase matched the sample arm (incorrect 
response) or did not match the sample arm (correct response);  
2. latency in seconds to enter the forced choice arm during the sample presentation phase;   
3. latency in seconds to enter an arm during the choice phase. 
Planned data analysis. Accuracy data was calculated by determining the 
percentage of correct trials performed by each rat during each of the 25 sessions. The 
individual accuracy scores were then averaged by genotype to allow for group 
comparison. Similarly, for both of the latency measures, each subject’s performance on 
the six trials within a session were averaged, and then group means were calculated as a 
function of genotype.  
Firstly, group accuracy scores on trial one were checked to ensure they were at or 
around 70 - 75% which would be indicative of a tendency to alternate their arm visits. 
Next, using group accuracy scores on trial one, an independent samples t-test was carried 
out with genotype as the between-subjects variable to assess for group differences in 
alternation behaviour prior to the DNMTP task being learned.  
Secondly, each of the three dependent measures (accuracy, latency to enter the 
forced choice arm during the sample run and latency to enter an arm during the choice 
run) observed across the 25 training sessions were then subjected to 2 (genotype) x 25 
(session) mixed measures ANOVAs, with genotype as a between-subjects variable and 
session as a within-subjects variable. The accuracy analysis was performed to assess for 
learning across the 25 sessions, and the latency comparisons were assessing for 
differences in movement. In the event that interactions between genotype and session are 
detected, independent samples t-tests will be conducted post hoc for each session 
separately with genotype as a between-subjects variable and accuracy as the dependent 
measure.  
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Results 
Sucrose Preference Test 
Figure 4 shows the total amount of water and sucrose consumed. As expected, a 
significant effect of solution was observed, F1,44 = 248.59, p < .001, with both genotypes 
consuming more sucrose solution (M = 81.04; SD = 34.13) than water (M = 4.67; SD = 
2.49). In line with the finding that DAD1-/- rats are smaller than the control rats, there was 
a significant effect of genotype, F1,44 = 5.34, p = .03, with DAD1
-/- rats (M = 74.61; SD = 
32.83) drinking less overall compared to DAD1+/+ rats (M = 96.83; SD = 32.36). There 
was also a significant interaction between solution and genotype, F1,44  = 5.06, p = .03, 
which, on the basis of follow-up independent samples t-tests indicates that the DAD1-/- 
rats consumed the same amount of water as controls, t44 = -.29, p = .77, yet significantly 
less sucrose than controls, t44 = -2.29, p = .03. However, due to the floor effect that can 
be observed with regard to the amount of water consumed, the interaction is likely driven 
by the finding that the DAD1-/- rats consumed less liquid overall than the DAD1+/+ rats 
(i.e. the main effect of genotype reported above). Indeed, when the percentage of sucrose 
solution consumed, relative to the total amount consumed across water and sucrose 
solution, is compared across genotype, no significant difference is observed, t44 = -.88, p 
= .38, with both genotypes showing a strong preference for the sucrose solution over 
water. As depicted by figure 5, approximately 94 - 95% of the total liquid consumed by 
both genotypes was sucrose solution. 
  
Figure 4. Amount of sucrose solution and water consumed in grams by DAD1-/- (n = 25) 
and DAD1+/+ (n = 23) rats over a 24 hour period on the choice day of the sucrose 
preference test.  
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Figure 5. Mean percentage of sucrose solution consumed relative to the total liquid 
consumed (water + sucrose solution) by DAD1-/- (n = 25) and DAD1+/+ (n = 23) rats 
over a 24 hour period on the choice day of the sucrose preference test.  
 
Consumption of Freely Available Sugar Pellets  
 A group comparison of the time taken to consume ten freely available sugar 
pellets (figure 6) revealed no significant effect of session, F1.01, 6.01 = 2.74, p = .10, no 
significant effect of genotype, F1,6 = 2.32, p = .18, and no significant interaction between 
session and genotype, F1.01,6.04 = 1.42, p = 0.28. However, in the first session the 
environment was novel and the subjects were not aware of the presence of the sugar 
pellets (also, an independent samples t-test revealed no significant difference between 
genotype in session one latencies, t6 = 1.30, p = .24). Thus, the first of the three sessions 
could be conceived of as qualitatively different from the following two sessions. As such, 
a 2 (session) x 2 (genotype) mixed measures ANOVA was conducted using latency to 
consume the ten pellets in sessions two and three. There was no significant effect of 
session observed, F1,6 = 5.32, p = .06, although the approaching significance p-value 
suggests there was a trend for rats to eat the pellets more slowly on session two (M = 
27.13, SD = 9.45) compared to session three (M = 17.00, SD = 10.60). A significant 
difference between genotype was detected, with the DAD1-/- rats (M = 28.50, SD = 2.40) 
consuming the sugar pellets more slowly than the DAD1+/- rats (M = 15.63, SD = 2.40), 
F1,6 = 14.3, p = .01. There was no significant interaction between genotype and session, 
F1,6 = 0.10, p = .77.  
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Figure 6. The time taken in seconds by DAD1-/- (n = 4) and DAD1+/- (n = 4) rats to 
consume ten freely available sugar pellets across three sessions. 
 
Autoshaping to Lever Press, FR-1 Reinforcement 
 The number of lever presses performed across the nine autoshaping sessions was 
compared by genotype. A significant effect of genotype was found, F1,6 = 30.09, p < .01, 
with the DAD1-/- rats (M = .83, SD = .49) making fewer lever presses than the DAD1+/- 
rats (M = 60.97, SD = 21.92). There was no significant effect of session, F8,48 = 1.31, p = 
.26, and no significant interaction between session and genotype, F8,48 = 1.26, p = .29. 
Depicted by figure 7, these data indicate that the DAD1-/- rat’s lever pressed markedly 
less than DAD1+/- rats which did not change as a function of session.  
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Figure 7. Operant responding for sugar pellets maintained under an FR-1 schedule of 
reinforcement. The number of lever presses made by DAD1-/- (n = 4) and DAD1+/- (n = 
3) rats is plotted over nine training sessions.   
 
Open Field 
Horizontal activity – distance travelled (cm). See figure 8 for comparison of the 
mean distance travelled by DAD1-/- and DAD1+/+ rats in both the centre and periphery of 
the chamber.  
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Figure 8. Mean distance travelled by DAD1-/- (n = 11) compared to DAD1+/+ (n = 13) 
rats in the centre and periphery of the open field chamber. Data is averaged across three 
30 minute sessions.  
 
Centre. As shown in figure 9 the time-course of horizontal activity in the centre of 
the chamber was fairly similar in both DAD1-/- and DAD1+/+ rats. While there was no 
significant effect of genotype, F1, 22 = .80, p = .38, and no significant interaction between 
genotype and time, F2.2, 49.4 = .89, p = .43, there was a significant effect of time, F2.2, 49.4 = 
70.19, p < .01. As shown in figure 9 the rats moved more in the first 5 minute time 
interval compared to the other time intervals, with rats travelling around 250 cm during 
the first 5 minutes. Furthermore, activity was consistent from around 10 minutes through 
until the end of the 30 minutes, with rats travelling approximately 50 - 100 cm during the 
remaining time intervals. 
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Figure 9. Time-course of distance travelled (cm) in the centre of the chamber by DAD1-/- 
(n = 11) and DAD1+/+ (n = 13) rats, averaged across three 30 minute open field sessions. 
 
Periphery. In a manner similar to distance travelled in the centre of the chamber, 
the time-course pattern of horizontal activity in the periphery was comparable across 
DAD1-/- and DAD1+/+ rats (figure 10). There was no significant effect genotype, F1, 22 = 
.15, p = .70, and no significant interaction between genotype and time, F1.8, 39.7 = .85, p = 
.43, but there was a significant effect of time, F1.8, 39.7 = 115.58, p < .01. As shown by 
figure 10, the rats were more active in the first 5 minute time interval, travelling 
approximately 550 cm, with the distance travelled diminishing to plateaux at around 100 - 
200 cm during each of the remaining 5 minute intervals.  
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Figure 10. Time-course of the distance travelled in cm in the periphery of the chamber 
by DAD1-/- (n = 11) and DAD1+/+ (n = 13) rats, averaged across three 30 minute open 
field sessions. 
 
Rearing counts. See figure 11 for a comparison of mean rearing counts made by 
DAD1-/- and DAD1+/+ rats in the centre or periphery of the chamber. 
 
 
Figure 11. Mean rearing counts made by DAD1-/- (n = 11) compared to DAD1+/+ (n = 
13) rats in the centre and periphery of the open field chamber. Data is averaged across 
three 30 minute sessions. 
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Centre. As shown by figure 12, the time-course of rearing counts performed in the 
centre of the chamber was similar DAD1-/- and DAD1+/+ rats. There was no significant 
effect of genotype, F1, 22 = .05, p = .83, and no significant interaction between genotype 
and time, F2.7, 59.2 = .63, p = .59, but there was a significant effect of time, F2.7, 59.2 = 20.22, 
p < .01. As with horizontal locomotor activity, figure 12 shows that rearing counts in the 
centre of the chamber peaked in the first 5 minute interval, at around 6 counts, and then 
plateaued fairly rapidly to around 1 - 2 counts for the remaining time intervals.  
 
 
Figure 12. Time-course of rearing counts in the centre of the chamber made by DAD1-/- 
(n = 11) and DAD1+/+ (n = 13) rats, averaged across three 30 minute open field sessions. 
  
Periphery. See figure 13 for a depiction of the time-course of rearing counts 
performed in the periphery of the chamber. Once again, the DAD1-/- and DAD1+/+ rats 
performed comparably. There was no significant effect of genotype, F1, 22 = .03, p = .86, 
no significant interaction between genotype and time, F2.4, 51.7 = .29, p = .79, but there 
was a significant effect of time, F2.4, 51.7 = 67.92, p < .01. Figure 13 displays the same 
pattern as above, with there being approximately 20 rearing counts in the first 5 minute 
time interval, with counts dropping to around 5 counts across all other intervals across 
genotype.  
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Figure 13. Time-course of rearing counts in the periphery of the chamber made by 
DAD1-/- (n = 11) and DAD1+/+ (n = 13) rats, averaged across three 30 minute open field 
sessions. 
 
Summary of open field data. DAD1-/- and DAD1+/+ rats displayed very similar 
patterns of locomotor activity (in terms of distance travelled and rearing counts) in both 
the peripheral and central zones of the chamber. Taken together, these data suggest that 
the DAD1-/- rats did not display altered spontaneous locomotor tendencies or anxiety-like 
behaviours compared to control rats in an open field. 
Balance Beam 
The number of subjects that completed each of the six balance beam trials was 
compared by genotype (figure 14). As determined using Fishers exact test for 
dichotomous categorical variables, for trials one, two and three there were no significant 
differences between the genotypes, p = 1.00, p = .43 and p = .43, respectively. In contrast 
for trials four and five there were significant differences between the genotypes, p = .03 
and p = .03 respectively, with no DAD1-/- rats completing either trial 4 or 5, yet all of the 
DAD1+/- rats completing both of these trials.  However, the genotype comparison for trial 
six was non-significant, p = .14, despite the fact that only one DAD1-/- rat completed this 
trial compared to all four of the DAD1+/- rats completing it. Therefore, it is likely that trial 
6 did not reach significance due to a lack of statistical power.  
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Figure 14. Mean percentage of balance beam trials completed by DAD1-/- (n = 4) and 
DAD1+/- (n = 4) rats across 6 trials. To complete a trial subjects were required to cross a 
narrow, elevated beam and enter their home cage within 2 minutes.  
 
Rotarod 
 Minimally handled group. The rotarod task was used to compare motor 
coordination across genotypes at three different speeds (10, 20 and 30 RPM). 
Surprisingly, the control rats in the minimally handled group did not acquire this task well 
and there were high levels of attrition (attrition rates for DAD1+/+ rats: 10 RPM - 3/8; 20 
RPM - 6/8; 30 RPM - 7/8; and DAD1-/- rats: 30 RPM - 6/10). As such, for the highest 
RPM, only one control rat remained meaning that the data from this speed cannot be 
subject to means testing. Therefore, a 2 (genotype) x 2 (RPM; 10 or 20) mixed measures 
ANOVA was conducted with RPM as the within-subjects variable and with time spent on 
the rotarod as the dependent measure (figure 15). There was an approaching significant 
effect of genotype, F1,10 = 4.42, p = .06, suggesting that the DAD1
-/- rats (M = 71.60; SD 
= 30.49) spent longer on the rotarod than the DAD1+/+ rats (M = 24.00; SD = 13.44), 
although this needs to be interpreted with caution due to being just shy of statistical 
significance. No significant effect of RPM, F1,10 = 1.84, p = .21, was observed and no 
significant interaction between RPM and genotype, F1,10 = .02, p = .90, was found.  
 
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6
P
e
rc
e
n
ta
ge
 o
f 
tr
ia
ls
 c
o
m
p
le
te
d
Trial
DAD1-/-
DAD1+/-
82 
 
 
Figure 15. The time in seconds that the minimally handled rats spent on the rotarod at 
three speeds (10 RPM: n = 10 DAD1-/- & 5 DAD1+/+; 20 RPM: n = 10 DAD1-/- & 2 
DAD1+/+; 30 RPM: n = 4 DAD1-/- & 1 DAD1+/+).  
 
Extensively handled group. Due to the high levels of attrition observed during 
the first rotarod experiment using minimally handled rats, a second cohort of rats who 
were extensively handled (four – five days per week for three and a half to four months) 
prior to this experiment were run through the same rotarod procedure. Again, however, 
high levels of attrition were observed with this being especially pronounced in the control 
animals, and the experiment was necessarily disbanded. Specifically, despite extensive 
habituation, too few control rats completed any of the speeds tested to conduct means 
testing on the data.  
Delayed non-matching to position 
 Accuracy. Group accuracy as a function of genotype was compared across the 25 
training sessions (figure 16). Firstly, on training trial one the DAD1-/- and DAD1+/+ rats 
displayed comparable levels of accuracy (~72 - 73%) with no significant difference 
between the groups, t28 = -.19, p = .85. This finding suggests that both DAD1
-/- and 
DAD1+/+ tend to alternate their arm choices prior to learning the DNMTP task. Secondly, 
group analysis of accuracy across all 25 training trials revealed no significant effect of 
genotype, F1, 28 = 2.85, p = .10, and no significant interaction between genotype and 
session, F25,700 = .66, p = .89, indicating that the DAD1
-/- and control rats performed the 
DNMTP task with a similar degree of accuracy over successive trials. There was a 
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significant effect of session, F25, 700 = 1.84, p = .02, which figure 16 indicates is due to the 
accuracy of both DAD1-/- and DAD1+/+ rats increasing as the sessions progress. Accuracy 
across both groups increased from ~72 - 73% on the first trial to around ~85 - 90% on 
trial 25. 
 
 
Figure 16. Accuracy of DAD1-/- (n = 15) and DAD1+/+ (n = 15) rats on the DNMTP task 
over 25 sessions. Each session contained six trials, with an accurate response defined as 
when subjects entered the opposite arm during the choice phase to the arm entered 
during the sample phase.  
 
Latency. Latency to enter the forced-choice sample arm during the sample phase 
was compared between genotypes across the 25 training trials. There was no significant 
effect of genotype, F1, 28 = .05, p = .82, and no significant interaction between genotype 
and session, F1.62, 45.37 = .26, p = .72, suggesting that DAD1
-/- and DAD1+/+ rats entered 
the sample arm within a similar time frame across sessions. There was a significant effect 
of session, F1.62, 45.37 = 10.18, p < .01, which figure 17 indicates was due to the latency to 
enter the sample arm being slower in the first few trials than later trials. In the first 
session the subjects took around 10 seconds to move into the sample arm, yet by the sixth 
session, and thereafter, this time was reduced to 2 - 3 seconds. 
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Figure 17. The time taken in seconds for DAD1-/- (n = 15) and DAD1+/+ (n = 15) rats to 
enter the forced-choice sample arm during the sample phase on the DNMTP task.  
 
 The latency to enter an arm during the choice phase was compared between 
genotypes across the 15 training sessions. There was no significant effect of genotype, F1, 
28 = 1.63, p = .21, as well as no significant interaction between genotype and session, 
F1.98, 55.43 = .29, p = .75. Interestingly, although there were no effects of genotype found, 
figure 18 indicates that after 12 sessions the DAD1-/- rats were consistently slower (taking 
around 3-4 seconds) than control animals (2 seconds). Again, there was an effect of 
session, F1.98, 55.43 = .8.32, p < .01, with figure 18 suggesting that this effect is due to 
subjects entering an arm during the choice phase slower in the first session (around 10 
seconds) than in subsequent sessions (2-4 seconds). Collectively, the latency data from 
both the sample and choice phases suggest that the DAD1-/- and DAD1+/+ rats entered the 
T-maze arms within a similar time frame, albeit slightly, but not significantly, slower 
during the choice phase, across the 25 sessions.  
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Figure 18. The time taken in seconds for DAD1-/- (n = 15) and DAD1+/+ (n = 15) rats to 
enter an arm during the choice phase on the DNMTP task. 
 
Discussion 
This chapter explored the drug-free behavioural tendencies of DAD1-/- rats compared 
to control rats on a number of tasks that were predicted to engage DA D1 receptors. In 
particular, behaviours relevant for reward, movement, and memory were investigated. 
Although on many tasks the DAD1-/- rats performed similarly to controls, important 
differences between the DAD1-/- rats and controls were detected that influence the 
experiment selection for chapter 5.  
Firstly, tasks that measured reward-related behaviours were conducted. In line with 
predictions deriving from the incentive salience hypothesis (Berridge 2007; Berridge & 
Robinson, 1998), DAD1-/- and control rats both displayed a strong preference for sucrose 
solution over water when they were freely available in the home cage. Both genotype groups 
consumed approximately 94 - 95 % of sucrose solution relative to water on the test day. This 
finding suggests that a genetic decrease in functional D1 receptors does not affect the hedonic 
impact of rewards, or reward ‘liking’. Next, the time taken for rats to consume ten freely 
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available odourless sugar pellets was tested across three sessions. These pellets are used as 
reinforcement in the operant-based DMTS paradigm which is a planned experiment for 
chapter 5, as well as in the autoshaping to lever press experiment presented below. 
Unexpectedly, compared to control rats the DAD1-/- rats took significantly longer to consume 
the pellets during sessions two and three. Important to note is that while the DAD1-/- rats were 
slower than controls, all of the subjects from both genotypes consumed all of the pellets and 
by the third session the DAD1-/- rats took approximately 25 seconds to consume the pellets, 
whereas the controls took around 10 seconds. This indicates that although the DAD1-/- rats 
were comparatively slower to consume the pellets than control rats, the DAD1-/- rats were 
seemingly motivated to consume the pellets shortly after being placed in the experiment cage. 
While the finding that the DAD1-/- rats took longer to consume the pellets could reflect lower 
motivation to consume rewards (i.e. decreased “wanting” for rewards) there are several other 
possibilities which will also be briefly considered during this discussion, and at greater length 
in the general discussion (chapter 6), such as differences in movement or anxiety-like 
behaviours.  
A third experiment relating to reward examined operant lever pressing for sugar 
pellets maintained by an FR 1 schedule of reinforcement. Strikingly, the DAD1-/- rats showed 
a complete attenuation of lever pressing for sugar pellets compared to controls, with virtually 
absent lever pressing observed in every DAD1-/- rat subject. Although the extent of the 
lever pressing impairment shown by DAD1-/- rats was more severe than expected, it is not 
surprising that the DAD1-/- rats displayed altered pressing relative to control rats. This 
finding is in line with El-Ghundi et al.’s (2003) study which found that D1 deficient mice 
demonstrated attenuated lever pressing maintained under an FR-1 schedule of 
reinforcement. However, the D1 deficient mice did engage in some lever pressing, and 
when food deprived these mice pressed on average 25 times per 30 minute session, with 
control mice pressing around 100 times per session. Similarly, although D1 receptor 
antagonists have been found to decrease the acquisition of lever pressing under similar 
conditions as those used in the current study, the extent of the decrease observed is 
generally less extensive (e.g. Baldwin et al., 2002; Koch, et al., 2000) compared to the 
decrease found here using the DAD1-/- rats.  
There are several reasons that could account for why the DAD1-/- rats did not 
acquire operant lever pressing for sugar pellets, as well as why they were slower to 
consume freely available sugar pellets. Firstly, DAD1-/- rats might be impaired with 
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regard to an aspect of motor function. However, the locomotor tendencies of DAD1-/- rats 
closely matched that of controls in terms of both distance travelled and rearing. In 
addition these were no differences found in terms of the location or pattern of locomotor 
activity indicating that the DAD1-/- rats did not exhibit different levels of anxiety-like 
behaviour compared with controls in the context of the open field. In an open field, 
however, there is a lack of stimuli to explore in the environment and no rewards to 
approach. Thus it is possible that the activity counts recorded from control subjects in the 
open field are at floor level, which could explain why the DAD1-/- and DAD1+/+ rats 
displayed a similar pattern of movement. Next, although the control rats did not perform 
the rotarod task well, the DAD1-/- rats displayed proficiency at this task, especially on the 
two slowest speeds (10 and 20 RPM). By contrast, the DAD1-/- rats were severely 
impaired at crossing the balance beam to reach their home cage. It is possible that DAD1-
/- rats do not find the beam to be aversive, or alternatively they may not possess the motor 
skills required to cross the beam. This explanation is unlikely however, because the 
experimenter noted that DAD1-/- rats would often groom themselves on the beam as well 
as stand up on their hind legs, presumably to look around, and even turn around, yet they 
would not walk the full extent of the beam. Thus, it appears that on tasks that do not 
involve a large reward component, DAD1-/- rats display intact movement.  
Considering that all of the tasks that the DAD1-/- rats displayed a deficit that 
involve a reward component suggests that the DAD1-/- rats have either altered reward 
processing or possess a learning deficit, rather than a motor deficit. However, a learning 
explanation cannot account for why the DAD1-/- rats performed ‘normally’ on the 
DNMTP spatial memory task. One procedural difference between the DNMTP T-maze 
task and operant lever pressing is that the maze task simulates foraging behaviour while 
lever pressing requires an operant response in order to receive the reward. If reward 
‘liking’ is still intact in the DAD1-/- animals, yet ‘wanting’ is impaired, then perhaps their 
willingness to work for rewards is decreased. Speculatively, it is possible that because the 
T-maze task simulates foraging, whereas lever pressing could be considered more abstract 
to a rat, the degree of difficulty or the effort required to attain a reward differs between 
these tasks. To test whether the DAD1-/- rats are less willing to work for rewards, future 
research could implement a progressive ratio task using a maze, incrementally increasing 
the amount of arm entries required to obtain a sugar pellet. If DAD1-/- rats ‘want’ rewards 
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less than control rats, then these rats would be expected to reach their break point earlier 
than control rats.  
 In summary, the findings presented in this chapter suggest that the DAD1-/- rats 
are impaired with regard to behaviours relevant for reward processing, most notably in 
terms of operant lever pressing. In addition, the DAD1-/- rats moved slower or less than 
control rats when consuming rewards (consumption of sugar pellets) or when escaping a 
mildly aversive environment (balance beam). Despite these differences, the DAD1-/- rats 
demonstrated intact hedonic processing (‘liking’) in the sucrose preference test. Potential 
explanations for the behavioural differences observed between DAD1-/- rats and controls, 
and the implications of these findings for D1 receptor function, will be further explored in 
the general discussion (chapter 6). The main consequence stemming from the finding that 
DAD1-/- rats did not autoshape to press a lever is that the DNMTP paradigm conducted in 
a T-maze will be employed in chapter 5 to explore the acute effects of MDMA on 
memory, rather than the planned operant DMTS task. Importantly, performance on the 
DNMTP task was comparable across DAD1-/- rats and controls suggesting that the 
DAD1-/- rats have intact spatial working memory function. Considering that D1-like 
receptors have consistently been implicated in working memory, the finding that the 
DAD1-/- rats performed the DNMTP task ‘normally’ suggests that the DAD1-/- rats 
possess sufficient DA transmission and D1-like receptor activation in the PFC to support 
effective working memory function.  
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Chapter 4: C-fos Expression and Locomotor Activity in DAD1-/- Rats Following 
Acute MDMA Administration 
MDMA and other DA enhancing drugs lead to the expression of the immediate-
early gene c-fos widely throughout the brain (Colussi-mas & Schenk, 2008; Dragunow, 
Logan & Laverty, 1991; Robertson, Peterson, Murphy & Robertson, 1989; Stephenson, 
Hunt, Topple & McGregor, 1999; Young, Porrino & Iadarola, 1991) with this effect 
being especially pronounced in the striatum, Nacc and in cortical areas such as the mPFC. 
DA D1-like receptor activation has been shown to, at least in part, mediate this response 
with D1-like agonist drugs increasing c-fos expression (Heijtz & Castellanos, 2006; 
Robertson et al., 1989; Young et al., 1991) and D1-like antagonists attenuating c-fos 
expression that is ordinarily caused by DA releasing agents (Young et al., 1991). In light 
of this, and to further validate the DAD1-/- rat model of down-regulated D1 receptor 
function, the neurochemical response of DAD1-/- rats to MDMA administration using c-
fos immunohistochemistry will be investigated here. Following administration of either 
MDMA (3 mg/kg) or saline, c-fos expression will be assayed in several regions or sub-
regions of the rat brain that contain rich DA innervation, namely the mPFC (cingulate 
(CG) cortex, prelimbic (PL) cortex and infralimbic (IL) cortex), the striatum (dorsolateral 
(DL) and dorsomedial (DM)), Nacc (core and shell), the VTA and substantia nigra pars 
compacta (SNPc). In addition, to assess whether DAD1-/- rats display a similar 
behavioural profile compared to controls in response to MDMA, locomotor activity will 
be recorded during the first hour post injection of either MDMA or saline. 
 Neuronal expression of c-fos, and its protein product Fos, occurs in response to a 
wide variety of treatments, stimuli and extracellular signals, including pharmacological 
manipulations and drug administration, growth factors, neurotransmitter release and 
induced seizures. Since the 1980s, c-fos has become one of the most commonly used 
functional anatomical markers for neuronal activity due to its expression being rapid, 
transient, and in relatively low levels under basal conditions (Herrera & Robertson, 
1996). The two primary pathways for the induction of c-fos expression are 1. via 
increased intracellular Ca2+ levels or increased levels of cyclic AMP acting through a 
calcium response/cyclic AMP responsive element on the c-fos promoter, or 2. via serum 
response factors which activate a DNA serum response element (i.e. independent of 
cyclic AMP) (Hoffman & Lyo, 2002). The fact that DA D1 receptors indirectly activate 
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cyclic AMP likely underlies the ability of these receptors to mediate c-fos expression 
(Carlezon Jr, Duman & Nestler, 2005; Sheng, McFadden & Greenberg, 1990).  
Based on the premise that MDMA leads to an increase in DA release which 
subsequently binds to D1 receptors, thereby increasing c-fos expression, it is predicted 
that DAD1+/+ control rats treated with MDMA will demonstrate increased c-fos 
expression compared to DAD1+/+ control rats treated with saline. By comparison, due to 
having down regulated D1 receptors it is predicted that, following MDMA, DAD1-/- rats 
will demonstrate attenuated c-fos expression compared to DAD1+/+ rats. As saline 
administration has not been linked to DA D1 receptor activation, it is predicted that levels 
of Fos in response to saline will be comparable across DAD1-/- and DAD1+/+ rats. The 
expression pattern of c-fos is also hypothesised to depend on the region assayed. For 
example, MDMA stimulates DA release in structures that contain DA neuron terminal 
regions which show dense expression of D1 receptors, such as in the mPFC, striatum and 
Nacc (Baumann et al., 2008; Fremeau et al., 1991). Thus it is predicted that the VTA and 
SNPc, which contain DA cell bodies rather than receiving DA afferents, will demonstrate 
less c-fos expression than in the mPFC, Nacc and DM striatum and that c-fos expression 
will be comparable in the VTA and SNPc across DAD1-/- and DAD1+/+ rats. In addition, 
the DL striatum was previously found to express considerably less c-fos than in the 
mPFC, Nacc and DM striatum in response to 5 and 10 mg/kg of MDMA (Colussi-mas & 
Schenk, 2008). Thus it is predicted that the DL striatum will express lower levels of c-fos 
relative to the mPFC, Nacc and DM striatum across all groups.  
Lastly, acute MDMA administration reliably produces an increase in locomotor 
activity (Ball et al., 2003; Bubar et al., 2004; Spanos & Yamamoto, 1989), an effect which 
is attenuated by SCH 23390 (Ball et al., 2003; Bubar et al., 2004). This suggests that 
MDMA-induced release of DA causes an increase in D1-like receptor activation, leading 
to hyperactivity. Thus it is predicted that the DAD1+/+ control rats will demonstrate an 
MDMA-produced increase in locomotor activity relative to saline, and that the DAD1-/- 
rats will demonstrate attenuated locomotor activation in response to MDMA relative to 
the DAD1+/+ rats. Lastly, in the previous chapter (chapter 3) it was reported that there 
were no baseline locomotor differences between the DAD1-/- and DAD1+/+ rats. Therefore 
it is predicted that DAD1-/- and DAD1+/+ rats treated with saline will demonstrate 
comparable locomotor activity.  
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Method 
Animals 
 Twenty-two drug-naïve Male Wistar rats (10 DAD1-/- and 12 DAD1 +/+) were 
used in this experiment. The subjects were handled for 5 - 10 minutes each for five 
consecutive days prior to the start of this experiment. See the general method section 
(chapter 2) for further information pertaining to the subjects. 
Activity Recording in an Open Field 
Locomotor activity was assessed using four open field activity-recording systems. 
The clear Plexiglas chambers (Med Associates Inc., USA; model ENV-515) measured 42 
cm x 42 cm x 30 cm and were set in sound- and light-attenuated boxes. Each subject’s 
location was tracked using four sets of 16 infra-red sensors spaced evenly on the walls of 
the chamber which created a lattice of beams, consisting of squares with dimensions of 25 
mm x 25 mm. Distance travelled (cm) was recorded by a computer (Activity Monitor 
Version 5 program; Med associates Inc., St Albans, VT, USA). For analysis, the activity 
chamber was split into central and peripheral zones. The central zone was defined as the 
innermost 19 cm x 19 cm of the chamber and the residual area consisting of the peripheral 
zone.  
While activity was being recorded, the main room lights remained on, but the 
lights in the sound- and light-attenuated boxes were off. A white noise generator masked 
extraneous noises during testing. Prior to and after each test session the inside floor and 
walls of the chamber were cleaned with Virkon ‘S’ disinfectant.  
Experimental Procedures and Brain Slice Harvesting 
Rats were assigned to either the drug condition (MDMA) or the control condition 
(saline) in a random manner, creating four independent groups: DAD1-/-/MDMA (n = 5), 
DAD1-/-/saline (n = 5), DAD1+/+/MDMA (n = 6), DAD1+/+/saline (n = 6). The drug 
condition was MDMA [(±)-MDMA hydrochloride; Institute of the Environmental 
Science and Research, Porirua, NZ] 3 mg/kg dissolved in 0.9 % saline solution. Both 
MDMA and saline solutions were delivered via i.p. injection at a volume of 1 ml/kg.   
On the day of testing, rats were habituated to the experimental room for 30 
minutes. They were then placed in the open field chambers to habituate to the apparatus 
for 30 minutes. After 30 minutes of habituation, they were then injected with their 
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assigned drug – either MDMA or saline – and then placed back in the activity chamber 
for a further 120 minutes. This time frame was selected on the basis of Fos expression 
peaking between 60 and 180 minutes post stimulation (Kovacs, 1998). However, only 
locomotor activity recorded during the first hour post-injection was used for analysis, due 
to MDMA-induced hyperlocomotion peaking 30 - 40 minutes after delivery of MDMA.  
Once 120 minutes post-injection had elapsed, rats were deeply anesthetised with 
sodium pentobarbital (50 mg/kg) via i.p. injection. Intracardial perfusion was then 
immediately performed to administer 150 - 200 mL of saline, containing heparin to 
prevent blood-clotting, followed by 300 - 350 mL of newly prepared 4% 
paraformaldehyde solution in 0.1 M phosphate buffer (PB) (pH 7.4). The brain was then 
rapidly removed and placed in fresh fixative, 4 % paraformaldehyde, overnight. Next, the 
brain was cryoprotected in 0.1 M PB containing 30% sucrose at 4 degrees Celcius, after 
which it was frozen for 4 minutes in isopentane at between -35 and -40 degrees Celcius.  
Coronal sections (35 microns thick) of the nine regions of interest were cut on a 
freezing microtome along the entire brain. For the current Fos analysis we used a one in 
six series of sections, with six slices per region of interest, excluding the mPFC where 3 
slices were used. The slices were immersed in 10 mM PB (pH 7.4) containing 0.9% NaCl 
(PBS) and 0.1% sodium azide, preventing bacterial growth, and then stored at 4 degrees 
Celcius prior to the immunostaining.  
Fos Immunohistochemistry 
The sectioned slices were reacted to show neurons expressing c-fos, with the 
experimenter being blind to which of the groups (i.e. genotype and drug conditions) the 
rat brain slices belonged. The slices were first transferred from the wells containing 10 
mM PB (pH 7.4) containing 0.9% NaCl (PBS) and 0.1% sodium azide into baskets, one 
basket per rat brain, that had perforated bottoms allowing for ease of transportation of the 
slices to and from each washing and staining solution. All of the following washes and 
incubations were conducted at room temperature and using mild agitation. 
First, the free-floating slices were washed with PBS containing 0.3% triton X-100 
(PBST) three times for 10 minutes each. They were then incubated overnight with the 
primary rabbit anti-Fos antibody (Ab-5; Calbiochem, EMD Biosciences, Darmstadt, 
Germany) diluted 1:20,000 in PBST and 1% bovine serum albumin. The anti-Fos 
antibody was raised against a synthetic peptide (SGFNADYEASSSRC) corresponding to 
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amino acids 4 - 17 of the human Fos protein. It recognizes the ~55-kDa c-fos and the ~62-
kDa V-Fos proteins, and does not respond to the 39-kDa Jun protein. The slices were then 
washed in PBST, again three times for 10 minutes per wash. They were then incubated 
for 90 minutes with secondary biotinylated goat anti-rabbit antibody (Vector 
Laboratories, Burlingame, CA, USA) diluted in 1:1,000 in PBST. After another wash 
with PBST, three times for 10 minutes each, the slices were incubated for 60 minutes 
with freshly preformed avidinbiotinylated (ABC) horseradish peroxidase complex diluted 
1:1,000 in PBST. Again, the slices were washed three times for 10 minutes each with 
PBST before visualization of the bound peroxidase was attained by incubating slices in a 
solution of 50 mM Tris-HCl (pH 7.4), containing 0.02% 3,3’-diaminobenzidine, 0.8% 
nickel chloride and 0.003% H2O2 to produce a blue-black precipitate. This reaction was 
stopped with three washes of PBST, 5 minutes per wash. The slices were then mounted 
on gelatin-coated slides, stained with neutral red and cover slipped with DePeX mounting 
medium (Scharlau Chemie, Barcelona, Spain).  
A negative control was also conducted, with slices in this condition experiencing 
all iterations of the above procedure except that they were not reacted with the primary 
antibody. This control was run to ensure the absence of non-specific immunostaining in 
the tissue.  
Cell Counts 
 The experimenter was blind to all treatment groups, with the counts being de-
coded at the end of the experiment. The sections were analysed using an Olympus BX-51 
microscope, with images captured at x100 magnification using a MBF Biosciences 
camera (CX 9000).  
The brain structures were identified using the rat brain atlas of Paxinos and 
Watson (2005). A counting template for each structure was made based on its size and 
shape (adapted from Colussi-Mas & Schenk, 2008). Images of each section were overlaid 
with the relevant templates and cells within the templates were manually counted (only 
nuclei with blue-black staining were included) using the computerised image analysis 
system Neurolucida (MBF Biosciences, v. 8). See figures 19, 20 and 21 for diagrams of 
the regions of interest with overlaid templates and the template areas (in mm2), with the 
corresponding bregma coordinates used for each structure.  
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Figure 19. Diagram of the templates used to quantify Fos-immunoreative cells at bregma 
= 3.72 mm. Identical templates were also applied to the right hemisphere. A = cingulate 
cortex, area: 0.24 mm2; B = prelimbic cortex – area: 0.50 mm2; C = infralimbic cortex, 
area: 0.20 mm2. Image adapted from Paxinos and Watson (2005).   
 
 
Figure 20. Diagram of the templates used to quantify Fos-immunoreative cells at bregma 
= 1.32 mm. Identical templates were also applied to the right hemisphere. D = DL 
striatum, area: 0.60 mm2; E = DM striatum, area: 0.60 mm2; F = Nacc core, area: 0.06 
mm2; G = Nacc shell, area: 0.06 mm2. Image adapted from Paxinos and Watson (2005).   
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Figure 21. Diagram of the templates used to quantify Fos-immunoreative cells at bregma 
=    -5.04 mm. Identical templates were also applied to the right hemisphere. H = SNPc, 
area: 0.03 mm2; I = VTA, area: 0.07 mm2. Image adapted from Paxinos and Watson 
(2005).   
 
Data Analysis 
 For each region of interest, raw cell counts were averaged across the two 
hemispheres and across all brain slices of that region for each rat. This led to one cell 
count average per rat for each of the nine sub-regions. These averages were then 
converted to c-fos density measures (number of Fos-immunoreactive cells/mm2) by 
dividing the areas (in mm2) of the templates used per region. Mean c-fos densities, 
grouped by genotype and drug treatment, were then calculated for each brain structure. 
Group comparisons of c-fos densities were conducted for each of the nine brain structures 
using 2 (genotype) x 2 (drug treatment) between-subjects ANOVAs. Subsequently, 
planned comparisons were conducted to assess whether either genotype demonstrated an 
MDMA-induced increase in c-fos relative to saline in any of the regions assayed. Using 
two independent samples t-tests, the following comparisons with regard to c-fos density 
per region were conducted: DAD1+/+/MDMA vs DAD1+/+/saline and DAD1-/-/MDMA vs 
DAD1-/-/saline. In addition, further planned comparisons were conducted to compare each 
genotype’s c-fos expression in response to saline or MDMA. Specifically, two 
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independent samples t-tests were used to compare the following groups with regard to c-
fos density in each of the nine regions: DAD1+/+/MDMA vs DAD1-/-/MDMA and 
DAD1+/+/saline vs DAD1-/-/saline.  
Locomotor activity was measured by quantifying the total distance travelled (in 
cm) in the centre and periphery of the open field for two separate time periods: 30 
minutes prior to the injection (habituation period), as well as 1 hour after the injection of 
either saline or MDMA. First, individual subject totals were calculated separately for both 
the habituation period and the 1 hour post-injection period. Activity during the 30 minute 
habituation period, in either the centre or periphery, was then grouped by genotype, but 
not drug treatment as the drug treatments had not been administered at this point. Group 
comparison of total activity in either the centre or periphery during the 30 minute 
habituation period was performed using two independent samples t-tests, with genotype 
as the grouping variable. Next, subject totals of distance travelled in either the centre or 
periphery during the 1 hour post-injection period were averaged by genotype and drug 
treatment. Distance travelled in either the centre or periphery was separately analysed 
using two 2 (genotype) x 2 (drug treatment) between-subjects ANOVAs. Planned 
analyses were subsequently carried out to specifically assess whether either genotype 
group displayed MDMA-induced hyperactivity. Using distance travelled in the centre or 
periphery during the 1 hour post-injection period, independent samples t-tests were 
performed between the DAD1+/+/MDMA and DAD1+/+/saline rat groups, and between the 
DAD1-/-/MDMA and DAD1-/-/saline groups. Lastly, further planned comparisons were 
conducted to directly compare the genotype groups with regard to their locomotor 
response to either MDMA or saline. Specifically, activity in the centre and periphery was 
separately compared between the DAD1+/+/MDMA and DAD1-/-/MDMA groups, and 
between the DAD1+/+/saline and DAD1-/-/saline groups. All statistical analyses were 
conducted using IBM SPSS Statistics version 19.0 for windows. The alpha level for 
statistical significance was set at p < 0.05. 
Results 
C-fos density 
Overall, the pattern of c-fos expression varied greatly across regions (figure 22). 
Regions with high levels of c-fos expression after injection of saline or MDMA were the 
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mPFC (CG, PL and IL corteces) and Nacc shell. There was moderate c-fos expression in 
the DM striatum and Nacc core, and low expression in the DL striatum, VTA and SNPc.
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Figure 22. Comparison of c-fos densities quantified in nine brain regions in DAD1-/- (MDMA: n = 5; saline: n = 5) and DAD1+/+ (MDMA: n = 6; saline: n = 6) 
rats who either received an acute injection of MDMA (3 mg/kg) or saline 2 hours prior to an intracardial perfusion of a tissue fixative. 
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See table 4 for the F statistics and p-values generated from the factorial ANOVA 
analyses of c-fos densities by region, and tables 5 and 6 for breakdowns of the means and 
standard deviations of c-fos densities by region. In addition, tables 7 and 8 display the t-
test results of the planned comparisons. 
MDMA-induced c-fos expression and genotype effects. As expected, MDMA 
(3 mg/kg) significantly increased c-fos expression, measured using c-fos density, 
compared to saline across several brain regions. Specifically, a significant main effect of 
MDMA was found in the PL cortex, IL cortex, DM striatum, Nacc shell, and VTA (table 
4). 
There were also significant effects of genotype found whereby the DAD1+/+ 
expressed significantly more c-fos than the DAD1-/- rats in the DM striatum and the Nacc 
shell, yet DAD1-/- rats expressed significantly more c-fos than the DAD1+/+ rats in the 
VTA. However, the difference in c-fos expression between DAD1+/+ and DAD1-/- rats in 
the VTA is slight given the very low levels of c-fos expression found in this region. 
Attenuated MDMA-induced c-fos expression in DAD1-/- rats. C-fos expression 
interacted significantly between genotype and drug treatment in the IL cortex, DM 
striatum and Nacc core. The planned comparisons reveal that these interactions are likely 
due to the MDMA-induced increase in c-fos expression being more pronounced in 
DAD1+/+ rats than in DAD1-/- rats. Compared to DAD1+/+ rats treated with saline, 
DAD1+/+ rats treated with MDMA displayed marked increases in c-fos expression that 
reached the level for significance in the CG cortex, PL cortex, IL cortex, DM striatum, 
Nacc core and Nacc shell (table 7). By contrast, DAD1-/- rats only displayed an MDMA-
induced increase in c-fos expression in the DM striatum and VTA, with the increase 
observed in the DAD1-/- rats in the DM striatum being of a lesser magnitude than 
demonstrated by the DAD1+/+ rats in this region. Furthermore, table 8 shows that 
DAD1+/+ rats treated with MDMA displayed significantly more c-fos expression than 
DAD1-/- rats treated with MDMA in the PL cortex, IL cortex, DM striatum, Nacc shell 
and SNPc, yet significantly less c-fos expression than DAD1-/- rats treated with MDMA 
in the VTA. Again, c-fos levels in the VTA are comparatively low, meaning that the 
difference between the genotypes in this region is very small.  
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Table 4 
Results of the 2 (genotype) x 2 (drug treatment) between subject ANOVAs conducted to 
compare c-fos densities in the nine brain regions assayed  
 Drug treatment Genotype Drug x genotype 
mPFC**    
Cingulate cortex F1,17 = 3.37, p = .08 F1,17 < .01, p = .93 F1,17 = 3.24, p = .09 
Prelimbic cortex F1,17 = 8.49, p = .01* F1,17 = 1.25, p = .28 F1,17 = 3.63, p = .07 
Infralimbic cortex F1,17 = 7.13, p = .02* F1,17 = .50, p = .49  F1,17 = 7.22, p = .02* 
Striatum    
Dorsomedial F1,18 = 39.7, p < .01* F1,18 = 11.8, p < .01*  F1,18 = 13.7, p < .01*  
Dorsolateral F1,18 = 1.73, p = .21 F1,18 = .90, p = .36 F1,18 = .71, p = .41 
Nacc    
Core F1,18 = 3.8, p = .07 F1,18 = .85, p = .37 F1,18 = 6.89, p = .02* 
Shell F1,18 = 6.90, p = .02* F1,18 = 6.41, p = .02* F1,18 = 1.64, p = .22 
VTA  F1,18 = 8.30, p = .01* F1,18 = 6.88, p = .02* F1,18 < .01, p = .99 
SNPc F1,18 = .52, p = .48 F1,18 = 1.30, p = .27 F1,18 = 3.69, p = .07 
Bold typeface and * is used when p < .05. ** For the mPFC analysis n = 21 - one rat in 
the DAD1+/+/saline group was removed due to damaged tissue. For all other regions, n = 
22. 
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Table 5 
Means and standard deviations of c-fos densities in nine brain regions grouped 
separately by drug treatment and genotype 
 Drug treatment  Genotype 
 MDMA Saline  DAD1+/+ DAD1-/- 
mPFC      
Cingulate cortex M = 306.06 
SD = 123.39 
M = 191.79 
SD = 164.03 
 M = 261.44 
SD = 165.01 
M = 240.88 
SD = 144.65 
Prelimbic cortex M = 318.13* 
SD = 115.90 
M = 184.86* 
SD = 107.2 
 M = 282.97 
SD = 158.92 
M = 223.54 
SD = 81.50 
Infralimbic cortex M = 226.23* 
SD = 81.08 
M = 154.62* 
SD = 76.01 
 M = 200.61 
SD = 108.47 
M = 182.81 
SD = 53.00 
Striatum      
Dorsomedial M = 175.94* 
SD = 75.06 
M = 67.55* 
SD = 26.53 
 M = 147.26* 
SD = 96.16 
M = 91.13* 
SD = 31.79 
Dorsolateral M = 19.78 
SD = 40.61 
M = 2.41 
SD = 3.84 
 M = 16.46 
SD = 39.62 
M = 4.66 
SD = 5.45 
Nacc      
Core M = 127.19 
SD = 53.51 
M = 89.66 
SD = 35.55 
 M = 115.60 
SD = 57.49 
M = 99.82 
SD = 35.42 
Shell M = 191.37* 
SD = 47.93 
M = 148.38* 
SD = 34.65 
 M = 187.93* 
SD = 46.24 
M = 148.21* 
SD = 38.03 
VTA  M = 28.91* 
SD = 8.46 
M = 20.23* 
SD = 7.16 
 M = 20.98* 
SD = 9.40 
M = 28.88* 
SD = 6.06 
SNPc M = 46.79 
SD = 31.23 
M = 53.84 
SD = 33.63 
 M = 57.01 
SD = 30.00 
M = 42.29 
SD = 33.75 
Bold typeface and * used when p < .05. 
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Table 6 
Means and standard deviations of c-fos densities grouped by DAD1-/- and DAD1+/+ rats 
treated with either MDMA or saline 
 DAD1+/+ 
MDMA 
n = 6 
DAD1+/+ 
Saline 
n = 6* 
DAD1-/- 
MDMA 
n = 5 
DAD1-/- 
Saline 
n = 5 
mPFC     
Cingulate cortex M = 358.95 
SD = 115.05 
M = 141.36 
SD = 131.95 
M = 246.02 
SD = 95.80 
M = 243.98 
SD =  190.47 
Prelimbic cortex M = 389.95 
SD = 114.96 
M = 167.92 
SD = 122.60 
M = 250.68 
SD = 71.94 
M = 204.16 
SD = 101.90 
Infralimbic 
cortex 
M = 270.60 
SD = 75.87 
M = 111.12 
SD = 81.29 
M = 169.66 
SD = 54.43 
M = 170.16 
SD = 53.82 
Striatum     
Dorsomedial M = 228.98 
SD = 55.41 
M = 65.54 
SD = 35.27 
M = 112.30 
SD = 31.02 
M = 69.95 
SD = 13.82 
Dorsolateral M = 29.91 
SD = 54.70 
M = 3.01 
SD = 5.22 
M = 7.62 
SD = 6.59 
M = 1.70 
SD = 1.24 
Nacc     
Core M = 154.82 
SD = 48.13 
M = 76.38 
SD = 35.56 
M = 94.03 
SD = 41.76 
M = 105.60 
SD = 31.56 
Shell M = 218.56 
SD = 36.06 
M = 157.30 
SD = 33.92 
M = 158.74 
SD = 40.95 
M = 137.68 
SD = 36.06 
VTA  M = 25.33 
SD = 9.66 
M = 16.64 
SD = 7.47 
M = 33.2 
SD = 4.50 
M = 24.55 
SD = 3.96 
SNPc M = 64.80 
SD = 31.39 
M = 49.22 
SD = 29.14 
M = 25.19 
SD = 11.68 
M = 59.39 
SD = 41.18 
* For the mPFC regions n = 5 due to one rat in the DAD1+/+/saline group being removed 
due to damaged tissue. 
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Table 7 
Results of the planned independent samples t-tests comparing c-fos densities in nine brain 
regions between DAD1+/+/MDMA vs DAD1+/+/saline and DAD1-/-/MDMA vs DAD1-/-
/saline subject groups to assess for MDMA-induced increases in c-fos expression 
 DAD1+/+/MDMA vs 
DAD1+/+/saline 
DAD1-/-/MDMA vs     
DAD1-/-/saline 
mPFC**   
Cingulate cortex t9 = 2.93, p = .02* t8 = .02, p = .98 
Prelimbic cortex t9 = 3.1, p = .01* t8 = .83, p = .43 
Infralimbic cortex t9 = 3.36, p < .01* t8 = -.02, p = .99 
Striatum   
Dorsomedial t10 = 6.1, p < .01* t8 = 2.79, p = .04* 
Dorsolateral t10 = 1.2, p = .26 t8 = 1.97, p = .12 
Nacc   
Core t10 = 3.21, p < .01* t8 = -.49, p = .64 
Shell t10 = 3.03, p = .01* t8 = .86, p = .41 
VTA  t10 = 1.74, p = .11 t8 = 3.23, p = .01* 
SNPc t10 = .89, p = .39 t8 = -1.79, p = .11 
Bold typeface and * is used to when p < 0.05, indicating that subjects in the MDMA 
group had significantly greater c-fos expression compared to subjects in the like-genotype 
saline group in the respective brain region. ** For the mPFC regions n = 5 due to one rat 
in the DAD1+/+/saline group being removed due to damaged tissue. 
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Table 8 
Results of the planned independent samples t-tests comparing c-fos densities in nine brain 
regions between DAD1+/+/MDMA vs DAD1-/-/MDMA and DAD1+/+/saline vs DAD1-/-
/saline subject groups 
 DAD1+/+/MDMA vs    
DAD1-/-/MDMA 
DAD1+/+/saline vs       
DAD1-/-/saline 
mPFC   
Cingulate cortex t9 = -1.74, p = .12 t8 = .99, p = .35 
Prelimbic cortex t9 = -2.34, p = .04* t8 = .51, p = .63 
Infralimbic cortex t9 = -2.48, p = .04* t8 = 1.35, p = .21 
Striatum   
Dorsomedial t9 = -4.17, p < .01* t9 = .28, p = .79 
Dorsolateral t9 = -.9, p = .39 t9 = -.55, p = .60 
Nacc   
Core t9 = -2.21, p = .05 t9 = 1.43, p = .19 
Shell t9 = -2.58, p = .03* t9 = -.93, p = .38 
VTA  t9 = 1.67, p = .13* t9 = 2.24, p = .06 
SNPc t9 = -2.86, p = .03* t9 = .48, p = .64 
Bold typeface and * is used to when p < 0.05, indicating that the MDMA treated DAD1+/+ 
rats had significantly more c-fos expression compared to MDMA treated DAD1-/- rats in 
the respective regions except in the VTA in which MDMA treated DAD1-/- rats 
demonstrated significantly more c-fos expression than MDMA treated DAD1+/+ rats. 
 
Locomotor activity 
 Figure 23 displays the time course of the distance travelled across the 90 minutes 
of recorded activity for each of the four groups – DAD1+/+/MDMA, DAD1+/+/saline, 
DAD1-/-/MDMA and DAD1-/-/saline, with activity being collapsed across the periphery 
and centre of the open field chamber. During the 1 hour post-injection period, the 
DAD1+/+ rats treated with MDMA demonstrate a pronounced increase in activity 
compared to all other groups. While the DAD1-/- rats treated with MDMA also display an 
increase in activity compared to saline groups, the magnitude of the increase is much 
smaller than seen in the control animals.  
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Figure 23. Time course of the distance travelled across the 90 minutes of recorded 
activity by each of the four groups: DAD1+/+/MDMA (n = 6), DAD1+/+/saline (n = 6), 
DAD1-/-/MDMA (n = 5) and DAD1-/-/saline (n = 5). The first 30 minutes constitutes the 
pre-injection habituation period. Injections of either saline or MDMA were administered 
after 30 minutes (represented by ‘0’ on the x axis), and the subsequent 60 minutes 
constitutes the post-injection period.  
 
30 minute habituation (pre-injection) period. Distance travelled during the 30-
minute habituation period was analysed to investigate whether the activity patterns of 
DAD1-/- rats differed from DAD1+/+ rats prior to injection of either MDMA or saline 
(figure 24). Because the injections had not been administered at this point, the drug 
groups were collapsed within genotypes. In contrast to findings presented in the previous 
data chapter (chapter 3), distance travelled in the periphery of the chamber by DAD1-/- 
rats (M =586.37, SD = 295.4) was significantly less than DAD1+/+ rats (M = 851.94, SD = 
180.47), t20 = -2.59, p = .02. However, there was no difference between the genotype 
groups in terms of distance travelled in the centre of the chamber, t20 = -1.34, p = .20.  
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Figure 24. Comparison of DAD1-/- (n = 10) and DAD1+/+ (n = 11) rat’s total distance 
travelled (cm), in either the periphery or centre of the activity chamber, during the 30-
minute habituation period. * p < .05.  
 
Post-injection period. Group comparisons of the total distance travelled in either 
the periphery (figure 25) or centre (figure 26) during the 1 hour period post-injection of 
either MDMA or saline were conducted. Consistent with the habituation period, in the 
periphery of the chamber the DAD1-/- rats (M = 1090.09, SD = 1122.53) moved less 
overall than the DAD1+/+ rats (M = 2420.85, SD = 2064.02), F1,18 = 5.78, p = .03. As 
expected, there was a significant effect of drug, F1,18 = 14.08, p < .01, with MDMA-
treated rats (M = 2887.57, SD = 2029.42) moving more than saline treated rats (M = 
744.34, SD = 375.9). However, there was no significant interaction between genotype and 
drug treatment found, F1,18 = 1.70, p = .21.  
In the centre of the chamber, there was no difference between the genotypes 
observed, F1,18 = 3.22, p = .09 and no interaction between genotype and drug treatment, 
F1,18 = 3.23, p = .09. Again there was an effect of drug treatment, with MDMA treated 
rats (M = 849.19, SD = 929.29) moving more than saline treated rats (M = 141.67, SD = 
85.87), F1,18 = 6.79, p = .02.  
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Despite a lack of drug x genotype interactions found in the factorial analysis, 
planned comparisons were conducted to more finely dissect the locomotor responses of 
DAD1+/+ and DAD1-/- rats after treatment with either MDMA or saline. The results 
demonstrate that in the periphery of the open field, DAD1+/+ rats treated with MDMA (M 
= 3820.17, SD = 2145.57) moved significantly more than DAD1+/+ rats treated with saline 
(M = 1021.52, SD = 263.64), t5.15 = 3.17, p = .02, indicating that MDMA produced 
peripheral hyperactivity in the control animals. Regarding DAD1-/- rats, there was an 
approaching significant difference between the MDMA and saline treated groups, t4.06 = 
2.34, p = .08, suggesting that the MDMA-treated (M = 1768.46, SD = 1292) DAD1-/- rats 
moved more than the saline treated (M = 411.72, SD = 113.27) DAD1-/- rats in the 
periphery. Although this finding should be interpreted with caution due to being shy of 
statistical significance, it suggests that MDMA produced peripheral hyperactivity in the 
DAD1-/- rats.  
Regarding activity in the centre of the open field, there was an approaching 
significant differences between DAD1+/+ rats treated with MDMA versus saline, t5.05 = 
2.49, p = .06, indicating that the DAD1+/+ rats treated with MDMA (M = 1266.22, SD = 
1103.23) moved more than those treated with saline (M = 141.28, SD = 76.77). Again, 
although this finding may indicate that the DAD1+/+ rats demonstrated MDMA-induced 
hyperactivity in the centre of the open field, this finding should be interpreted with 
caution due to not reaching statistical significance. There was no significant difference 
found between DAD1-/- rats treated with MDMA compared to saline, t5.35 = 1.69, p = .15, 
indicating that MDMA did not produce central hyperactivity in the DAD1-/- rats.  
Comparison of the groups treated with MDMA revealed no differences between 
DAD1-/- and DAD1+/+ rats in either the periphery, t9 = -1.87, p = .10 or centre, t5.62 = -
1.81, p = .10, of the open field. These analyses suggest that DAD1-/- and DAD1+/+ rats 
treated with MDMA moved a comparable amount. However, the high degree of 
variability present in the data and small sample sizes could also explain the lack of 
significant differences observed between these groups. Lastly, analyses of distance 
travelled in the periphery by the saline treated groups revealed a significant difference 
between the genotypes, suggesting that DAD1-/- rats (M = 411.72, SD = 113.27) moved 
less than the DAD1+/+ rats (M = 1021.52, SD = 263.64), t7.03 = -5.13, p < .01. Thus in line 
with data from the 30 minute habituation period, at baseline the DAD1-/- rats moved less 
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in the periphery than the DAD1+/+ rats. By contrast, there was no difference in activity 
found between saline treated DAD1-/- and DAD1+/+ rats in the centre of the open field.  
 
 
Figure 25. Total distance travelled (cm) in the periphery during the 1 hour post injection 
period. The graph compares DAD1+/+ (MDMA: n = 6; saline: n = 6) and DAD1-/- 
(MDMA: n = 5; saline: n = 5) rats after treatment with either MDMA (3 mg/kg) or 
saline.  
 
 
Figure 26. Total distance travelled (cm) in the centre during the 1 hour post injection 
period. The graph compares DAD1+/+ (MDMA: n = 6; saline: n = 6) and DAD1-/- 
(MDMA: n = 5; saline: n = 5) rats after treatment with either MDMA (3 mg/kg) or 
saline. 
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Discussion  
This chapter compared c-fos expression and locomotor activity in DAD1-/- and 
DAD1+/+ rats in response to an acute dose of MDMA (3 mg/kg) or saline (i.p). C-fos 
expression was quantified in the mPFC (CG, PL and IL corteces), striatum (DL and 
DM), Nacc (core and shell), VTA and SNPc.  
As predicted, MDMA-treated DAD1+/+ control rats demonstrated an increase in c-
fos expression compared to saline-treated DAD1+/+ rats in the CG cortex, PL cortex, IL 
cortex, DM striatum and Nacc core and shell. In these control rats, MDMA did not appear 
to increase c-fos expression relative to saline in the two regions that contain DA cell 
bodies, namely the VTA and SNPc. On the contrary, DAD1-/- rats demonstrated 
attenuated c-fos expression in response to MDMA relative to the MDMA-treated 
DAD1+/+ rats. Specifically, increased c-fos expression in MDMA-treated DAD1-/- rats, 
compared to saline treated DAD1-/- rats, was only observed in the DM striatum and VTA, 
with the increase in the VTA being of a very small magnitude. Furthermore, MDMA-
treated DAD1+/+ rats demonstrated increased c-fos expression compared to MDMA-
treated DAD1-/- rats in the PL cortex, IL cortex, DM striatum, Nacc shell, VTA and 
SNPc. Finally, by contrast to the differences observed between MDMA-treated DAD1+/+ 
and DAD1-/- rats, saline-treated DAD1+/+ and DAD1-/- rats demonstrated comparable 
levels of c-fos expression across all regions, as predicted.  
The observation that DAD1-/- rats displayed reduced levels of c-fos expression 
compared to DAD1+/+ rats in response to acute MDMA suggests that MDMA acts to 
stimulate DA release which subsequently binds to D1 receptors thereby inducing c-fos 
expression. If decreased MDMA-induced c-fos expression in the DAD1-/- rats is 
attributable to less functional D1 receptors, then the attenuation of MDMA-induced c-fos 
expression in DAD1-/- rats across most regions assayed suggests that the down-regulation 
of D1 receptors in DAD1-/- rats is fairly widespread throughout DA’s terminal regions, 
rather than simply being localised to a particular area of the brain. In particular, that 
DAD1-/- rats demonstrated decreased MDMA-induced c-fos expression compared to 
control rats in the mPFC can be interpreted as being in line with the inverted-U theory of 
DA transmission in the PFC. This idea will be considered in the general discussion 
(chapter 6) in order to take into account the effects of MDMA on memory performance in 
the DAD1-/- rats which is the focus of the following chapter (chapter 5). 
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In contrast to findings from the previous data chapter (chapter 3), DAD1-/- rats 
moved less at baseline than DAD1+/+ rats in the 30 minute habituation period as well as 
after treatment with saline during the post-injection period. In chapter 3 the DAD1-/- and 
DAD1+/+ rats displayed almost identical levels of locomotor activity across three 30 
minute sessions, which closely aligns to the procedure used in the current chapter, albeit 
there was only one 30 minute session of activity recorded. Because the groups of animals 
used for these separate experiments had starkly different experimental histories prior to 
the open field experiments, it is possible that the different histories of the rat groups 
contributed to these contrasting findings. The subjects in the open field experiment 
presented in chapter 3 had previously experienced 3 and a half months of extensive 
handling during a maze experiment (presented in chapters 3 and 5) in which subjects 
were trained to find sugar pellets using the DNMTP paradigm. In comparison, the 
subjects employed for the current chapter had not been exposed to previous experiments 
or experienced extensive handling prior to the start of the open field/c-fos experiment. 
Perhaps as a result of exploring a maze for an extended period of time, as well as having 
exploration paired with the receipt of reward, the DAD1-/- subjects used in chapter 3 were 
more explorative in novel environments compared to the rats used in the current chapter. 
In light of this view, the data from the current chapter suggests that a down-regulation of 
D1 receptors leads to decreased spontaneous locomotor activity under basal conditions.   
Lastly, in line with predictions the DAD1+/+ rats demonstrated pronounced 
MDMA-induced hyperactivity in the periphery of the chamber. However, the DAD1-/- rats 
demonstrated this pattern of activity in a less conclusive manner. On average, the 
MDMA-treated DAD1-/- rats did display a large increase in activity compared to saline-
treated DAD1-/- rats in the periphery of the chamber, yet means testing revealed this 
difference as an approaching significant difference (p = .08). Considering the low 
baseline levels of activity in the DAD1-/- rats, as well as the high variability present in the 
data and low sample size (n = 5), it is possible that MDMA-treated DAD1-/- rats do 
display MDMA-induced hyperactivity, yet a lack of statistical power has obscured this 
finding. Nevertheless, since D1-like receptors have been implicated in MDMA-induced 
hyperactivity, it is likely that the DAD1-/- rats demonstrate an attenuated locomotor 
response to MDMA, in a similar fashion to MDMA-induced c-fos expression. It would be 
beneficial for future research to further investigate the behavioural and neural responses 
of DAD1-/- rats to MDMA in order to characterise the neurochemical effects of MDMA.  
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Chapter 5: Acute MDMA-induced memory deficits and the role of the DA D1 
receptor 
Acute MDMA exposure reliably impairs memory performance in human and rat 
subjects (e.g. humans: Kuypers & Ramaekers, 2005; 2007; Ramaekers, Kuypers, Wingen, 
Heinecke & Formisano, 2009; rats: Braida et al., 2002; Galizio et al., 2009; 2014; Harper, 
2013; Harper et al., 2005; 2006; 2011; Hawkey et al., 2014; Kay et al., 2010; Moyano et 
al., 2004; 2005; Young et al., 2005), yet the neurological mechanisms by which acute 
MDMA disrupts memory function are unclear. In light of recent research implicating the 
D1-like receptor in acute MDMA-induced memory deficits in rats (Harper, 2013; Harper 
et al., 2011; Rozas et al., 2012), and given that DA is an important neurotransmitter for 
memory function (Goldman-Rakic, 1995; Seamans et al.,1995; 1998; Williams & 
Goldman-Rakic, 1995; Zahrt et al., 2007), this chapter investigates the role of D1 
receptors in MDMA’s acute effects on memory performance using DAD1-/- rats.  
There are two main research questions under consideration. The first question 
investigates whether acute MDMA administration increases memory errors by MDMA-
induced DA release causing over-stimulation of DA D1 receptors. Harper (2013) found 
that the DA D1-like receptor antagonist SCH 23390, when applied concurrently with 
MDMA, attenuated MDMA-induced memory deficits in a delayed matching-to-sample 
(DMTS) operant working memory task. The current chapter provides a partial replication 
of Harper’s (2013) study by examining MDMA’s acute effects on DNMTP memory 
performance using DAD1-/- rats. Importantly, although the DMTS and DNMTP tasks 
differ procedurally in many respects the parameters of the DNMTP task closely match the 
DMTS task used by Harper (2013).  
During the DMTS paradigm subjects are presented with a ‘sample’ lever (either 
the left or right lever) and required to press this lever. Following a short delay, the subject 
is then required to press this same lever during the ‘choice’ phase in order to receive 
reinforcement. A similar format is used with DNMTP in that the subject is allowed two 
arm visits, their first arm visit being the equivalent to the sample lever presentation, and 
the second arm visit corresponding to the choice phase. However, in DMTS the rat is 
required to respond on the same lever during both the sample and choice phases, for the 
purpose of DNMTP, accurate responding during the choice phase will require the subject 
to select the opposite arm from the one they visited during the sample phase. Secondly, 
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the DMTS and DMNTP both have two response options available to the subject (two 
levers in DMTS vs two arms in a T-maze). Thirdly, the intertrial interval will be matched 
across the tasks. Fourthly, the delay period between the sample and choice phases in 
DNMTP will approximately correspond to that used in Harper (2013). Lastly, on both the 
DMTS and DNMTP, perseverative errors can be isolated from other memory errors for 
separate analysis.  
A benefit of the current study relates to the use of DAD1-/- rats rather than D1-like 
receptor antagonists to model decreased D1 receptor function. Employing DAD1-/- rats to 
investigate MDMA’s impact on memory eliminates the confounding, non-selective 
effects (e.g. activation of D5 receptors) associated with D1-like receptor antagonists. 
Based on the hypothesis that acute MDMA administration impairs memory via over-
stimulation of D1 receptors, it is predicted that MDMA-treated DAD1-/- rats will perform 
more accurately on the DNMTP task compared to MDMA-treated DAD1+/+ rats. Using a 
range of behaviourally relevant doses of MDMA (1.5, 2.25 and 3 mg/kg), it is expected 
that the 3 mg/kg dose will impair accuracy to a greater extent than the lower doses. 
Stemming from the findings presented in chapter 3 illustrating that DAD1-/- and DAD1+/+ 
rats performed comparably during 25 training sessions of DNMTP, it is predicted that 
there will be no group differences following treatment with saline. Lastly, to further 
explore the hypothesis that MDMA impairs memory by way of over-stimulation of D1 
receptors, performance on DNMTP was also assessed following acute treatment with a 
range of doses (0.5, 1, 1.5, 3 and 4.5 mg/kg) of the D1-like receptor agonist SKF 81297. 
Based on the idea that MDMA impairs memory via over-stimulation of D1 receptors, it is 
similarly predicted that over-stimulation of D1 receptors induced by SKF 81297 will 
impair accuracy in a dose-dependent manner in the control rats, compared to saline. On 
the contrary, DAD1-/- rats are not expected to demonstrate reduced accuracy following 
treatment with SKF 81297.  
The second research question addressed in the current study relates to the nature 
of the memory errors observed following acute MDMA exposure. Specifically, if acute 
MDMA does impair memory on the DNMTP task, do the MDMA-induced impairments 
reflect a direct disruption of memory function, such as compromised working memory 
processes, or do the impairments reflect an indirect disruption of memory such as by way 
of proactive interference? Proactive interference on tests of memory can be thought of as 
when a subject’s current response is influenced by previous trial information or stimuli. 
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Acute MDMA has been found to increase proactive interference during operant based 
tasks, leading to a perseverative pattern of responding. Specifically, subjects treated with 
MDMA tended to repeat the response they made on the immediately preceding trial, 
rather than perform the current trial’s required response (Harper and colleagues, 2005; 
2006; 2013). Furthermore, the alleviation of MDMA-induced memory errors via 
concurrent administration of SCH 23390, outlined above, was found to correspond to a 
reduction in proactive interference (Harper, 2013).  
To explore whether MDMA increases proactive interference, and whether the D1 
receptor is involved, accuracy on trials that require the same response from the previous 
trial (‘previous same trials’) will be compared to accuracy on trials that require a different 
response from the previous trial (‘previous different trials’). Lowered accuracy during 
‘previous different’ trials is indicative of perseverative responding or proactive 
interference. This is because during ‘previous different’ trials, in order to execute the 
correct response the subject is required to perform the opposite response that it emitted on 
the previous trial. On the contrary, during ‘previous same’ trials, the required response or 
arm entry is the same as on the previous trial, meaning that if the subjects were influenced 
by proactive interference on these trials, their response would still be deemed accurate. 
Therefore, by separating the trials on the basis of whether they are ‘previous same’ or 
previous different’ allows for examination of whether rats are influenced by proactive 
interference in certain conditions, such as following drug administration.  
Based on the hypothesis that MDMA interferes with memory performance by 
increasing proactive interference via over-activation of D1 receptor, it is predicted that 
MDMA-treated DAD1+/+ rats will demonstrate increased errors on previous different 
trials compared to their accuracy on previous same trials. Furthermore, the 3 mg/kg dose 
of MDMA is expected to produce the greatest difference in accuracy between trial types 
compared to the 1.5 and 2.25 mg/kg doses of MDMA. Applying the same logic as used 
for MDMA, SKF 81297-treated DAD1+/+ rats are expected to display increased errors on 
previous different trials compared to previous same trials. However, following treatment 
with saline DAD1+/+ rats are expected to demonstrate comparable accuracy scores 
irrespective of whether the trial was a previous same or previous different trial. In 
contrast to DAD1+/+ rats, it is predicted that MDMA- and SKF 81297-treated DAD1-/- rats 
will not demonstrate a decrease in accuracy on previous same trials compared to previous 
different trials due to possessing down-regulated D1 receptor function. Similarly, 
114 
 
following saline the DAD1-/- rats are not expected to demonstrate a difference between 
accuracy on previous same and previous different trials.  
Method 
Subjects 
Thirty adult male Wistar rats (15 DAD1-/- and 15 DAD1+/+ - groups two and three 
from cohort three) were used in this experiment. See the general method section (chapter 
2) for information pertaining to the generation of the DAD1-/- rats. Water and wood 
shavings were available ad libitum, and their weights were maintained at 85% of their 
free feeding weights with food pellets delivered to their home cages 7 days a week and 
after experimentation had been completed for the day. Data from these rats on the 
acquisition of this DNMTP were presented in chapter 3. These rats were drug naïve, and 
were prior subjects in the sucrose preference test described in chapter 3.  
Apparatus 
This paradigm was conducted using a wooden T-maze which had metal inners 
inserted into it to form the walls of the maze. This was done in order to create taller walls 
and shorter arm and stem lengths than provided by the wooden maze. The metal inserts 
were 30 cm high, the two arms were 30 cm long and the stem was 45 cm long. The width 
of the maze throughout was 9 cm. The stem was painted grey and the arms were painted 
black. Two pieces of black plexi-glas that were the same height as the maze walls were 
used to block the maze arms. These “doors” were attached at the top of the maze, and 
acted as sliding doors that were controlled manually when they were needed to block off 
either of the arms. Where the doors crossed the arms to block entry were defined as the 
entry lines to the arms.  
White odourless sugar pellets (45 mg Bio-serv®) were used as reinforcement. The 
sugar pellets were delivered at the end of each T-maze arm, in round white plastic 
containers (3 cm across) which were secured to the floor of the maze using adhesive.  
Procedure 
The subjects were habituated to the apparatus for four days and trained on the 
DNMTP procedure over 25 sessions as presented in chapter 3. The trial structure during 
training, described in chapter 3, was identical to that used here during the drug phase of 
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this experiment. Briefly, there were six trials per session with each trial being separated 
by a 5 minute inter- trial interval. Rats experienced 4 – 5 sessions per week (no more than 
1 per day) with a training session conducted between each drug session in order to ensure 
subjects remained at baseline accuracy. Each trial involved a sample presentation phase, a 
delay and a choice phase. During sample presentation either the left or right arm was 
baited with one sugar pellet and entry to this arm was unimpeded. Entry to the opposite 
arm was blocked using the Plexiglas door thus only the sample arm was able to be 
accessed by the rat. The rat was placed at the end of the stem of the maze, facing the 
junction between the stem and the arms, and was given 2 minutes to consume the pellet. 
Once the rat entered the baited arm (deemed the sample arm) defined as when all four feet 
had crossed the entry line, the door was slid closed to confine the subject to this arm. On 
the contrary, if the subject did not enter the sample arm within the allotted 2 minutes, the 
rat was removed from the maze and the trial was terminated. Once the rat had consumed 
the pellet, it was removed from the arm and placed in a holding cage for 10 seconds 
which was situated on a table behind the stem end of the maze. During this brief delay 
both doors were slid open and both arms appeared to be re-baited. In reality, only the 
previously blocked arm was baited and the sample arm was unbaited. Thus in order to 
retrieve the reward the rat was required to visit the opposite arm to the sample arm. The 
choice phase began after the delay period. The rat was placed in the stem of the maze and 
given 2 minutes to explore. If the rat entered one of the arms, the door to that arm was 
slid closed and the rat was confined to that arm. In the event that the arm entered was the 
previously baited arm (i.e. the sample arm) which was now unbaited, the rat was confined 
to this arm for 2 minutes. If the rat alternated their arm entry and entered the baited arm, 
the rat was allowed to consume the pellet and then removed from the maze and placed 
back into their home cage. If the rat did not enter either of the arms during the 2 minutes 
given then the rat was removed from the maze and the trial was terminated. Lastly, the 
experimenter monitored the consumption of the sugar pellets and in the event that a rat 
entered an arm but did not consume an available sugar pellet within 1 minute, the trial 
was terminated.   
Whether the baited arm during the sample phase was on the left or right side was 
pseudo-randomly selected and counterbalanced across both groups of rats. Of the six 
trials conducted per session per rat, three of the sample arms were on the left, and three 
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were on the right. Between each trial the maze was wiped out thoroughly with Virkon ‘S’ 
disinfectant.  
Drug Administration 
All drugs were dissolved in 0.9% saline solution, which also served as the control 
condition, and were administered 15 minutes prior to the start of a session via i.p. 
injection at a volume of 1ml/kg. Three doses of MDMA [(±)-MDMA hydrochloride; 
Institute of the Environmental Science and Research, Porirua, NZ] (1.5 mg/kg, 2.25 
mg/kg and 3 mg/kg) and five doses of SKF 81297 (0.5, 1, 1.5, 3 and 4.5) were 
administered. Each rat was administered saline and all doses of MDMA (1.5, 2.25 and 3 
mg/kg) 3 times each and all doses of SKF (0.5, 1, 1.5, 3, 4.5 mg/kg) once each. Drugs 
were administered in four blocks, with a block being defined as all doses of given drug 
(either MDMA + saline or SKF + saline). To illustrate, all doses of MDMA (1.5, 2.25 and 
3.0 mg/kg + saline) were administered in a counterbalanced manner (i.e. block one) 
before moving on to the next block. Firstly, rats experienced an MDMA block, then 
secondly the SKF block, thirdly another MDMA block, and lastly the final MDMA block.  
Performance Measures 
Three performance measures were collected:  
1. whether the arm entered during the choice phase matched the sample arm 
(incorrect response) or did not match the sample arm (correct response);  
2. latency in seconds to enter the forced choice arm during the sample presentation 
phase;   
3. latency in seconds to enter an arm during the choice phase. 
Data Analysis 
Accuracy. Firstly, each rat’s accuracy following each of the drug sessions was 
separately determined. Accuracy scores were then averaged by genotype for each of the 
drug sessions. To assess the effect of each drug dose on accuracy for the genotype groups, 
for each of the four drug blocks (MDMA 1, MDMA 2, MDMA 3 and SKF) group 
comparisons of mean accuracy scores were conducted using four mixed-measures 
ANOVAs with genotype as a between-subjects variable and drug dose as a within-
subjects variable. Follow-up t-tests will be conducted where necessary to explore any 
effects found.  
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Secondly, in the event that any of the drug block comparisons reveal significant 
effects of drug or genotype x drug interactions, the following analyses will be conducted 
using group accuracies from the respective drug blocks. To explore the prediction that 
MDMA-treated DAD1+/+ rats will demonstrate increased errors on previous different 
trials compared to their accuracy on previous same trials, whereas MDMA-treated DAD1-
/- rats will show no difference in accuracy across previous same or previous different trial 
types,  individual accuracy scores for each drug session will be averaged across trial 
types. Previous same and previous different trials are determined by identifying whether 
the correct response on the current trial was the same or different, respectively, from the 
response made by the subject on the immediately previous trial. Lowered accuracy during 
previous different trials is indicative of perseverative responding. Individual averages for 
previous same and previous different trials for each of the drug sessions will then be 
averaged by genotype. Split by genotype, accuracy will be analysed using two repeated 
measures ANOVAs per drug block assessed, with drug dose and trial type (previous same 
or previous different) as within-subject variables. Post hoc paired-samples t-tests will be 
conducted where necessary. 
Lastly, in between each drug session a training session (no injection) was run to 
ensure that the subjects maintained accurate baseline responding, with 18 maintenance 
sessions occurring in total. Accuracy over these sessions was averaged as a function of 
genotype and compared using a 2 (genotype) x 18 (session) mixed-measures ANOVA 
with genotype as a between-subjects factor and session as a within subjects factor. 
Latency. Each rat’s latency on sample and choice phases were averaged within 
each drug session. Individual latencies were then averaged as a function of genotype. For 
each of the four drug blocks, a group comparison was conducted using mixed-measures 
ANOVAs with run (sample or choice) and drug dose as within-subject variable, and 
genotype as a between subject variable. Follow-up t-tests will be conducted where 
necessary to explore any effects found. All statistical analyses were conducted using IBM 
SPSS Statistics version 19.0 for windows. The alpha level for statistical significance was 
set at p < 0.05. Greenhouse-Geisser corrections were used in the event of Mauchly’s test 
of sphericity being violated.  
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Results 
Accuracy   
Baseline responding during maintenance sessions. Accuracy across the 
maintenance sessions (no injection) was compared by genotype to ensure that baseline 
responding in between the drug sessions remained stable (figure 27). There were no 
significant effects of genotype, F1, 22 = .23, p = .635, or session, F17,374 = .91, p = .56, and 
no genotype x session interaction observed, F17,374 = .91, p = .56. These results 
demonstrate that DAD1-/- and DAD1+/+ rats performed with comparable accuracy during 
the maintenance sessions. Across genotype, accuracy during the maintenance sessions 
always remained at or above 80%, and was 86% on average, suggesting that accuracy did 
not alter over the course of the drug sessions.  
 
 
Figure 27. Accuracy of DAD1-/- (n = 11) and DAD1+/+ (n = 13) rats across 18 baseline 
maintenance sessions that occurred in between each drug session. Each session 
contained six trials, with an accurate response defined as when subjects entered the 
opposite arm during the choice phase to the arm entered during the sample phase. No 
drugs were administered during these sessions.  
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 Drug block one: MDMA. Figure 28 displays group means for accuracy following 
saline and the three MDMA doses tested. There were high levels of attrition during this 
drug block, especially among the DAD1+/+ group. Only two out of thirteen (15%) 
DAD1+/+ and six out of eleven (55%) DAD1-/- rats responded on at least four out of six 
trials for each dose. With these small sample sizes in mind, there was no main effect of 
drug, F3,18 = 2.58, p = .09, or genotype, F1,6 = .87, p = .39, and no interaction between 
drug and genotype observed, F3,18 = .66, p = .59. 
 
 
Figure 28. Accuracy of DAD1-/- (n = 6 (55%)) and DAD1+/+ (n = 2 (15%)) rats on the 
DNMTP task during the first block of MDMA and saline doses. Each session contained 
six trials, with an accurate response defined as when subjects entered the opposite arm 
during the choice phase to the arm entered during the sample phase. Drugs were 
administered via i.p. injection 15 minutes prior to the start of a session.   
 
Drug block two: MDMA. Figure 29 displays group means for accuracy 
following saline and the three MDMA doses tested. Less attrition was observed during 
this drug block than the 1st block, with eight out of thirteen (62%) DAD1+/+ and ten out of 
eleven (91%) DAD1-/- rats responding on at least four out of six trials for each dose. 
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Again, there was no main effect of drug, F3,48 = 2.06, p = .12, or genotype, F1,16 = .01, p = 
.91, found. There was an approaching significant interaction between drug and genotype 
observed, F3,18 = 2.65, p = .06, yet follow-up t-tests revealed that there were no 
differences between genotypes at any of the drug doses including saline. 
 
 
Figure 29. Accuracy of DAD1-/- (n = 10 (91%)) and DAD1+/+ (n = 8 (62%)) rats on the 
DNMTP task during the second block of MDMA and saline doses. Each session 
contained six trials, with an accurate response defined as when subjects entered the 
opposite arm during the choice phase to the arm entered during the sample phase. Drugs 
were administered via i.p. injection 15 minutes prior to the start of a session.   
  
Drug block 3: MDMA. Figure 30 displays group means for accuracy following 
saline and the three MDMA doses tested.  Attrition was minimal during this final drug 
block, with 12 out of 13 (92%) DAD1+/+ and 11 out of 11 (100%) of the DAD1-/- rats 
responding on at least 4 out of 6 trials for each dose. There was an approaching 
significant effect of genotype, F1,21 = 4.12, p = .06, with DAD1
-/- rats tending to be more 
accurate across doses (M = 89.92, SD = 11.95) than DAD1+/+ rats (M = 83.26, SD = 
17.20). There was a main effect of drug dose found, F3,63 = 5.03, p < .01, suggesting that 
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accuracy varied as a function of the drug dose administered. However, this effect should 
be interpreted in light of the significant interaction between drug and genotype that was 
observed, F3,63 = 3.05, p = .04. Follow-up independent sample t-tests comparing genotype 
accuracies for each drug dose suggest that the two highest doses of MDMA (2.25 and 3 
mg/kg) significantly decreased accuracy for the DAD1+/+ rats (2.25 mg/kg: M = 73.61, SD 
= 16.60; 3 mg/kg: M = 76.11, SD = 19.32) compared to the DAD1-/- rats (2.25 mg/kg: M 
= 87.88, SD = 13.10; 3 mg/kg: M = 91.51, SD = 13.28), 2.25 mg/kg: t21 = 2.27, p = .03; 3 
mg/kg: t21 = 2.21, p = .04, whilst no differences between saline, t21 = -.48, p = .64, or 
MDMA 1.5 mg/kg, t21 = -.22, p = .83, were found. The finding that the two highest doses 
of MDMA decreased the accuracy of DAD1+/+ rats, but not DAD1-/- rats, during the third 
block of MDMA doses is in line with predictions and suggests that the D1 receptor is 
involved in acute MDMA’s impact on memory performance.    
 
 
Figure 30. Accuracy of DAD1-/- (n = 11 (100%)) and DAD1+/+ (n = 12 (92%)) rats on the 
DNMTP task during the third block of MDMA and saline doses. Each session contained 
six trials, with an accurate response defined as when subjects entered the opposite arm 
during the choice phase to the arm entered during the sample phase. Drugs were 
administered via i.p. injection 15 minutes prior to the start of a session.   
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Drug block 4: SKF 81297. Figure 31 displays group means for accuracy 
following saline and the five doses of SKF 81297 tested. Group comparison revealed no 
significant effects of genotype, F1,14 = .60, p = .45, or drug dose, F5,70 = 1.00, p = .42, as 
well as no significant interaction between drug dose and genotype, F5,70 = .53, p = .75. 
The lack of differences found suggest that the D1-like receptor agonist did not affect 
performance on the DNMTP task. However, the fact that only five out of thirteen (~38%) 
DAD1+/+ rats completed four or more trials at the highest dose (4.5 mg/kg) of SKF 81297, 
compared to eleven out of eleven (100%) DAD1-/- rats suggests that the genotypes did 
respond differently to this drug. The high rates of attrition among DAD1+/+ rats may have 
contributed to the lack of effects found. Furthermore, figure 31 indicates that the 3 mg/kg 
dose of SKF 81297 appeared to enhance the performance of DAD1-/- rats compared to 
DAD1+/+ rats. As such, exploratory independent samples t-tests were conducted to further 
investigate the effects of SKF 81297 on accuracy across the genotypes. No differences 
between groups were observed for saline or the 0.5, 1, 1.5 and 4.5 mg/kg doses of SKF 
81297 (p = .12, .68, .78, .33, & .33, respectively). However, following 3 mg/kg the 
DAD1+/+ rats (M = 66.90, SD = 22.98) were found to be significantly less accurate than 
DAD1-/- rats (M = 89.39, SD = 17.11), t16 = 2.38, p = .03. However, as this analysis was 
exploratory, it should be interpreted with caution.  
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Figure 31. Accuracy of DAD1-/- (n = 11 (100%)) and DAD1+/+ (n = 5 (38%)) rats on the 
DNMTP task during the block of SKF 81297 and saline doses. Each session contained 
six trials, with an accurate response defined as when subjects entered the opposite arm 
during the choice phase to the arm entered during the sample phase. Drugs were 
administered via i.p. injection 15 minutes prior to the start of a session.   
 
 MDMA-induced proactive interference in DAD1+/+ rats. On the basis that the 
third block of MDMA administration revealed a significant drug dose x genotype 
interaction, these data were submitted to further analyses to assess whether trial type 
(either previous same or previous different) influenced accuracy. Figure 32 displays the 
accuracy of DAD1-/- rats, split by trial type, over the drug doses tested. The analysis 
revealed no significant differences in accuracy as a function of drug dose, F3, 27 = 1.10, p 
= .37, or trial type, F1, 9 = .49, p = .50, as well as no interaction between drug dose and 
trial type, F3, 27 = .80, p = .51. These results suggest that trial type did not affect accuracy 
in DAD1-/- rats on any of the MDMA doses tested.  
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Figure 32. Accuracy, as a function of trial type, as demonstrated by DAD1-/- rats (n = 11) on 
the third drug block of MDMA administration. Trials were categorised as being either 
‘previous same’ or ‘previous different’ trials on the basis that the accurate response on the 
current trial was either the same or different, respectively, as the required response on the 
immediately preceding trial. 
 
 Figure 33 displays the accuracy of DAD1+/+ rats, split by trial type, over the drug 
doses tested during the third block of MDMA administration. In contrast to DAD1-/- rats, 
the DAD1+/+ rats demonstrated a significant effect of trial type, F1, 11 = 4.83, p = .05, 
suggesting that DAD1+/+ rats were more accurate on previous same trials (M = 88.62, 
SD = 8.53) than previous different trials (M = 78.06, SD = 19.42) across drug doses. 
Furthermore there was a significant effect of drug dose, F3, 33 = 3.44, p = .03, and a 
significant interaction between drug dose and trial type, F3, 33 = 5.24, p = < .01. Paired-
sample t-tests revealed that DAD1+/+ rats displayed no difference in accuracy on previous 
same or previous different trials following saline, t12 = .19, p = .85 or MDMA 1.5 mg/kg, 
t11 = -1.78, p = .10. However, there were significant differences found between accuracy 
on previous same and previous difference trials following administration of the two 
highest doses of MDMA. Specifically, and in line with predictions, following MDMA 
2.25 mg/kg DAD1+/+ rats were significantly more accurate on previous same trials (M = 
91.67, SD = 15.07) than previous different trials (M = 57.64, SD = 38.67), t11 = 2.96, p = 
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.01. In a similar fashion, following MDMA 3 mg/kg, DAD1+/+ rats were significantly 
more accurate during previous same trials (M = 90.28, SD = 22.98) than previous 
different trials (M = 65.28, SD = 28.61), t11 = 2.25, p = .05.  
 
 
Figure 33. Accuracy, as a function of trial type, as demonstrated by DAD1+/+ rats (n = 12) on 
the third drug block of MDMA administration. Trials were categorised as being either 
‘previous same’ or ‘previous different’ trials on the basis that the accurate response on the 
current trial was either the same or different, respectively, as the required response on the 
immediately preceding trial. 
 
Latency  
 Drug block one: MDMA. A comparison of the times taken by DAD1-/- and 
DAD1+/+ rats during the sample or choice phases following the first block of MDMA 
doses is displayed in figure 34. There were no significant effects of drug, F3, 66 = .19, p = 
.91, trial stage, F1, 22 = .16, p = .69, or genotype, F1, 22 = 1.79, p = .20. Furthermore, no 
interactions were observed between drug and genotype, F3, 66 = 1.43, p = .24, trial phase 
and genotype, F1, 22 = .02, p = .90, drug and trial phase, F3, 66 = 1.15, p = .34, or drug, trial 
phase and genotype, F3, 66 = 1.14, p = .34. These results indicate that DAD1
-/- and 
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DAD1+/+ rats moved into the arms of the T-maze within similar time frames across the 
first block of MDMA doses.  
 
 
Figure 34. The time taken in seconds for DAD1-/- (n = 6 (55%)) and DAD1+/+ (n = 2 
(15%)) rats to enter an arm on the sample or the choice phase during the first drug 
block of the DNMTP task. Fifteen minutes prior to the start of each DNMTP session 
the subjects were administered either saline, 1.5, 2.25 or 3 mg/kg of MDMA.  
 
 Drug block two: MDMA. A comparison of the times taken by DAD1-/- and 
DAD1+/+ rats during the sample or choice phases following the second block of MDMA 
doses is displayed in figure 35. There was an approaching significant effect of drug, F1.1, 
18.6 = .3.64, p = .07, which as displayed by figure 35 is likely due to rats taking longer to 
enter both the sample and choice arms following MDMA 3 mg/kg compared to the other 
drug doses. There were no effects of trial stage, F1, 17 = 1.83, p = .19, or genotype, F1, 17 = 
.14, p = .72 found. Furthermore, no interactions were observed between drug and 
genotype, F3, 51 = .03, p = .99, trial phase and genotype, F1, 17 = .08, p = .78, drug and trial 
phase, F1.15, 19.59 = 1.66, p = .22, or drug, trial phase and genotype, F1.15, 19.69 = .67, p = .44. 
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These results indicate that DAD1-/- and DAD1+/+ rats moved into the arms of the T-maze 
within similar time frames across the second block of MDMA doses.  
 
 
Figure 35. The time taken in seconds for DAD1-/- (n = 10 (91%)) and DAD1+/+ (n = 8 
(62%)) rats to enter an arm on the sample or the choice phase during the second drug 
block of the DNMTP task. Fifteen minutes prior to the start of each DNMTP session 
the subjects were administered either saline, 1.5, 2.25 or 3 mg/kg of MDMA. 
 
 Drug block three: MDMA. A comparison of the times taken by DAD1-/- and 
DAD1+/+ rats during the sample or choice phases following the third block of MDMA 
doses is displayed in figure 36. There was a significant effect of drug, F1.03, 21.67 = 6.23, p 
= .02, an effect which figure 36 suggests is driven by rats taking longer to enter either a 
sample or choice arm following MDMA 3 mg/kg compared to the other drug doses. 
There were no effects of trial stage, F1, 21 = .01, p = .97, or genotype, F1, 21 = .35, p = .56. 
Furthermore, no interactions were observed between drug and genotype, F3, 63 = .44, p = 
.73, trial phase and genotype, F1, 21 = .2.11, p = .16, drug and trial phase, F1.04, 21.93 = .19, p 
= .67, or drug, trial phase and genotype, F1.04, 21.93 = .2.40, p = .14. However, as shown on 
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figure 36, DAD1-/- and DAD1+/+ latencies to enter a choice arm following MDMA 3 
mg/kg seem contrasting, with DAD1-/- rats appearing to move faster than DAD1+/+ rats. 
Given that accuracy at this dose during this drug block was decreased in DAD1+/+ 
compared to DAD1-/- rats, an exploratory independent samples t-test was carried out to 
further examine this difference further. Nonetheless, the result of this test indicated that 
the difference observed was not significant, t12.04 = -1.49, p = .16. In sum, these results 
indicate that DAD1-/- and DAD1+/+ rats moved into the arms of the T-maze within similar 
time frames across the third block of MDMA doses, yet that there was a trend for 
DAD1+/+ rats to be slower than DAD1-/- rats during the choice phase following MDMA 3 
mg/kg.  
 
 
Figure 36. The time taken in seconds for DAD1-/- (n = 11 (100%)) and DAD1+/+ (n = 
12 (92%)) rats to enter an arm on the sample or the choice phase during the third drug 
block of the DNMTP task. Fifteen minutes prior to the start of each DNMTP session 
the subjects were administered either saline, 1.5, 2.25 or 3 mg/kg of MDMA. 
 
Drug block four: SKF 81297 (D1-like receptor agonist). A comparison of the 
times taken by DAD1-/- and DAD1+/+ rats during the sample or choice phases following 
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the block of SKF 81297 doses is displayed in figure 37. There were no significant effects 
of drug, F1.46, 30.58 = 1.02, p = .35, trial stage, F1, 21 = .06, p = .81, or genotype, F1, 21 = .49, 
p = .49. Furthermore, no interactions were observed between drug and genotype, F5, 105 = 
1.01, p = .42, trial phase and genotype, F1, 21 = .64, p = .43, drug and trial phase, F1.19, 25.02 
= 1.02, p = .34, or drug, trial phase and genotype, F1.19, 25.02 = 1.44, p = .25. These results 
indicate that DAD1-/- and DAD1+/+ rats moved into the arms of the T-maze within similar 
time frames across the block of SKF 81297 doses.  
 
 
Figure 37. The time taken in seconds for DAD1-/- (n = 11 (100%)) and DAD1+/+ (n = 5 
(38%)) rats to enter an arm on the sample or the choice phase during the SKF 81297 
drug block of the DNMTP task. Fifteen minutes prior to the start of each DNMTP 
session the subjects were administered either saline, 0.5, 1, 1.5, 3 or 4 mg/kg of SKF 
81297. 
 
Discussion 
 This chapter explored the hypothesis that acute MDMA exposure acts to interfere 
with memory performance in rats due to an MDMA-induced DA release causing the 
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over-stimulation of D1 receptors. Within this framework, developed by Harper and 
colleagues, the over-stimulation of D1 receptors is posited to induce proactive 
interference, or perseverative responding, whereby subjects tend to repeat the previous 
trial’s required response, rather than performing the current trial’s required response. To 
test this hypothesis, memory performances of DAD1-/- rats, that possess down-regulated 
D1 receptors, and DAD1+/+ rats were assessed using the DNMTP paradigm, conducted in 
a T-maze. Once the subjects were trained on the DNMTP task, a range of acute doses of 
MDMA, as well as saline, were administered to explore the impact of acute MDMA 
exposure on task performance. It was predicted that DAD1+/+ rats would display 
decreased accuracy following the highest dose of acute MDMA, specifically 3 mg/kg, and 
that this decrease in accuracy would be due to a greater number of errors on ‘previous 
different’ trials (indicative of proactive interference). In contrast to DAD1+/+ rats, it was 
predicted that DAD1-/- rats would be relatively protected from acute MDMA-induced 
memory deficits, due to having less D1 receptor function, and that this group would not 
display more errors during ‘previous different’ compared to ‘previous same’ trials during 
acute MDMA exposure. As a further control, memory performance was also assessed 
following administration of the D1-like receptor agonist SKF 81297. The rationale 
applied was that if MDMA interferes with memory performance via over-stimulation of 
D1 receptors, then application of a D1-like agonist should similarly interfere with 
memory by increasing perseverative errors in the DAD1+/+, but not the DAD1-/- animals. 
 Overall, the two central hypotheses regarding the impact of acute MDMA 
exposure on the memory performances of DAD1+/+ and DAD1-/- rats were supported by 
the data. During the third block of MDMA doses, the DAD1+/+ rats demonstrated 
significant decreases in accuracy following administration of the 2.25 and 3 mg/kg doses 
of MDMA. Furthermore, the magnitude of decrease in accuracy induced by the two 
highest doses of MDMA is comparable to that observed in previous studies using the 
DMTS paradigm (Harper and colleagues, 2005; 2006; 2013). Importantly, the decrease in 
accuracy at these doses observed in the control rats appears to be directly attributable to 
an increase in proactive interference. Specifically, accuracy at these doses was 
significantly decreased during ‘previous different’ trials compared to ‘previous same’ 
trials, yet accuracy following saline and MDMA 1.5 mg/kg was comparable during 
‘previous same’ and ‘previous different’ trials. This means that when exposed to the 
highest doses of MDMA, DAD1+/+ rats were tending to enter the maze arm that they 
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entered on the immediately preceding trial, rather than enter the correct arm required for 
the current trial. In direct comparison, on the third block of MDMA trials DAD1-/- rats did 
not display a significant decrease in accuracy following any of the doses of MDMA 
tested. What is more, DAD1-/- rats did not display an increase in errors on ‘previous 
different’ trials at these doses, indicating that MDMA did not increase proactive 
interference in these rats. 
 Although it was expected that MDMA 3 mg/kg would interfere with memory in 
the DAD1+/+ rats, it was not expected that the magnitude of the impairment would be 
matched following administration of the 2.25 mg/kg dose. However, the difference 
between these doses is relatively small, thus is possible that past research has not 
explored the behavioural effects of the 2.25 mg/kg dose as extensively as 3 mg/kg. If 
MDMA 2.25 mg/kg were to impair memory in a similar fashion using the DMTS task, 
then future research investigating the acute effects on memory may like to employ the 
2.25 mg/kg dose for the practical reason of utilising less MDMA. However, if memory is 
relatively preserved during DMTS following MDMA 2.25 mg/kg, then this may suggest 
that the DNMTP maze task is more sensitive to perseverative errors than the DMTS 
operant task. Furthermore, although performance deficits were observed in the third block 
of MDMA doses, accuracy was unimpaired during the first and second blocks of MDMA 
doses. However, it is possible that due to high levels of attrition in the DAD1+/+ rats 
during these two blocks that statistical differences between the genotypes were obscured.  
Despite the finding that accuracy in the DAD1+/+ rats was impaired following the 
two highest doses of MDMA, the time taken for DAD1-/- and DAD1+/+ rats to enter the 
arms during the sample and choice phases were similar, and did not differ significantly. 
However, in the third drug block, following MDMA 3 mg/kg, there was an apparent trend 
evident in which the DAD1+/+ rats were slower to enter the choice arm than DAD1-/- rats. 
It is possible that the motor capabilities of DAD1+/+ rats were more greatly affected 
following this dose compared to DAD1-/- rats. Nonetheless, since the latencies observed 
for the 2.25 mg/kg dose of MDMA, which also  procured accuracy impairments in 
DAD1+/+ rats but not DAD1-/- rats, during the third MDMA block were highly 
comparable, it is unlikely that motor deficits contributed to the decreased accuracy in 
DAD1+/+ rats at the 3 mg/kg dose.  
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 The results from the SKF 81297 investigation did not completely support 
predictions. It was predicted that SKF 81297 administration in DAD1+/+ rats would lead 
to decreased accuracy in comparison to saline, yet that DAD1-/- rats would not 
demonstrate a decrease in accuracy following SKF 81297. Importantly, the DAD1+/+ rats 
demonstrated high levels of attrition, with only six control rats (46%) completing four out 
of six trials across all doses of SKF 81297. By comparison, none of the DAD1-/- rats 
demonstrated a general impairment following SKF 81297 administration, and all of these 
rats were included in the analysis. This suggests that the higher doses of SKF 81297 
produced a general performance impairment in the DAD1+/+ rats due to over-stimulation 
at D1 receptors. Although there was a large degree of variation present in these data, 
which is especially pronounced in the DAD1+/+ rats likely due to high attrition, the non-
significant trend observed suggests that both genotype groups were similarly affected by 
SKF 81297, with accuracy lowering slightly as the dose increased, except at the 3 mg/kg 
dose. Following administration of SKF 81297 3 mg/kg, the DAD1-/- rats displayed 
increased accuracy compared to the DAD1+/+ rats. This finding raises the possibility that 
at 3 mg/kg, DAD1-/- rats may benefit from enhanced memory performance due to an 
increase in D1-like receptor stimulation. However, considering SKF 81297 is not 
completely selective for D1 receptors, non-selective effects cannot be ruled out.  
Lastly, based on research demonstrating that enhanced activation of D1-like 
receptors in the PFC impairs memory function in rats (Vijayraghavan et al., 2007; Zahrt 
et al. 1997), it is surprising that the SKF-treated DAD1+/+ rats that did manage to perform 
4 out of 6 trials across doses did not display a larger decrease in accuracy than observed. 
However, studies that have examined memory function following activation of D1-like 
receptors have not always provided consistent results. For example, although low doses of 
D1-like receptor agonists have been shown to improve memory function, higher doses do 
not necessarily impair memory function relative to saline (Cai & Arnsten, 1997). A 
further study demonstrated that excessive DA release in the PFC in response to ketamine 
administration impaired memory in rats via D2-like receptor mechanisms, as opposed to 
D1-like receptors mechanisms (Verma & Moghaddam, 1996). In the face of such 
discrepant findings, it has been posited that the effects of D1-like receptor agonists on 
memory function depend on the endogenous levels of D1 activation prior to 
administration of a D1-like receptor ligand (e.g. Vijayraghavan et al., 2007). Thus, 
perhaps the DAD1+/+ subjects did not demonstrate an impairment following 
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administration of SKF 81297 due to having low baseline levels of PFC D1 receptor 
activation during the DNMTP task. Such individual differences in baseline levels of D1 
activation could also provide an explanation for why the majority of DAD1+/+ rats 
displayed a general impairment following administration of the higher doses of SKF 
81297 and stopped responding altogether.  
 In summary, the results presented in this chapter suggest that acute MDMA 
administration acts to interfere with memory due to the over-stimulation of D1 receptors. 
The wider implications of these findings, with regard to recent research suggesting that 
MDMA-induced memory deficits are a product of indirect memory interference rather 
than direct working memory impairment will be discussed in the general discussion 
(chapter 6). 
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Chapter 6: General Discussion 
This project employed the DAD1-/- rat model of down-regulated D1 receptor 
function to investigate the behavioural and neurological mechanisms by which acute 
MDMA impairs memory performance. Memory deficits observed following MDMA 
administration are often ascribed to a direct working memory impairment caused by 5-HT 
dysfunction (e.g. Braida et al., 2002; Kuypers & Ramaekers, 2005). However, there is 
evidence to suggest that, instead, MDMA-induced release of DA may indirectly interfere 
with memory performance (Harper, 2013; Harper et al., 2011; Rozas et al., 2012). Using 
rat subjects, Harper (2013) found that MDMA-induced impairments on a DMTS working 
memory task were ameliorated by concurrent administration of a D1-like receptor 
antagonist, SCH 23390. Specifically, SCH 23390 decreased MDMA-induced proactive 
interference, demonstrated by a reduction in perseverative responding. Accordingly, the 
central hypothesis of the current research was that MDMA-induced release of DA may 
lead to the over-stimulation of D1 receptors, thereby causing an increased susceptibility 
to proactive interference. Firstly, in control rats, proactive interference was posited to 
result in perseverative responding during the DNMTP maze task. In this regard it was 
predicted that control rats would demonstrate an MDMA-induced increase in errors 
during ‘different’ trials relative to ‘same’ trials. Secondly, if MDMA impairs memory via 
over-stimulation of D1 receptors then it was predicted that DAD1-/- rats would be 
protected from an MDMA-induced deficit on the DNMTP task compared to control rats. 
Key findings presented in chapter 3 support this hypothesis and expand on previous 
research (e.g. Harper, 2013) by employing a model of down-regulated D1 receptor 
function that isolates D1 receptor function from D5 receptor function.  
Prior to testing the effects of acute MDMA using DAD1-/- rats, a drug-free 
behavioural investigation was conducted. Because the DAD1-/- model is a novel animal 
model of down-regulated D1 receptor function, a behavioural assessment was vital to 
evaluate the performance of these subjects on tasks that are thought to involve intact D1 
receptor function, namely basic tests of reward, movement and memory. The rationale 
behind this assessment was that behaviours that are required for performance on memory 
tests, conducted in chapter 3, might be altered in the DAD1-/- rats due to possessing 
down-regulated D1 receptor function. The DAD1-/- rats were impaired on some 
behavioural tests, yet demonstrated intact performance on others. Regarding behaviours 
that measured hedonic liking of rewards, the DAD1-/- rats behaved in line with control 
136 
 
rats in that they readily discriminated and consumed palatable foods when they were 
freely available. This finding supports predictions stemming from the incentive salience 
hypothesis which holds that mesocorticolimbic DA systems mediate wanting, but not 
liking, of rewards (Berridge 2007; Berridge & Robinson, 1998). Intact hedonic impact of 
palatable rewards in DAD1-/- rats suggests that these animals can detect and prefer 
rewards, for example DAD1-/- rats demonstrated a preference for sucrose solution over 
water. However, when we attempted to autoshape DAD1-/- rats to press a lever for sugar 
pellets their responding was completely abolished compared to controls rats. Such a 
fundamental impairment in lever pressing by the DAD1-/- rats was unexpected, especially 
when compared to a study undertaken by El-Ghundi et al. (2003), who found an 
attenuation in lever pressing by DA D1 deficient mice, but not a complete abolishment in 
their responding. Perhaps this discrepancy highlights species specific differences in DA 
D1 receptor function regarding food reinforcement.  
The finding that DAD1-/- rats did not autoshape to press a lever for reinforcement 
could reflect impairment of one or a combination of several behavioural mechanisms. It is 
possible that DAD1-/- rats simply move less than control rats, resulting in less exploration 
within the operant chamber, meaning that the DAD1-/- rats failed to discover the 
contingency between lever pressing and the receipt of a sugar pellet. Considering 
antagonism of D1-like receptors reduces spontaneous movement (Hoffman & Beninger, 
1985; Meyer et al., 1993), this account is certainly plausible. If reduced movement in 
DAD1-/- rats resulted in the observed lever pressing deficits, we would expect that DAD1-
/- rats moved or reared less than controls in the open field experiments presented in 
chapters 1 and 2. Interestingly, during the behavioural assessment in chapter 1, DAD1-/- 
rats that had experienced extensive handling and exposure to the DNMTP task prior to the 
open field experiment displayed similar locomotor tendencies to controls in the open 
field. On the contrary, experimentally-naïve DAD1-/- rats moved less than control rats 
during open field testing presented in chapter 2. Given that the autoshaping experiment 
subjects were similarly experimentally-naïve, it is possible that decreased exploration 
contributed to the finding that DAD1-/- rats displayed abolished lever pressing.  
What is more, DAD1-/- rats demonstrated an impaired ability to cross the balance 
beam compared to control rats, which may further illustrate decreased movement in naïve 
DAD1-/- rats. However, motivation to cross and move off of the beam may not only 
require intact movement, but also the perception that being atop a narrow, elevated beam 
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is aversive. Since D1-like receptors have been found necessary for the acquisition of 
conditioned taste aversion and conditioned place aversion (Fenu, Bassareo & Di Chiara, 
2001; Hoffman & Beninger, 1988), it is possible that the DAD1-/- rats are impaired with 
regard to learning about and responding to aversive stimuli. Further evidence for this idea 
derives from the performance of the DAD1-/- rats on the rotarod task. The data suggest 
that the DAD1-/- rats may have found rotarod task to be less aversive than the control rats. 
On the rotarod task, in which subjects are compelled to move due to being placed on an 
already rotating rod, the DAD1-/- rats out-performed the control rats, with the two groups 
of control rats (minimally handled versus extensively handled) appearing to find the 
rotarod procedure as highly aversive and rarely voluntarily stepped on to the rotarod. Not 
only does the ability of DAD1-/- rats to perform on the rotarod task suggest that their lack 
of beam crossings reflect less aversion to the beam compared to controls, their 
performance on the rotarod also strengthens the argument that these rats have intact 
movement abilities required for the tests conducted here.  
Furthermore, during training on the DNMTP task, the time taken by DAD1-/- and 
DAD1+/+ rats to enter an arm during the sample and choice phases were identical and the 
DAD1-/- rats had no trouble learning this task. Taken together, these findings suggest that 
although the DAD1-/- rats may have moved less during the autoshaping experiment, 
resulting in fewer lever presses, it is also likely that the DAD1-/- rats possess a further 
deficit that contributed to the abolished lever pressing, such as with regard to translating 
motivation into action (i.e. wanting rewards). As argued in chapter 3, the autoshaping 
task could be considered more complex, and less naturalistic from a rat’s perspective, 
than the DNMTP test. This difference may account for the finding that DAD1-/- rats 
performed poorly during autoshaping, but normally during DNMTP. In order to test this, 
future research could conduct a progressive ratio maze task to compare the breakpoints of 
DAD1-/- and control rats. Alternatively, future research could increase the amount of 
reinforcement obtained during autoshaping. Perhaps if lever pressing were paired with a 
more potent reinforcer, such as cocaine, then DAD1-/- rats would be relatively more 
willing to perform and acquire lever pressing. Using self-administration to assess wanting 
in DAD1-/- rats could also provide insight into the neural mechanisms that mediate drug 
dependence.  
Although discussion of the behavioural functions of the D1 receptor is valuable, 
the finding that the DAD1-/- rats would not lever press was crucial because it meant we 
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could not employ the planned DMTS operant task to assess memory function in DAD1-/- 
rats during acute MDMA exposure. On the basis that DAD1-/- rats demonstrated intact 
memory performance during training on the DNMTP T-maze task, this task was 
subsequently selected to assess memory function in DAD1-/- rats during acute MDMA 
exposure. Although the DNMTP and DMTS tasks are procedurally different, effort was 
made to align the two procedures as closely as possible in order to extend previous 
research from our laboratory that investigated the acute effects of MDMA on 
performance using the DMTS task.  
 Acute MDMA administration has been found to decrease accuracy on the DMTS 
task (Harper and colleagues, 2005; 2006; 2013). Rather than reflecting an impairment of 
working memory, MDMA’s effects on DMTS performance are characterised by an 
increased susceptibility to proactive interference. Following acute MDMA administration, 
rat subjects demonstrate a tendency to repeat a response that they performed on the 
directly previous trial, rather than the required response for the current trial (Harper and 
colleagues, 2005; 2006; 2013). This MDMA-induced proactive interference was 
ameliorated by a D1-like receptor antagonist that was applied concurrently with MDMA 
(Harper, 2013). This finding suggests that MDMA interferes with performance on the 
DMTS task by increasing perseverative responding via over-stimulating D1-like 
receptors. Using DAD1-/- rats to test this idea in the current project, Harper’s (2013) 
finding was supported using the DNMTP task.  
During the third block of MDMA administration presented in chapter 5, control 
rats demonstrated decreased accuracy on the DMNTP task at both the 2.25 and 3 mg/kg 
doses. The decreases in accuracy at these two doses of MDMA were of comparable 
magnitude, and, moreover, were of similar scale to the MDMA-induced deficits observed 
in previous research (Harper and colleagues, 2005; 2006; 2013). On the contrary, DAD1-/- 
rats were not impaired on the DNMTP task following acute MDMA at any of the doses 
tested. In itself, this genotype difference provides strong evidence for the notion that D1 
receptors are implicated in MDMA’s detrimental effects on memory performance on the 
DNMTP task. In order to test whether the deficit observed following MDMA in the 
control rats was due to increased proactive interference, accuracy during ‘previous 
different’ and ‘previous same’ trials was compared. Following MDMA (2.25 and 3 
mg/kg) the control rats displayed decreased accuracy during ‘previous different’ trials, 
compared to ‘previous same’ trials, whereas following saline and the low dose of MDMA 
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(1.5 mg/kg) they displayed comparable levels of accuracy during ‘previous different’ and 
‘previous same’ trials. This pattern of errors was expected, and indicates that the two 
highest doses of MDMA impaired memory by way of increased proactive interference in 
the control rats. Very clearly, this pattern of errors reflects perseverative responding, with 
the subjects repeating their response that they emitted on the previous trial. By 
comparison, DAD1-/- rats did not demonstrate any differences in accuracy on ‘previous 
same’ and ‘previous different’ trials following saline or any dose of MDMA. That DAD1-
/- rats were protected from an MDMA-induced impairment on the DNMTP task and did 
not demonstrate MDMA-induced proactive interference is consistent with previous 
research suggesting that the D1 receptor is a neural substrate through which acute 
MDMA impairs memory (Harper, 2013). Furthermore, Harper’s (2013) study employed a 
non-selective D1-like receptor antagonist (SCH 23390) to decrease D1 receptor function 
in order to explore MDMA’s effect on memory. Thus, a question posed during this thesis 
was whether the amelioration of MDMA’s detrimental effect on memory by SCH 23390 
was in part due to D5 receptor signalling. Although the role played by D5 receptors 
cannot be completely ruled out, the data presented provides direct evidence for the 
involvement of D1 receptors in MDMA’s acute effects on memory performance.  
Currently, the conditions under which MDMA produces perseverative responding 
are unclear. It is possible that during the current DNMTP task as well as the DMTS task 
employed by Harper and colleagues (2005; 2006; 2013), perseverative errors following 
MDMA administration occurred due to motoric perseveration. Motoric perseveration 
would result in the subject being compelled to repeat the same motor output across trials. 
Alternatively, perseveration might have arisen due to the fact that the subject’s previous 
response was reinforced, with the subject performing the response again in order to 
receive reinforcement once more. Although this issue is not directly investigated in the 
current thesis, Harper and Hunt (2011) and Lie, Macaskill and Harper (in press) explored 
whether acute MDMA may cause disruptions to stimulus control which could account for 
the impairments observed following acute MDMA across a range of conditional 
discrimination tasks. Harper and Hunt (2011) and Lie et al., (in press) employed the 
concurrent choice procedure devised by Davison and Baum (2000) to investigate whether 
MDMA altered subjects’ sensitivity to different rates of reinforcement offered across 
concurrently available response options (levers). These studies found that following the 
highest dose of acute MDMA administered (2 mg/kg), rats displayed increased sensitivity 
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to reinforcement. That is, following a response on a lever that led to reinforcement, the 
rats were more likely to respond on that lever again immediately following receipt of 
reward. This perseverative pattern of responding, dubbed ‘preference pulses’, resulted in 
the lever that was currently associated with the richest reinforcement schedule being 
responded on more than the alternative lever (Harper & Hunt, 2011, Lie et al., in press). 
These studies suggest that the perseverative responding observed during the current 
investigation following acute MDMA in control rats may be related to their behaviour 
being directed by the pursuit of reward.  
As well as appearing to increase a subject’s susceptibility to proactive 
interference, acute (as well as sub-chronic) MDMA administration increases impulsivity 
(Bird & Schenk, 2013; Dalley et al., 2007; van Wel et al., 2012). Impulsivity has 
traditionally been thought of as a disorder of frontal ‘executive’ systems. More recently, 
the actions of DA, 5-HT and NE have all been implicated in varying aspects behavioural 
inhibition, with the PFC, striatum and Nacc considered vital for action inhibition (Eagle 
& Robbins, 2003; Eagle, Bari & Robbins, 2008). In behavioural terms, action inhibition 
could refer to either ‘action restraint’ (inhibition of an action before the response has 
begun) or ‘action cancellation’ (inhibition of motor output during the response) (Schachar 
et al., 2007). Although impulsivity and proactive interference have been operationalised 
as distinct phenomena in the current project, it is possible that they in fact encompass the 
same underlying behavioural components. Essentially, proactive interference is referring 
to the inability of a subject to engage in ‘action restraint’, with MDMA appearing to 
decrease a subject’s ability to inhibit a prepotent behavioural response. Similarly, the 
opposing processes (i.e. ‘action’ vs ‘action inhibition’) required for accurate performance 
on behavioural memory tasks are reliant on intact working and reference memory traces. 
Given the extensive overlap between impulsivity, susceptibility to proactive interference, 
and inaccurate memory performance, it is possible that aspects of these behavioural 
disruptions reflect a common neurological or behavioural change. Thus, to further 
understand the basis of the memory alterations observed following acute MDMA, future 
studies could focus on the relationship between memory performance and impulse 
control. 
In contrast to MDMA’s acute effects, chronic exposure to MDMA has not been 
found to increase impulsivity in rats. On the contrary, subjects that exhibit trait 
impulsivity are predisposed to becoming MDMA-dependent (Bird & Schenk, 2012). 
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Despite chronic MDMA exposure not leading to increased impulsivity, chronic MDMA is 
associated with memory impairments, yet there is some debate over whether these 
impairments are permanent. Interestingly, both acute and chronic MDMA-induced 
memory impairments are characterised by an increase in reference memory errors, as 
opposed to working memory errors (Able et al., 2005; Braida et al., 2002; Harper et al., 
2011; 2013; Kay et al., 2010; 2011; Piper & Meyer, 2004; Skelton et al., 2008; Sprague et 
al., 2003; Vorhees et al, 2004). This suggests that there may be common neurological 
changes associated with both acute and chronic MDMA exposure that lead to altered 
reference memory performance. Future research may like to employ the DAD1-/- rat 
model to test whether these short and long-term cognitive changes caused by MDMA 
reflect common, or distinct, neurological mechanisms. That DAD1-/- rats were protected 
from acute MDMA-induced memory impairments is argued to be due to the inability for 
MDMA to over-stimulate D1 receptors in these rats. If acute and chronic regimes of 
MDMA impair memory via distinct mechanisms, then it follows that the DAD1-/- rats 
may not be protected from chronic memory impairments associated with MDMA 
exposure. On the contrary, if common mechanisms underlie these changes, then DAD1-/- 
rats may similarly display intact memory following chronic regimens of MDMA.  
Further evidence consistent with the hypothesis that MDMA impairs memory 
through the over-activation of D1 receptors can be drawn from the analysis of c-fos 
expression presented in chapter 4. DAD1-/- rats expressed significantly less MDMA-
induced c-fos expression in the mPFC compared to control rats. Intact DA signalling in 
the PFC has been associated with effective performance on tests of working memory. 
Specifically, the inverted-U hypothesis of DA function in the PFC (e.g. Williams and 
Goldman-Rakic, 1995; Zahrt et al., 1997) posits that too much or too little DA 
transmission in the PFC leads to detrimental effects on working memory performance. In 
particular, stimulation of D1-like receptors by DA has been implicated in this effect 
(Zahrt et al., 1997). Perhaps, in a drug-free state, DAD1-/- and DAD1+/+ rats both exhibit 
levels of PFC DA transmission that fall within the ‘optimum’ range required for the 
normal execution of DA-mediated behaviours, such as working memory. However, 
during MDMA exposure, DAD1+/+ rats have a significant increase in DA release causing 
excess D1 receptor stimulation, leading to impaired memory performance. On the 
contrary, it is possible that during acute MDMA exposure, DAD1-/- rats experience less 
MDMA-induced D1 receptor activation (brain-wide, including the PFC), resulting in less 
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PFC DA transmission compared to controls. A reduction in PFC DA transmission 
following MDMA exposure, compared to controls, could mean that DAD1-/- rats remain 
within the ‘optimum’ range of DA transmission required for memory function and are 
protected from memory interference caused by stark increases in DA release associated 
with drugs of abuse (Baumann et al., 2008).  
That DAD1-/- rats expressed less c-fos in the mPFC in response to 3 mg/mg 
MDMA, compared to control rats, provides an indirect neural marker for the supposition 
that DAD1-/- rats exhibit less DA transmission in the PFC during acute MDMA exposure, 
compared to controls. However, it would be interesting to further characterise the neural 
responses of DAD1-/- rats to MDMA, and other DA exerting drugs, using direct measures. 
As such, future studies may like to conduct micro-dialysis in the DAD1-/- rats to quantify 
neurochemical release in these rats in response to a range of drugs. It is possible that a 
genetic down-regulation of D1 receptors in DAD1-/- rats will result in lowered DA 
transmission in response to DA agonist drugs. Alternatively, it is possible that DAD1-/- 
rats will display similar levels of DA release in response to DA exerting drugs, yet that 
DA’s effects are dampened due to less functional D1 receptors available for DA to bind 
to.  
While the use of c-fos expression as a marker for neural activation is certainly a 
widely used and useful approach, it is also important to recognise the shortcomings of this 
technique. Firstly, c-fos expression and neuron depolarization do not have a 1 : 1 
relationship in that it is possible to observe neuronal depolarisation without c-fos 
expression and vice versa (Hoffman & Lyo, 2002). Secondly, c-fos expression is 
modulated by numerous brain receptors, not simply DA receptors. As outlined in chapter 
1, acute MDMA preferentially stimulates the release of 5-HT, in addition to increasing 
the release of NE and DA. Importantly, the brain regions selected for the analysis of c-fos 
expression presented in chapter 4 receive rich 5-HT input (e.g. Bonsi et al., 2007; Herve, 
Pickel, Joh & Beaudet, 1987; Martin-Ruiz et al., 2001), with various 5-HT receptors 
known to modulate c-fos expression (Leslie, Moorman, Coulson, & Grahame-Smith, 
1993; Mitsikostas, del Rio, Moskowitz & Waeber, 1999). Given that we do not know the 
developmental or neurological consequences of having a genetic down-regulation of 
functional D1 receptors means that there are potential compensatory mechanisms 
unaccounted for in this study. It is possible that the decrease in c-fos expression observed 
in DAD1-/- rats following MDMA was in part due to a compensatory change in 5-HT 
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receptors in DAD1-/- rats. In order to test this, future researchers could administer a drug 
that primarily exerts its effects on DA (i.e. amphetamine) to DAD1-/- rats to investigate 
whether the reduction in c-fos expression is of the same magnitude as found here. 
Alternatively, if decreased D1 receptor function can account for the pattern of c-fos 
expression reported in the current study, then systemic antagonism of 5-HT receptors in 
DAD1-/- rats prior to the administration of MDMA should still result in a comparable 
pattern of c-fos expression to that reported here.  
Lastly, alternative explanations that may account for why acute MDMA 
administration impaired memory performance in control rats, yet not the DAD1-/- rats, 
should also be considered. One possibility is that acute MDMA administration could slow 
down response selection in control rats, thereby increasing the delay between the sample 
and choice runs, leading to poorer memory performance. However, analysis of response 
latencies on the DNMTP task did not reveal any systematic, or significant, differences 
between DAD1-/- and DAD1+/+ rats, indicating that this explanation cannot account for 
our findings. Another possibility is that during acute MDMA exposure control subjects 
were distracted from the task by visual distortions or other subjective effects. Although it 
is difficult to assess the subjective effects of drugs using non-human animal models, as 
pointed out by Kay et al. (2010), if visual distortions or other subjective effects were 
behind acute MDMA’s disruptive effects on memory performance then it would be 
expected that during MDMA exposure all types of memory errors would increase (in this 
case errors during both ‘previous same’ and ‘previous different’ trials). On the contrary, 
we found that in the control animals, acute MDMA exposure at the two highest doses 
administered (2.25 and 3.0 mg/kg) selectively increased errors during ‘previous 
difference’ trials compared to ‘previous same’ trials.  
Conclusions 
 In contrary to the commonly held view that MDMA’s acute impacts on memory 
are due to dysfunctional 5-HT mechanisms, the current research highlights the importance 
of DA signalling in MDMA’s acute effects on memory. Using the DNMTP spatial 
memory paradigm conducted in a T-maze, control rats displayed decreased accuracy 
following acute MDMA administration (2.25 and 3 mg/kg i.p) that was due to a selective 
increase in perseverative errors. This MDMA-induced perseverative pattern of responding 
in control rats is argued to reflect an increased susceptibility to proactive interference. On 
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the contrary, DAD1-/- rats that possess down-regulated D1 receptor function were 
protected from MDMA-induced memory impairments, and did not demonstrate an 
increased susceptibility to proactive interference. Thus, the current project provided 
further evidence for the hypothesis that acute MDMA exposure impairs memory 
performance in rats via over-stimulation of D1 receptors. 
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